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Abstract 
The pathogenesis of diabetes mellitus type 2 (T2DM) has been associated with 
vitamin D deficiency which plays a role in impaired insulin action in humans. 
The purpose of this research is to investigate the effect of vitamin D3 
supplementation on biomarkers of glycaemia, lipidaemia and oxidative stress 
in Saudi men aged >18 years with poorly controlled T2DM. A double-blind, 
randomised, placebo-controlled, parallel trial was used to investigate 128 
Saudi men with poorly-controlled T2DM randomised to receive: 1) a placebo 
supplement, 2) 50µg/day vitamin D3 or 3) 100µg/day vitamin D3 as capsules 
matched in shape and size over a 16-week period. Fasting glucose, HbA1c, 
fasting insulin, lipid profile, serum 25(OH)D, and total antioxidant status were 
measured, and advanced glycation end products (AGEs) in skin were also 
measured using an AGE-reader. Vitamin D supplementation of either 100µg or 
50µg per day were found to give a significant improvement in the HbA1c 
(p<0.001) and a reduction in glucose levels (p<0.001) after 16-weeks’ 
intervention as compared to the placebo group in both supplementation 
groups. Significant reductions in total cholesterol (p<0.001) and improvements 
in HDL levels (p<0.001) after 16-weeks’ intervention were seen compared to 
the placebo group in both treatment groups. Triglycerides were significantly 
reduced after 16-weeks’ intervention (p<0.001) only with the higher dose of 
vitamin D3 (100µg/day) without any change in the 50µg/day vitamin D3 group. 
Vitamin D supplementation failed to demonstrate any improvement in insulin 
resistance, insulin secretion or oxidative stress such as total antioxidant levels 
or AGEs as compared to the placebo group after 16-weeks’ intervention. 
Vitamin D status seems to have a significant role in controlling the development 
and treatment of diabetes. It is likely that optimised levels of serum vitamin D 
may be variable between those at high risk. 
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2 
1.1. Diabetes mellitus  
Diabetes is a group of metabolic diseases characterised by hyperglycaemia, 
which is a common effect of uncontrolled blood glucose concentration and, 
therefore, of long-term of diabetes, causes serious complications both 
macrovascular and microvascular, and associated with failure of the eyes, 
kidneys, and nerve (American Diabetes Association, 2017). These 
complications result in a significant cause of mortality and morbidity (Ozfirat 
and Chowdhury, 2010). There are three common types of diabetes, including 
type 1 diabetes, type 2 diabetes and gestational diabetes (Rhodes et al., 
2007). 
Diabetes are observed in about 422 million people worldwide (Roglic and the 
World Health Organization, 2016) and estimates are that 90 % cases suffer 
from type 2 diabetes (T2DM) (WHO, 2014). The prevalence of diabetes is 
about 4.9% in UK, 8.3% in Germany, 9.2% in USA, 19% in United Arab 
Emirates and 24.0% in Saudi Arabia (Guariguata et al., 2014). About 1.6 
million deaths are attributed to diabetes each year, and by 2030, it expected 
that diabetes would be the seventh cause of global deaths (Roglic and the 
World Health Organization, 2016).  
Diabetes, especially T2DM, is a complex disorder, which genetically means 
there is not a single genetic cause, so there are multiple gene effects in 
combination with lifestyle and environmental factors (Andersen et al., 2016). 
Complex disorders often cluster in families, which do not have a clear-cut 
pattern of inheritance (Flannick & Florez, 2016). The genetic variations are 
likely to act together with health and lifestyle factors to influence the patient’s 
overall risk of T2DM (Mohlke & Boehnke, 2015). 
T2DM has become a major public health problem in recent years, which 
increases the risk for developing coronary heart disease, vascular disease, 
stroke, and also they have a high risk of having hypertension, dyslipidaemia, 
and obesity (Tuomilehto et al., 2003). Obesity has a significant risk of impaired 
glucose tolerance and a higher prevalence of obesity with 80% to 90% of 
people diagnosed with T2DM  (Daousi et al., 2006). A study of 14252 Saudi 
3 
diabetic patients reported that the majority of the obese diabetics were 
diagnosed with poor glycaemic control (Shahrani & Al-Khaldi, 2013). Another 
study, in Kuwait, showed that 48% and 77% obese males and females 
(respectively) were diabetics (Alarouj et al., 2013). Obesity has been 
increasing to over 650 million adults worldwide (WHO, 2016). The prevalence 
of obesity in the UK is about 26% (NHS, 2018), and in Saudi Arabia was 52.9% 
in 2017 and projected to reach 59.5% by 2022 (Alqarni, 2016). Increasing 
health awareness, especially in diabetes and its complications, is essential in 
the prevention of developing diabetes (Aljoudi & Taha, 2009). Thus, an 
increased health awareness level will help to expand the knowledge in health 
and diabetic education and that can help to reduce the risk factors for diabetes. 
It would achieve the self-care, healthy diet and improvement in physical activity 
to control the development of diabetes (Shrivastava et al., 2013; Agrawal, 
2016). 
1.1.1. Prevalence of diabetes in Saudi Arabia 
The prevalence of diabetes has been increasing since 1987 in all regions of 
Saudi Arabia. From 1987 to 1999, the prevalence of diabetic males was 2.9 % 
to 9.7% (Fatani et al., 1987; El-Hazmi et al., 1999). Then, between 2004 and 
2007, the prevalence of diabetic males increased from 24.2% to 26.2% (Al 
Osaimi, 2007; Al-Nozha et al., 2004). In 2011 and 2014, the prevalence of 
diabetes increased from 30.8% to 43.1% (Alqurashi et al., 2011; Al-Quwaidhi 
et al., 2014). Saudi Arabia had the 7th highest prevalence of diabetes (24.0%) 
worldwide in 2013 and is anticipated to be the 6th in 2035 (24.5%) for both 
genders (Guariguata et al., 2014).  
The region-specific prevalence of diabetes among the Saudi population is 
reported to be 27.9% in the Northern region, 26.4% in the Eastern region 
followed by the Southern region where the prevalence reported to be 18.2% 
(Al-Nozha, et al., 2004). Although it is well documented that life style 
contributes significantly to the increased prevalence of T2DM, 
consanguineous marriage has proved to be a contributing factor to increasing 
the prevalence of T2DM among Arabs (Bittles, 2001). Anokute (1992) reported 
a positive correlation between consanguinity and T2DM among the Saudi 
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population where 80% of all related marriages had a positive family history of 
T2DM as compared to 20% in non-consanguineous marriages. This could be 
explained in the lens of genetics , e.g. the SNP marker (rs4812829) (located 
at 20q13 in the intronic region of HNF4A  (Hepatocyte nuclear factor 4 alpha) 
is linked to an increased susceptibility to T2DM among the Saudi population 
(Al-Daghri et al., 2013, Al-Daghri et al., 2014). rs4812829 is also linked to 
T2DM in the South Asia population and in the Japanese population in which 
five other risk alleles have been identified (Kooner et al., 2011; Fukuda et al., 
2012). The rs4812829 marker encodes a transcription factor that binds DNA 
as a homodimer (Battle et al., 2006). HNF4α is known to control the expression 
of several genes as the HNF1α (hepatocyte nuclear factor 1 alpha), another 
transcription factor that in turn regulates hepatic gene expression (Shankar et 
al., 2013). Nevertheless, mutations in HNF4α have been reported previously 
to cause mature-onset type 1 diabetes (Eeckhoute et al., 2001). 
Another SNP (rs10965250) of the Cyclin-dependent kinase inhibitor-2A/B 
(CDKN2A/B) has been reported among the Saudi population where the 
CDKN2A/B has an important role in β-cell function and regeneration (Al-Daghri 
et al., 2013; Al-Daghri et al., 2014). The rs5215 marker in the potassium 
inwardly-rectifying channel, subfamily J, member 11 (KNJ11) gene was linked 
to be associated  with type 1 diabetes in a study by Al-Daghri, et al., (2014). 
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Table 1.1. The prevalence of diabetes in Saudi Arabia 
Study Age Gender Prevalence of 
DM (%) 
Methods Region 
of Saudi 
Fatani et al., 
1987 
14–55 male 2.9 Survey Western 
Region 
Al-Nuaim, 
1997 
>15 male 12 Urban; 7 
Rural 
 All 
Regions 
El-Hazmi et 
al., 1998 
2–77 
years 
male 5.86   All 
Regions 
(Warsy & El-
Hazmi, 1999) 
>14 
years 
male 9.7   All 
Regions 
Al-Nozha et 
al., 2004 
30–70 
years 
male 26.2  Health survey All 
Regions 
Al Osaimi, 
2007 
18–60  male 24.2 Cross 
sectional study 
Riyadh 
Al-Daghri et 
al., 2011 
7–80 male and 
female 
23.1 Cohort study Riyadh 
Alqurashi et 
al., 2011 
12≥70 male 34.1 Cross-
sectional study 
All 
Regions 
Al-Quwaidhi et 
al., 2014 
 male and 
female 
30.8 in 2013 
39.5 in 2022 
 All 
Regions 
1.1.2. Type 2 Diabetes  
Type 2 diabetes is known as non-insulin-dependent diabetes and develops 
because of insufficient production of insulin from β-cell s in the pancreas 
and/or insulin resistance, in contrast to type 1 diabetes, which is characterised 
by an absolute deficiency of insulin (American Diabetes Association, 2017). 
Type 2 diabetes can be characterised by insulin resistance. Insulin resistance 
is a pathological condition, in which the body’s cells are unable to respond 
effectively to normal levels of insulin (American Diabetes Association, 2009; 
Cubbon et al., 2016). Therefore, reduced insulin production or insulin 
resistance leads to the accumulation of glucose in the bloodstream. Insulin 
acts as a key, unlocking the cells so that they take up glucose, so if there is 
insufficient insulin, or if it is not working properly, the cells are not completely 
unlocked or they remain fully locked and glucose accumulates in the 
bloodstream (Muller-Wieland et al., 2016). 
Type 2 diabetes can be diagnosed by fasting blood glucose and glycated 
hemoglobin (HbA1c) measurements. HbA1c indicates the average level of 
blood glucose over the previous 3 months and fasting blood glucose tests 
confirm the diagnosis of diabetes (WHO, 2006; WHO, 2011). Fasting blood 
glucose test results of ≥ 7.0 mmol/L indicate a diagnosis of diabetes; and a 
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result of 6.1-7.0 mmol/L or more indicates a high risk of diabetes (WHO, 2006). 
HbA1c of 6.5% is the cut-off point for identifying diabetes. A level of HbA1c ≥ or 
8% indicates poorly controlled type 2 diabetes (Rotchford et al., 2002) (Table 
1.2).  
Table 1.2. The clinical indicators for diabetes diagnosis 
Diagnosis Fasting blood 
glucose 
HbA1c References 
High risk of diabetes 6.1–7.0 mmol/L 6–6.4% (WHO, 2006; 
WHO, 2011) Diabetes ≥7.0 mmol/L 6.5–7.5% 
Poorly controlled diabetes ≥10 mmol/L ≥8% 
1.1.3. Pathophysiology of type 2 diabetes 
The pathophysiology of type 2 diabetes is caused by a complex interplay 
between genetic and environmental factors such as poor dietary intake, 
obesity and a sedentary lifestyle (Jia et al., 2016).  
The changes in glucose metabolism by skeletal muscle and liver can affect 
normal glucose homeostasis (Lowell & Shulmanz, 2005). Hyperglycaemia can 
also increase the production of advanced glycation end products (AGEs) 
which are proteins or lipids that are glycated post exposure to sugars (Bos et 
al., 2011). AGEs and diabetes are associated with several complications, 
including oxidative stress (Codoñer-Franch et al., 2012).  
Insulin regulates carbohydrate and fat metabolism in the body and triggers 
cells in the liver, fat tissue and muscle to take up glucose from the blood and 
store it as glycogen (American Diabetes Association, 2017). Therefore, insulin 
is secreted in the body in precise amounts to remove excess glucose from the 
blood, which otherwise would become toxic (Figure 1.1). Excess glucose in 
the blood for a prolonged duration can lead to accumulation of toxic end 
products in the eye which will eventually lead to vision impairment. In addition, 
damage to blood vessels increase the risks of cardiovascular disease, which 
is a major complication associated with higher blood glucose levels (Jenssen 
et al., 2017). 
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Figure 1.1. Pathogenesis of type 2 diabetes 
Adapted from Lowell & Shulmanz, 2005. 
1.2. Diabetic complications 
Long-term of exposure to high levels of sugar and genetically determined 
susceptibility factors, such as high blood pressure and dyslipidaemia, 
accelerate the development of diabetic complications (Xu et al., 2014).  
The main conditions caused by complications of diabetes are microvascular 
diseases such as retinopathy, nephropathy, and neuropathy. In addition, 
macrovascular disease is associated with arterial accelerated atherosclerosis 
that affect the blood supply to the heart, brain and limbs (Ullah et al., 2016). 
Figure 1.2 provide a schematic overview of type 2 diabetic comlications.  
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Figure 1.2. Type 2 diabetic complications 
Adapted from Giacco & Brownlee, 2010. 
1.3. The pathogenesis of diabetic complications 
Hyperglycaemia can be recognised as a major risk of diabetic 
complications. Several mechanisms have been proposed for pathological 
alterations related to hyperglycaemia in diabetic patients. These include: 
aldose reductase (polyol) pathway, protein kinase C (PKC) pathway, the 
ooxidative stress and advanced glycation end products (AGEs) pathway 
(Giacco & Brownlee, 2010) (Figure 1.3). All of these pathways contribute to 
oxidative stress. 
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Figure 1.3. Role of hyperglycaemia in diabetic complications 
Adapted from Hadi & Suwaidi, 2007. 
1.3.1. Aldose reductase (polyol) pathway  
Two enzymatic reactions are involved in the aldose reductase (polyol) 
pathway. The first reaction entails reducing glucose molecules to sorbitol while 
the second reaction entails oxidising sorbitol to fructose (Chang et al., 2015). 
In diabetes, activation of the polyol pathway is increased resulting in 
nicotinamide adenine dinucleotide phosphate depletion, which leads to a 
reduction in cellular levels of glutathione (Berlanga-Acosta et al., 2013). 
1.3.2. Protein kinase C pathway  
Multiple isoforms of PKC such as (PKC-α, -β1, -β2, and -γ). These isoforms 
are activated by phorbol esters, calcium, DAG and phosphatidylserine (Yu et 
al., 2013). Diabetes changes the multiple PKC isoforms resulting in many 
vascular and cellular processes that are abnormal (Giacco & Brownlee, 2010). 
For instance, the basement membrane becomes thick, changes occur in 
vessel dilation, and there are endothelial dysfunctions among many others 
(Saberi et al., 2014). 
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1.3.3. Oxidative stress  
Oxidative stress is an imbalance between oxidants and antioxidants, and 
causes a reduction in antioxidant capacity (Ceriello, 2000). However, 
increased in oxidative stress could be related to complications in patients with 
diabetes such as oxidative DNA damage and insulin resistance (Furukawa et 
al., 2004; Tiwari et al., 2013). Insulin resistance leads to hyperglycaemia, 
therefore, acute hyperglycaemia increases the production of reactive oxygen 
species (ROS) (Choudhury et al., 2017). 
1.3.4. Advanced glycation end products (AGEs)  
AGEs are irreversibly formed during glycation reactions between sugar and 
protein (Singh et al., 2014). Levels of AGEs in the circulation could be a related 
to several diabetic complications (Goh & Cooper, 2008; Singh et al., 2014; 
Vikram et al., 2014). In type 2 diabetes, the majority of glycation and AGE 
formation is from glucose (Ahmed, 2005).   
1.3.4.1 Glycation Reaction 
The glycation reaction pathway starts when glucose binds to proteins forming 
glycosylation products (Babizhayev et al., 2015). The products are known as 
Schiff bases and Amadori adducts (Meerwaldt et al., 2008).  As time goes by, 
these adducts go through slow and complex rearrangements that form AGEs 
(Ott et al., 2014).  
Protein glycation occurs when a protein binds covalently to a sugar molecule 
like glucose or fructose without any enzyme controlling the reaction (Ahmed, 
2005; Vlassara & Uribarri, 2014). A compound that is unstable (Schiff base) is 
formed from the reaction between a sugar molecule like glucose and a free 
amino group of biological amines (Goh & Cooper, 2008).  The Schiff base then 
goes through rearrangement to form a compound that is more stable called an 
Amadori product (Bohlooli et al., 2016).  
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In intermediate stage, there is a breakdown of the Amadori product to a range 
of dicarbonyl compounds like methylglyoxal, glyoxal and deoxyglucosones 
that are reactive (Singh et al., 2014). This breakdown of the Amadori product 
occurs through dehydration and oxidation (Younus & Anwar, 2016). In the 
advanced stage, oxidation, dehydration and cyclisation reactions result in the 
formation of AGEs which are compounds that are stable and the reaction is 
irreversible (Narender et al., 2011). AGEs accumulate over time and interfere 
with normal physiological functions (Singh et al., 2014) (Figure 1.4).  
 
Figure 1.4. The three stages of glycation 
Adapted from (Ahmed, 2005) 
1.3.4.2. Autoxidative Glycation  
The autoxidative glycation pathway exist glucose with their enediol in 
equilibrium (Prabhakar et al., 2016). Glucose undergoes autoxidation in the 
presence of transition metals to form an enediol radical (Ahmed, 2005). This 
radical reduces molecular oxygen to generate the superoxide radical (O2•) and 
becomes oxidised itself to a dicarbonyl ketoaldehyde (Phaniendra et al., 
2015). That reacts with protein amino groups forming a ketoimine, which is 
similar to or more reactive than Amadori products, and participates in AGE 
formation (Ahmed, 2005). Oxidation reactions are also involved in AGE 
formation, which is accelerated in the presence of oxygen and reduced under 
anaerobic conditions (Singh et al., 2014) (figure 1.5). 
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Figure 1.5. Autoxidative glycation pathway 
Adapted from (Ahmed, 2005) 
1.3.4.3. AGE Receptors 
The AGEs interact with their cellular receptors to play an important role in 
developing diabetic complications (Giacco & Brownlee, 2010). AGEs possess 
cell receptors including macrophage scavenger receptors (Ahmed, 2005; Ott 
et al., 2014). The AGEs’ receptor (RAGE) is a multi-ligand receptor and a 
member of the immunoglobulin superfamily of cell surface molecules, and is 
found on smooth muscle cells, endothelial cells and astrocytes (Ramasamy et 
al., 2011; Yagihashi et al., 2011). 
Studies have shown that RAGE stimulation upregulates key transcription 
factors implicated in inflammatory responses such as NF-κB (Shamoon et al., 
1993; Chang et al., 2011). NF-κB modulates gene transcription for endothelin-
1, tissue factors and the generation of pro-inflammatory cytokines (Ahmed, 
2005; Yagihashi et al., 2011). There is also enhanced expression of adhesion 
molecules including vascular cell adhesion molecule-1 and intercellular 
adhesion molecule-1. The intracellular signalling pathways following activation 
of RAGE by AGEs (Ramasamy et al., 2011), such as the binding of AGEs with 
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RAGE in endothelial cells, show the importance of oxidative stress markers as 
NF-κB becomes activated (Shamoon et al., 1993; Ahmed, 2005) (figure 1.6). 
In chronic inflammation of tissues in diabetic patients, RAGE is implicated in 
the sustained activation of NF-κB that is likely to contribute to the chronicity 
and unrelenting nature of diabetic target cell stress and dysfunction (Yan et 
al., 2009). To examine the roles of RAGE in inflammatory mechanisms, 
experiments have been performed to illustrate the effects of RAGE deletion or 
antagonism in a range of infectious settings (Ramasamy et al., 2011). Blocking 
RAGE action was shown to be beneficial and resulted in either improved 
survival or markedly reduced tissue damage (Ramasamy et al., 2011). 
 
Figure 1.6. Interaction of AGE with RAGE on microphages induces oxidative stress 
and activation of intracellular signalling causing inflammation  
Adapted from (Ahmed, 2005; Yagihashi et al., 2011) 
1.4. Role of AGEs in the pathogenesis of diabetic complications  
AGEs are usually formed as a result of chronic hyperglycaemia (American 
Diabetes Association, 2017). Thus, with time, they accumulate in the body and 
affect the tissues leading to the development of microvascular complications 
such as diabetic neuropathy, nephropathy and retinopathy (Bos et al., 2011). 
Additionally, macrovascular complications like atherosclerosis can develop as 
well (Basta et al., 2004) Figure 1. 7.  
AGEsOxidative 
Stress 
NF-κB
RAGE
Cell activation 
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Figure 1.7. Inflammation and the presence of oxidative stress leading to diabetic 
complications 
Adapted from Vlassara & Uribarri, 2014) 
1.4.1. Diabetic Retinopathy  
Diabetic retinopathy is a complication, which could develop through AGEs. 
AGEs usually find their way into the retinal vessels of patients with diabetes. 
Once inside, they cause the basement membrane to thicken and the inner 
blood-retinal barrier to break down (Goh & Cooper, 2008). Moreover, 
abnormalities in the endothelial nitric oxide synthase expression are usually 
observed in retinal vascular endothelial cells that have come into contact with 
AGEs (Tiwari et al., 2013). This may be the factor contributing to several vaso-
regularity abnormalities that occur in the retinal microcirculation in diabetes. 
AGEs also favor the neovascularisation of the retina and cause the 
permeability to proteins across the barrier of the retina to increase (Ullah et 
al., 2016). Microaneurysm formation has also been associated with AGEs in 
various studies (Giacco & Brownlee, 2010). 
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1.4.2. Diabetic Nephropathy 
Diabetic nephropathy could develop through AGEs. AGEs in the kidneys form 
complex cross-links which may promote renal damage by stimulating the 
growth of fibrotic factors (Shera et al., 2004). AGEs also cause the structure 
of the glomerulus to change by making the basement membrane thicken, thus 
affecting normal filtration in the kidneys (Giacco & Brownlee, 2010). 
1.4.3. Diabetic Neuropathy 
Neuropathy in diabetes complication could also develop through AGEs, as 
they also find their way to the nerves and damage them. For instance, 
monocytes and endothelial cells are induced to increase cytokines and 
adhesion molecule production when the AGEs act on specific receptors 
(Babizhayev et al., 2015). AGEs also affect matrix metalloproteinases leading 
to damage of nerve fibres. The AGE-RAGE axis plays a role in some 
mechanisms that cause neuropathy, particularly in sensory deficits. Not only 
do AGEs contribute to the development of neuropathy, but they also make 
diabetic neuropathy to become worse (Singh et al., 2014), by reducing the 
sensorimotor conduction velocity. They also decrease flow of blood to the 
peripheral nerves (Babizhayev et al., 2015). 
1.4.4. Dyslipidaemia  
Dyslipidaemia is an essential part of the underlying insulin resistance. Defects 
in insulin action and hyperglycaemia lead to dyslipidaemia in patients with 
diabetes (Verges, 2015). In the case of in type 2 diabetes, the obesity/insulin-
resistant state that is at the basis of the development of this disease can lead 
to lipid abnormalities independently of hyperglycemia (Gaggini et al., 2013). 
The lipid changes associated with diabetes mellitus are attributed to increased 
free fatty acid flux secondary to insulin resistance (Verges, 2015). 
Several factors are likely to be responsible for diabetic dyslipidaemia: insulin 
effects on liver apoprotein production, regulation of lipoprotein lipase, actions 
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of cholesteryl ester transfer protein, and peripheral actions of insulin on 
adipose and muscle (Filippatos et al., 2017). The release of stored fatty acids 
from adipocytes requires conversion of stored triglyceride into fatty acids and 
mono-glycerides that can be transferred across the plasma membrane of the 
cell (Szalat et al., 2016).  
AGEs are prevalent in the diabetic vasculature and contribute to the 
development of atherosclerosis (Basta et al., 2004). AGEs accumulate in 
many different cell types that affect the extracellular and intracellular structure 
and function (Goldin et al., 2006).  They lead to macrovascular complications 
via engagement with the receptor for advanced glycation end products 
(RAGE) (Goldin et al., 2006). AGEs-bind to the RAGE and increase the 
endothelial permeability to macromolecules, promoting endothelial 
dysfunction and thus causing the levels of vascular low-density lipoproteins to 
go up (Chang et al., 2011).  High levels of LDL occur because AGEs reduce 
their uptake and hence promote the destabilisation of plaquse. Therefore, the 
development of atherosclerosis is accelerated (Schofield et al., 2016). 
 
Figure 1.8. The pathogenesis of dyslipidaemia 
(Adapted from Gaggini et al., 2013) 
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1.5. Antioxidants 
Antioxidants play a vital role in preventing the complications of diabetes.  A 
total antioxidant capacity test in plasma is a marker to assess the situation and 
the potential of oxidative stress in the body (Aouacheri et al., 2015). Plasma 
contains many compounds that indicate oxidation in the body and thus protect 
cells and biological molecules from cellular damage (Rizvi & Maurya, 2007).  
Low antioxidant capacity can be related to complications in patients with 
diabetes type diabetes 2 (Kharroubi et al., 2015). Oxidative stress in diabetes 
develops with a decrease in antioxidant status, which can increase the harmful 
effects of free radicals (Tiwari et al., 2013). 
1.6. Vitamin D  
Epidemiological data has shown that an inadequate amount of vitamin D in the 
body is commonly associated not only with diseases such as rickets, 
osteomalacia and osteoporosis, but also with cancer, heart disease and type 
1 and type 2 diabetes (Martin & Campbell, 2011). A recent report stated that 
insufficient vitamin D is associated with impaired insulin synthesis as well as 
insulin secretion (Durmaz et al., 2017). Vitamin D has two forms that are 
commonly consumed; ergocalciferol (vitamin D2) and cholecalciferol (vitamin 
D3) (Christakos et al., 2016).  
1.6.1. Vitamin D synthesis 
The synthesis of vitamin D is through pre-vitamin D3, which is unstable and 
swiftly changes through a process that is temperature regulated, so that it can 
become vitamin D3. After turning into vitamin D3, it is released from the skin 
cells into the extracellular space, where it goes to the dermal capillary bed 
through the vitamin D–binding protein (DBP) (Holick, 2004). Vitamin D enters 
the bloodstream and binds with DBP and lipoproteins (Holick, 2004). Vitamin 
D is discharged from DBP to the liver and undergoes hydroxylation through 
the vitamin D-25-hydroxylases (25-OHase) to 25-hydroxyvitamin-D (25(OH)D) 
(Holick, 2004). 25(OH)D is the primary circulating form of vitamin D that can 
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be used to measure a person’s vitamin D level because, it has a half-life in the 
circulation of 2 weeks and it correlates with secondary hyperparathyroidism, 
rickets, and osteomalacia (Holick, 2006). 
25(OH)D is linked with DBP, and this complex links further to megalin on the 
plasma membrane of the renal tubule cell and is transferred into the cell 
(Holick, 2004). While inside the cell, 25(OH)D is released and is changed in 
the mitochondria by the 25-hydroxyvitamin D-1α-hydroxylase to generate 25-
dihydroxyvitamin D, or 1,25(OH)2D, which is the biologically active form of 
vitamin D responsible for maintaining calcium and phosphorus homeostasis 
(Holick, 2006). It attains this through interacting with the nuclear receptor, the 
vitamin D receptors (VDR) that are located in the cells of the small intestines 
(Holick, 2006). The 1,25(OH)2D–VDR structure combines with the retinoic 
acid X receptor (RXR) in the nucleus to create the vitamin D complex. The 
1,25(OH)2D-VDR-RXR complex merges with the vitamin D-responsive 
element (VDRE) for the epithelial calcium channel (Holick, 2006). The 
augmented expression of the calcium channel allows more calcium to enter 
the cell, where the vitamin D–dependent calcium-binding protein calbindin 9K 
assists calcium’s movement into the bloodstream (Holick, 2006). 
 
Figure 1.9. Vitamin D synthesis 
(Adapted from Bikle, 2012) 
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1.6.2. Vitamin D Deficiency in Saudi Arabia  
The prevalence of vitamin D deficiency is high among Saudi Arabian men. 
Vitamin D deficiency was 72.4% in men (Ardawi et al., 2012). Vitamin D 
deficiency was determined by levels of 25-hydroxy vitamin D (25OHD): The 
studies of Saudi Arabian men define deficiency as a 25(OH)D serum 
concentration of ≤ 20 ng/mL, insufficiency as a serum level between > 20ng / 
mL and < 30ng / mL and normal as a serum level ≥ 30 ng / mL (Sadat-Ali et 
al., 2009). 
Table 1.3. Cut-off points of Vitamin D concentration 
Vitamin D 
concentration 
(ng/mL) 
Vitamin D 
concentration 
(nmoL/L) 
Classification References 
<20  <50 Deficiency (Hollis, 2005; 
Alshahrani & 
Aljohani, 
2013) 
20-32  50–80 Insufficiency 
32-54  80-135 Normal 
54-90  135–225 Normal in sunny countries 
>100  >250 Excess 
>150  >325 Intoxication 
1.6.3. Role of Vitamin D in diabetes  
Vitamin D affects β-cell function (there are particular vitamin D receptors in 
pancreatic cells, the 1-α-hydroxylase enzyme exists in pancreatic cells and 
there is a vitamin D reaction element in the human insulin gene promoter) 
(González-Molero et al., 2012). Another pathway is that vitamin D can adjust 
insulin sensitivity (vitamin D triggers the expression of insulin receptor and 
enhances insulin responsiveness for glucose transport in vitro and contributes 
to the normalisation of extracellular calcium by ensuring normal calcium influx 
through the cell membranes) (Kulie et al., 2009). Vitamin D stops systemic 
inflammation by combining with the promoter region of cytokine genes to 
impede nuclear transcription factors that can lead to cytokine generation and 
action) (González-Molero et al., 2012). An active form of vitamin D (dihydroxy 
vitamin D3), in the blood, binds to the vitamin D receptor on pancreatic β-cell 
s and boosts insulin receptor expression, which can enhance insulin sensitivity 
(Thacher & Clarke, 2011). 
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Table 1.4. The role of vitamin D 
Gene Action References 
VDR Transcription factor when bound to 1,25-
dihydroxyvitamin and affects insulin resistance, 
both with regards to insulin secretion  
(Sung et al., 2012; 
Vangoitsenhoven et 
al., 2016; 
Nakashima et al., 
2016; Angellotti & 
Pittas, 2017) 
DBP The serum carrier of vitamin D metabolites 
1α-hydroxylase Involved in the metabolism of vitamin D, may 
influence the susceptibility to type 2 diabetes  
1.6.4. The potential mechanisms of vitamin D in type 2 diabetes 
The potential mechanisms of vitamin D are that deficiency of both vitamin D 
and calcium intake may alter the balance of normal insulin release, especially 
in response to glucose load, which may interfere with extra-cellular and 
intracellular β-cell calcium pools (Pittas et al., 2007b). The beneficial effects of 
vitamin D have been demonstrated in both β-cell function and insulin 
sensitivity studies (Kampmann et al., 2014). It is suspected that vitamin D 
deficiency might induce higher inflammatory responses and the associated 
insulin resistance. Therefore, this study supports the assumption that a 
decrease in vitamin D levels in the body can elevate the chances of type 2 
diabetes developing.  
The effects of vitamin D and calcium on glucose control in patients with type 2 
diabetes has been reported by Pittas et al., (2007b), who conducted a 
MEDLINE review in January 2007 of clinical trials and observational studies in 
adults, where the outcome was related to glucose homeostasis. They 
conducted a meta-analysis study and proposed that a lack of vitamin D and 
calcium interrupts or pauses glucose control and that nutrient supplementation 
could be essential to improving glucose management. This suggests that 
calcium and/or vitamin D may have a role in the future management of type 2 
diabetes. In a randomised trial in the UK, Sugden et al. (2008) studied the 
impact of a single dose of 2500 µg vitamin D2 or placebo for participants with 
type 2 diabetes. Sampling had a mean age of 64 years and a baseline intake 
of 25(OH)D of 38 nmol/L. They observed that vitamin D2 enhanced endothelial 
function, and noted the absence of considerable variation between groups for 
glycaemic control or insulin sensitivity.  
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A) Insulin resistance  
Vitamin D may have a beneficial effect on insulin action (Sung et al., 2012), 
directly, by stimulating the expression of insulin receptors and thus enhancing 
the ability to respond to insulin to transport glucose (Maestro et al., 2000). 
Indirectly, through its role in extracellular calcium regulation, vitamin D ensures 
the normal flow of calcium through the cell membranes and cytosolic calcium 
pools because calcium is necessary for the operation of cell-mediated insulin 
responses in tissues such as skeletal muscle and adipose tissue (Alvarez & 
Ashraf, 2010). 
B) β-cell 
The role of vitamin D in pancreatic β-cell function has direct and indirect effects 
(Al-Shoumer & Al-Essa, 2015). The direct effect is where vitamin D binds 
directly to the β-cell vitamin D receptor. The indirect effect is through calcium 
regulation and the influx of extracellular calcium in β-cells (Wolden-Kirk et al., 
2011; Sung et al., 2012). 
 
Figure 1.10. The effect of vitamin D on insulin resistance and β-cell function 
(Adapted from Van Belle et al., 2013) 
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1.6.5. Intervention studies of vitamin D and type 2 diabetes 
Intervention studies have shown that vitamin D supplementation may increase 
insulin resistance in patients with type 2 diabetes and may improve their 
diabetic metabolic control (Martin & Campbell, 2011; Sugden et al., 2008; Al-
Shoumer & Al-Essa, 2015), table 5.1.  
A 50µg / day dose of vitamin D3 for 16 weeks in 92 American adults produced 
a slight improvement in β-cell function (Mitri et al., 2011).  A total of 59 non-
diabetic, overweight and obese Saudi adults were recruited (31 men, 28 
women), who took a similar dose of vitamin D3 for 18 months (Al-Daghri et al., 
2012a) had a favourable outcome in the HDL/LDL ratio and HOMA-β function, 
which were found to be beneficial for insulin levels. Another study comprising 
100 Iranians (70 women and 30 men) who took 1250 µg / week of vitamin D3 
for 8 weeks (Talaei et al., 2013) found that this supplementation level had a 
significant effect on insulin resistance, and the fasting plasma glucose was 
significantly reduced. 
Nazarian et al., (2011) studied the outcomes of high-dose vitamin D3 
supplements on insulin sensitivity in subjects with vitamin D deficiency and 
impaired fasting glucose levels, eight of whom were classed as pre-diabetic. 
Participants were given 250 µg / day of vitamin D for 4 weeks. The findings 
showed that the acute insulin response to glucose was reduced significantly 
and insulin sensitivity was enhanced. The authors concluded that high-dose 
vitamin D3 supplementation improved insulin sensitivity in subjects with 
impaired fasting glucose. Thus, in relation to public health, it has been 
recommended that high-dose vitamin D3 might deliver an economic means of 
averting the transition from impaired fasting glucose to diabetes (Nazarian et 
al., 2011). However, an intake of 17.5 µg / day of vitamin D3 and 500 mg / day 
of calcium citrate prevented an increase in plasma glucose and insulin 
resistance in patients with impaired fasting glucose levels compared with 
patients treated with a placebo, and found that fasting glucose was unchanged 
in non–glucose-impaired subjects (Pittas et al., 2007). Support for the findings, 
of no effects being evident on blood glucose and/or insulin metabolism in non-
diabetic subjects when vitamin D levels were corrected has come from Tai et 
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al., (2008). It has also been that an intake of 20µg / day of vitamin D does not 
prevent the development of type 2 diabetes (Avenell et al., 2009).  
Table 1.5. Intervention studies of vitamin D on glycaemia in diabetes 
Study Intervention sample Outcome 
Sugden et al., 
(2008) 
2500µg/week 
vitamin D2 for 8 
weeks 
34 subjects 
 
Significantly improved 
Tai et al., 
(2008) 
250µg vitamin D3 
over 2 weeks 
33 subjects No effect on glycaemia 
Jorde et al., 
(2009) 
1000µg/week 
Vitamin D3 or 
placebo for 6 
months 
36 subjects with 
T2DM 
No significant effects on 
glucose metabolism  
Gallagher et 
al., (2009) 
20µg vitamin D 
24 to 62 months 
5,292 subjects in 
England and 
Scotland 
No improvement in 
glycaemia 
Nagpal et al., 
(2009) 
3000µg of vitamin 
D3 over 6 weeks 
41 male subjects Increased insulin sensitivity  
Nazarian et al., 
(2011) 
250µg/day vitamin 
D3 
4 weeks 
8 subjects (3 men, 
5 women) 
Improved insulin sensitivity 
in subjects with impaired 
fasting glucose 
Nikooyeh et 
al., (2011) 
Fortified yogurt 
drink (25 µg /d 
vitamin D3), or 
fortified yogurt 
drink (25 µg /d and 
calcium 500 mg/d) 
or plain yogurt 
drink for 12 weeks 
90 patients with 
T2DM 
Fasting serum glucose, 
HOMA-IR and HbA1c 
decreased significantly 
more in both vitamin 
D groups than in the plain 
yogurt group  
Mitri et al., 
(2011) 
50µg/day vitamin 
D3  
For 16 weeks 
92 American 
adults 
Slight improvement in β-cell 
function 
Al-Daghri et 
al., (2012a) 
50µg vitamin D 
 for 18 months 
92 type 2 Saudi 
diabetics (34 men, 
58 women) 
Improved insulin levels 
more in women than men. 
Breslavsky et 
al., (2013) 
25µg/day vitamin 
D3 or 
placebo 
for 12 months 
32 subjects  
 
No improvement in glucose 
homeostasis parameters 
Talaei et al., 
(2013) 
1250µg/week 
vitamin D3 
8 weeks 
100 Iranians (70 
women and 30 
men) 
Significant effect on insulin 
resistance 
fasting plasma glucose 
Study Intervention sample Outcome 
Elkassaby et 
al., (2014) 
150 µg /d vitamin 
D3 or placebo 
6 months 
50 patients with 
type 2 diabetes 
Improvement of fasting 
plasma glucose after 3 
months that not shown 
after 6 months 
Ryu et al., 
(2014) 
25 µg /d vitamin D3 
or placebo after 24 
weeks 
158 Korean 
patients with 
T2DM 
No effect on glycaemic 
control 
Jehle et al., 
(2014) 
7500 µg vitamin D3 
or placebo for 6 
months 
55 patients with 
T2DM 
Insulin sensitivity (HOMA-
IR) and HbA1c improved in 
the vitamin D group 
Tabesh et al., 
(2014) 
1250 µg /week 
vitamin D3, calcium 
118 patients with 
T2DM  
Significant decrease in 
serum insulin, HbA1c, 
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1000 mg/d, or 
placebo for 8 
weeks 
 HOMA-IR, and LDL 
cholesterol, and an 
increase in β-cell 
function 
Sadiya et al., 
(2015) 
150 µg /d vitamin 
D3 for 3 months 
followed by 
75 µg /d for 3 
months or placebo 
for 6 months 
87 vitamin D 
deficient obese 
patients with 
T2DM 
No effects on fasting blood 
glucose, HbA1c  
Krul-Poel et al., 
(2015b) 
1250 µg /month 
vitamin D3  
or placebo  
for 6 months 
261 non-insulin 
dependent T2DM 
Significant 
decrease of HbA1c after 6 
months in the vitamin D 
group compared 
with the placebo group 
1.6.6. Intervention studies of vitamin D and dyslipidaemia 
Intervention studies have found an association between vitamin D 
supplementation and improvement in dyslipidaemia (Alkharfy et al., 2013; 
Mohamad et al., 2016). Dyslipidaemia is a major risk factor in developing 
cardiovascular disease (Paciaroni et al., 2007). Vitamin D deficiency has been 
related to an increase in total cholesterol and increase in triglycerides (Martins 
et al., 2007; Karhapaa et al., 2010; Chaudhuri et al., 2013), Table 1.6. 
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Table 1.6. Effect of vitamin D intervention studies on dyslipidaemia in diabetes 
Study Intervention sample Outcome 
Jorde & 
Figenschau 
(2009) 
1000 µg / week 
of vitamin D for 
6 months 
36 T2DM patients No change in lipid profiles 
Ponda et al., 
(2012) 
1250 µg / week 
of vitamin D for 
8 weeks 
151 subjects with 
high risk of 
cardiovascular 
disease 
No effect on the lipid profile  
Talaei et al., 
(2013) 
1250 µg / week 
of vitamin D for 
8 weeks 
100 Iranian T2DM 
patients 
No  change in the levels of serum 
total cholesterol, LDL, HDL or 
triglycerides  
Alkharfy et al., 
(2013) 
50µg vitamin D 
daily for 12 
months 
499 Saudi T2DM 
patients 
Significant improvements in serum 
triglycerides and total cholesterol, 
as well as HDL in men 
Breslavsky et 
al., (2013) 
25µg / day of 
vitamin D for 12 
months 
24 T2DM subjects No significant result in serum total 
cholesterol, LDL, HDL and 
triglycerides levels. 
Eftekhari et al., 
(2014) 
0.25 µg of 
vitamin D twice 
per day or 
placebo tablets 
for 12 weeks 
70 Iranian T2DM 
subjects 
No statistically significant changes 
between all the variables of groups 
Ramiro-
Lozano & 
Calvo-
Romero, 
(2015) 
400 µg of 
vitamin D per 
week for 2 
months 
28 T2DM patients Not statistically significant changes 
Mohamad et 
al., (2016) 
112.5µg /day of 
vitamin D for 8 
weeks 
100 T2DM patients Significant increase in serum HDL 
and significant decrease in total 
cholesterol and LDL levels 
Sadiya et al., 
(2015) 
150 µg / day of 
vitamin D for 12 
weeks, then 
another 75 µg / 
day for 12 
weeks 
87 Emirati obese 
T2DM patients 
No effect on the lipid profile 
1.6.7. Intervention studies of vitamin D and oxidative stress 
Evidence of the action of vitamin D against oxidative stress has been 
established. A study by Salum et al. (2013) compared diabetic rats that 
received 12.5 µg/day of vitamin D3 for 10 weeks with untreated diabetic rats. 
The researchers found there was a significant improvement in the total 
antioxidants in diabetic rats with an intake of vitamin D3 compared with 
untreated diabetic rats (P < 0.001). A Turkish study of 23 subjects deficient in 
vitamin D who took 250 µg/day of vitamin D3 for 12 weeks, determined that 
vitamin D had a significant effect on reducing oxidative stress (Tarcin et al., 
2009).  
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Table 1.7. Effect of vitamin D intervention studies on oxidative stress in diabetes 
Study Intervention sample Outcome 
Salum et al. 
(2013) 
12.5µg/day of 
vitamin D3 for 
10 week 
Diabetic rats  Significant improvement in the 
total antioxidants P<0.001 
Tarcin et al., 
(2009) 
250µg/day of 
vitamin D3 for 
12 weeks 
23 Turkish 
subjects  
Significant effect on reducing 
oxidative stress 
Yiu et al., 
(2013) 
125µg/day 
vitamin D3 for 
12 weeks 
100 Hong 
Kong subjects  
No significant effect on serum 
biomarkers of inflammation and 
oxidative stress with T2DM 
Eftekhari et al., 
(2014). 
0.25 µg of 
vitamin D twice 
per day or 
placebo tablets 
for 12 weeks 
70 T2DM 
patients 
Reduction of malondialdehyde, 
but not statistically significant 
Nikooyeh et 
al., (2014) 
Fortified yogurt 
drink (25 µg/d 
vitamin D3), or 
(25 µg/d and 
calcium 500 
mg/d) or plain 
yogurt drink for 
12 weeks 
90 T2DM 
subjects aged 
30-50 years 
Significant decrease in serum 
AGEs and increased levels of the 
antioxidant superoxide dismutase 
Krul-Poel, 
Agca, et al., 
(2015a) 
1250µg/month or 
a placebo for 6 
months 
245 patients 
with T2DM 
No effect observed on skin AGE 
accumulation compared to the 
placebo 
Shab-Bidar et 
al., (2015) 
Fortified yogurt 
containing 25µg 
of vitamin D3 and 
after 12 weeks 
100 T2DM 
patients 
Significant improvement in serum 
total antioxidant capacity and 
malondialdehyde 
1.7. Aims and Objectives  
1.7.1. Aims  
The purpose of this study is to test whether vitamin D3 supplementation can 
reduce the parameters of glycaemia, oxidative stress and lipoedema in Saudi 
men aged 18 to 60 years with poorly controlled T2DM. Study participants were 
divided into three study groups and evaluated for 16 weeks. One group 
received a placebo, the second group a vitamin D supplement with a dose of 
50µg and the third group a supplement with a dose of 100µg. 
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1.7.2. Objectives 
• To study the effect of vitamin D3 supplementation on glycaemia, 
including blood glucose levels, insulin levels and glycated haemoglobin 
(HbA1c). 
• To study the effect of vitamin D3 supplementation on lipidaema, including 
low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides 
and total cholesterol.  
• To study the effect of vitamin D3 supplementation on oxidative stress, 
including total antioxidant levels and advanced glycation end products 
(AGEs).  
  
28 
 
 
 
 
 
 
 
 
 
 
Chapter 2 Methods and materials 
 
 
 
 
 
  
29 
2.1. Materials, equipment and software  
2.1.1. Materials 
§ Microcrystalline cellulose placebo; 50µg vitamin D3; 100µg vitamin D3  
(Metabolics Ltd, Devizes,UK) 
§ 96-well microtitre plate format (Eppendorf, Germany) 
§ Uric acid standard 100mg; reaction buffer 400uL; copper ion reagent 1.0mL; stop 
solution 1.5mL (Cell Biolabs, USA) 
§ 1N NaOH (Sigma Aldrich, USA)  
§ Albumin (BCP) kit (Konelab i20, Finland) 
§ HbA1c DCA Vantage Analyzer (Siemens, Germany) 
§ Calcium kit (Konelab i20, Finland) 
§ Glucose (GOD-POD) kit (Konelab i20, Finland) 
§ Cholesterol kit (Konelab i20, Finland) 
§ Triglycerides kit (Konelab i20, Finland) 
§ HDL-Cholesterol Plus kit (Konelab i20, Finland) 
§ Insulin immunoassay kit (Roche Diagnostics, USA) 
§ Total vitamin D immunoassay kit (Roche Diagnostics, USA) 
§ Eppendorf tubes (Eppendorf company, Germany) 
§ Sterile Gloves (Ansell, Canada) 
§ Deionised water (Local store, Saudi Arabia) 
2.1.2 Equipment  
§ Automated electrochemiluminescence assays (Roche Cobas E401, USA) 
§ OxiSelect TAC assay kit (Cell Biolabs, USA) 
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§ Pipettes (Eppendorf, Germany) 
§ Spectrophotometric microplate reader (BioTek, USA) 
§ AGE reader (Diagnoptics Technologies B.V., Groningen, The Netherlands) 
§ 50uL to 300uL adjustable single and multichannel micropipettes (Eppendorf, 
Germany) 
§ Standard tape measure (Seca, Germany) 
§ Free-standing stadiometer (Seca, Germany)  
§ Weighing scales (Seca, Germany) 
§ 21G syringe needles (BD, USA) 
§ EDTA, serum and lithium heparin tubes for blood collection (BD Vacutainer®, 
USA) 
§ Centrifuge 5702 (Eppendorf, Germany) 
§ Laboratory freezer – 20C (Philip Kirsch, Germany) 
§ Laboratory freezer - 80C (Philip Kirsch, Germany) 
§ Laboratory fridge (Philip Kirsch, Germany) 
§ Orbital shaker (Labtech, Korea) 
§ Informed consent form (see appendices)  
§ Pre-screening questionnaire (see appendices) 
§ Supplement recording calendar (see appendices) 
§ Debriefing questionnaire (see appendices) 
§ Blood analysis flow chart (see appendices) 
2.1.3 Software  
§ Microsoft Office 2013 (Microsoft, USA) 
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§ Statistics Package for Social Sciences (SPSS, version 24 for Windows, Chicago, 
USA) 
§ Microsoft Excel 2013 (Microsoft, USA) 
§ Powerful statistical software (Minitab 17) (Minitab Inc, USA) 
§ Microsoft Paint 2013 (Microsoft, USA) 
§ BMI calculator (NHS Tools, UK) 
2.2. Ethical approval 
Ethical approval was granted by the Faculty Research Degrees office of 
Manchester Metropolitan University on 1st of May 2014 (SE121327A1) 
appendix 1. The research was approved by King Fahad Medical City (KFMC) 
on 1st April 2014 in Riyadh appendix 2. The clinical laboratory was approved 
to analyse the blood samples by Prince Mutaib, Chair for Biomarkers of 
Osteoporosis, King Saud University, Riyadh, KSA on 15th May 2014 
(4/67/429706) appendix 3.  
In addition, the study had to be registered in the Saudi clinical trials registry 
(SCTR) appendix 4, application #14062303, in order to clear the supplement 
products for entry to Saudi by the Saudi Food and Drug Authority (SFDA) on 
18th August 2014 appendix 5. These ethics approvals can be found as 
appendices 1-5. 
2.3. Study design  
The study was conducted over 16 weeks and took the form of a randomised 
double-blind clinical trial in order to avoid any potential bias. If researchers 
know that they are administering a placebo, they may convey doubts about its 
effectiveness to the subject (Schulz & Grimes, 2002). In double-blind clinical 
trials, it is often necessary to blind products using over-encapsulation. Double-
blind designs can also increase the number of units a patient needs to take 
each day.  
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Figure 2.1. Flowchart of the parallel-randomised trial of the three groups 
Individuals in the vitamin D groups received 100µg or 50µg vitamin D3 per day, and those in 
placebo received a cellulose tablet per day as controls, at study baseline to the 16 weeks of 
the intervention.  
2.4. Total sample size 
A power analysis was conducted using G*Power 3 software (Faul et al., 2009) 
to determine the minimum total sample size for conducting two mixed ANOVA 
repeated measurements between the groups in this study. For this study, the 
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measurements were repeated at two different times (baseline and after 16 
weeks) between the three groups (A, B and C).  
G*Power 3 computed that a minimum total sample size of n=120 patients was 
necessary to correctly test the hypotheses of two mixed ANOVA repeated 
measurements between the groups at the conventional α=0.05 significance 
level and an effect size=0.25. To make allowances for the expected loss of 
patients and missing patients between the baseline and final measurements, 
a further 20% was added, so that the total sample size at the baseline should 
be about n=144. Had the loss of patients during the trial been more than 20%, 
then the results would have been invalid and not been publishable (Schulz & 
Grimes, 2002; Thoma et al., 2010). 
2.5. Intervention trial 
The patients were randomly assigned to receive one of three oral treatments: 
100µg/day of vitamin D3 (Group A), 50µg/day of vitamin D3 (Group B), or a 
placebo (Group C) as control. This placebo contained only microcrystalline 
cellulose as used previous studies (Pittas et al., 2007; Zhu et al., 2012; Asemi 
et al., 2016). Cellulose was chosen as the placebo because it cannot be 
absorbed by the body and it binds the ingredients of the supplement together 
as well as being used as a filler (Grossmann & Tangpricha, 2010; Kaptchuk et 
al., 2010). Including a placebo group in a trial provides a normal baseline of 
serum vitamin D and shows any fluctuations throughout the seasons. This type 
of study has been particularly that the doses of vitamin D you have used have 
been successful in previous studies to raise blood concentrations of vitamin D 
(Nagpal et al., 2009; Mitri et al., 2011; Beilfuss et al., 2012; Aljohani, 2016).  
The patients were randomly allocated to one of the three intervention groups 
to avoid selection bias (Misra, 2012), and were recruited by requests 
introduced at their follow-up appointment with the diabetic specialist. These 
arrangements were distributed by an unprejudiced third party (Biostatistician 
Specialist at KFMC) to this investigation by block randomisation methods 
(Suresh, 2011).  
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Block randomisation design was used allocate a balanced number of subjects 
to each group by Excel (Kim & Shin, 2014). It is recommended to apply this 
method when total sample numbers are more than 100 (Kim & Shin, 2014). 
The allocator must conceal the block size from the executer and utilise 
randomly blended block sizes (Kim & Shin, 2014). In this study, 13 blocks, 
each of 12 patients, were used for a total for 156 patients (appendix 11). This 
randomisation was done by a third party at the clinical pharmacy of KFMC, 
and disguised the allocation to the groups from the diabetic consultant and 
researcher, subsequently reducing the bias further.  
A clinical pharmacist prepared tablets “A", “B" or "C" and placed them into 
bottles as indicated by the distribution orders. In addition, the diabetic 
consultant, researcher and patients were all blinded to which meeting would 
be allocated with which supplement dosage or placebo tablets, all tablets and 
packaging appearing identical. Blinding has been a key feature of trials 
examining vitamin D3 supplementation on controlling diabetes with a particular 
effort to avoid bias (Pittas et al., 2007; Nagpal et al., 2009; Mitri et al., 2011; 
Krul-Poel et al., 2015b; Sadiya et al., 2015). 
2.6. Safety doses of vitamin D 
A safety margin of vitamin D is recommended to avoid toxicity as consequence 
of hypercalcaemia, though, this is problem is very rare (Ozkan et al., 2012). 
There is an upper safety limit of 250 µg/day for vitamin D supplementation to 
avoid unfavourable results (Hathcock et al., 2007; Vogiatzi et al., 2014). In our 
study, the doses of vitamin D3 supplementation were 50µg or 100µg/day so all 
supplementation was within the safe dose limit. Corrected calcium levels were 
measured before the intervention commenced and patients who had a higher 
corrected calcium level were excluded from the intervention study to avoid 
hypercalcaemia. 
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2.7. Recruitment and setting of the trial 
The study was conducted in the outpatient clinic of King Fahad Medical City in 
Riyadh, Saudi Arabia. Patients with T2DM, aged 18–60 years old, were 
recruited to take part in the study over a 16-week period, following invitations 
to consecutive clinical attenders. 
The researchers and nurses then conducted interviews so the consent forms 
and the medical questionnaires could be completed, and made the 
anthropometric measurements and took AGE readings for each patient who 
was included in the study. Subjects were randomly assigned to individual 
recalls based on their subject number and follow-up appointment. Following 
collection of all data, all participants were given presentations about the study 
by the researchers, who then helped them to fill out a questionnaire, and 
explained how to fill in a supplement-recoding calendar at baseline. Then, 
patients collected their intervention supplement tables from the pharmacy 
window after the consultant prescribed the blinded supplements for this study 
by special code of this trial in KFMC the system. These codes were made 
available to the clinical pharmacy by a special system in KFMC.  At the end of 
the study, the researchers and nurses filled out a debriefing questionnaire, and 
recorded the anthropometric measurements and AGE readings for each 
patient.  
Patients’ demographic data and medication before and after supplementation 
was recorded. They were advised to maintain their usual diet and about other 
habits that could affect their level of vitamin D and metabolism, as well as 
being advised to avoid taking any supplements during the study. Blood 
samples were taken both at baseline and at the end of the study by a 
phlebotomist.  
Laboratory tests were carried out by trained laboratory staff at the clinical 
laboratory in the Prince Mutaib Chair for Biomarkers of Osteoporosis, King 
Saud University, Riyadh, Saudi Arabia. Study coordination, statistical analysis 
and subsequent work were undertaken at Manchester Metropolitan University. 
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2.8. Inclusion and exclusion criteria  
All participants were Saudi men with T2DM with the following inclusion criteria: 
a glycated haemoglobin (HbA1c) > 8 mmol/L (Talaei et al., 2013), a BMI > 25, 
an age between 18 and 60 years (Mitri et al., 2011) Al-Daghri et al., 2012) and 
being of Saudi Arabian origin.  
All subjects with renal disease, diabetes mellitus type 1, major systemic 
illnesses such as gastrointestinal malabsorption, parathyroid disease, 
hypercalcaemia, or diabetes requiring medication, were excluded from the 
present study. Participants who do not use all the capsules were defined as 
non-compliant and excluded from the study (Table 2.1). 
Table 2.1. Inclusion and exclusion criteria of the intervention study 
Inclusion criteria Exclusion criteria 
18 - 60 years Major systemic illness such as renal disease 
HbA1c> 8% Diabetes mellitus type 1 
BMI > 25 Diabetes requiring medication including vitamin D supplements  
Saudi citizen Participants who may have altered their hypoglycaemic 
medication during study  
2.9. Consent forms  
The consent form sheets showed the trial information to make sure all subjects 
were convinced to be a part of the intervention (Hernandez et al., 2014). 
Consent forms should be written in simple language to avoid 
misunderstanding, particularly with literacy levels (Gupta, 2013).  The best 
consent forms demonstrate a brief overview of a study with the focus on 
important points (Grady et al., 2017). In this study, the consent form sheets 
were given to subjects and the researcher explained to them how the 
intervention study worked. Subjects had a one-to-one interview with 
researchers to fully understand the study pathway at all stages. Before the 
subjects signed the consent sheet to be part of this study, researcher asked 
them to make sure if they accepted or declined (Appendix 7).   
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2.10. Pre-study screening questionnaire 
Potential participates attended a meeting with the researcher where their 
eligibility for the study was assessed. The researcher sat with the potential 
patients and first checked if they met the inclusion criteria, then those who did, 
completed the pre-study screening questionnaire with the researcher.  
The pre-study screening questionnaire asked questions were simple and 
translated so as to be understandable. It was recommended to be not too 
formal and not too medical. (Sullivan, 2011). The present study questionnaire 
was in two categories. The first category was the personal information, were 
the questions were closed and the participant chose the appropriate answer 
(Tonna et al., 2007). Some questions were open-ended but these are hard to 
analysis. (O'Cathain & Thomas, 2004) 
The questionnaires were conducted via a face-to-face interview with the 
researcher to make sure that any misunderstanding that could lead to 
unanswered questions could be solved (Patterson et al., 2015). The 
questionnaires covered basic background to indicate the patient’s gender, 
age, marital status, education, employment and smoking status. It also 
indicated the medical condition and the patient’s intake of vitamin D for the 
three months prior the study. (Appendix 8). 
2.11. Anthropometric measurements  
Body mass index (BMI) is a strong tool to predict the percentage of body fat 
and incidence of T2DM (Schulze et al., 2012). It measures the body fat based 
on height and weight that applies to adults and is universally expressed in units 
of kg/m2 (Gorstein & Akre, 1988).  
2.12. Advanced glycation end products (AGEs) 
A skin autofluorescence reader was used to measure tissue AGEs. 
Autofluorescence has been validated against AGE measurements by skin 
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biopsies from the site of skin autofluorescence measurements (Meerwaldt et 
al., 2005; Bos et al., 2011; Krul-Poel et al., 2015b).  
This is a method of assessing AGE levels within the skin in less than 30 
seconds and is a non-invasive procedure. The AGE reader has a UV light 
source which penetrates the skin to a depth of 1 mm. The AGEs become 
excited, and emit auto-fluorescence at particular wavelengths. The 
wavelengths of auto-fluorescence produced by the AGEs, and its intensity, 
correlate to the quantity of AGEs present within the skin tissue (Diagnoptics, 
2012).  
2.13. Blood collection  
Subjects were asked to fast overnight (at least 8 hours with no food or 
beverage). Venous blood samples were required for each patient and were 
taken by registered phlebotomists in the procedure room in KFMC next to the 
clinic, using an aseptic technique.  A normal 4 mL vacutainer tube was used 
to collect the sample for serum insulin and vitamin D tests and a 2 mL 
vacutainer tube with EDTA was used to get whole blood for glycated 
haemoglobin (HbA1c) tests. A 4 mL vacutainer containing lithium and heparin 
was to collect the blood sample to test lipids, fasting glucose, calcium, albumin 
and antioxidant levels. All blood samples were obtained within a consistent 
time period and the patient’s information was recorded on these containers as 
Name, Date of Birth and Hospital number (or equivalent) for identification. The 
withdrawn blood was taken to lab to be centrifuged and kept in the freezer at 
- 20°C until end of each week. All samples were then transferred to store off-
site at the laboratory of the Prince Mutaib Chair for Biomarkers of 
Osteoporosis, King Saud University at a temperature of -80°C until the 
intervention study had finished. The researcher along with clinical technicians 
ran all the samples to analyse them. 
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2.14. Supplement compliance  
In this intervention study, patients were followed up using a supplement 
calendar sheet (Jimmy & Jose, 2011) (Appendix 10). It is technique helpful to 
measure compliance at the end of a study (Hubbard et al., 2012). Previous 
intervention studies have used the same technique of supplement calendar 
sheets (von Hurst et al., 2010). There were follow-up phone messages to 
remind the patients to take their medication as directed. Patients were asked 
to take their vitamin D or placebo capsules after a meal with water.  
Compliance was assessed through interviews and the number of unused 
capsules that were returned in the tablet bottle to the clinical pharmacy. 
Participants who did not use 80% of the capsules were defined as 
noncompliant and excluded from the study (Dodd & Webb, 2000). Subjects 
reported difficulty in taking 4 capsules per day for 6 months (von Hurst et al., 
2010). This was taken into account in the present study to reduce the number 
of capsules, as this could negatively affect compliance. 
2.15. Debriefing questionnaire 
The debriefing questionnaire contained questions about the need for 
assistance and the presence of questionnaire items which were confusing, or 
difficult to answer. The questionnaire was used assess how easy the 
participants found it to comply with the study, any changes in medical status 
or medication, and any changes to diet. It also invited comments for any other 
information or opinions patients might wish to give (Bjordal et al., 2000). 
(Appendix 9).  
2.16. Blood analysis 
All methods were in accordance with the procedures in place and the clinical 
laboratory and information were received at the Prince Mutaib Chair for 
Biomarkers of Osteoporosis, King Saud University, Riyadh, Saudi Arabia. 
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Storage and deposition of blood samples followed the Human Tissue Act and 
Manchester Metropolitan University guidelines.  
 
Figure 2.2. Blood analysis flowchart 
2.16.1. Measurement of vitamin D concentration 
The technique that was used in this study was a competitive 
electrochemiluminescent protein-binding assay (Orwoll et al., 1994; Pittas et 
al., 2007). Analysis was carried out using a Roche Cobas E411 analyser. 
Controls for the various concentration ranges were run individually at least 
once every 24 hours when the test is in use, once per reagent kit, and following 
each calibration. This was designed to measure total vitamin D concentration 
(25-OH-vitamin D) in serum or plasma (see the insert sheet in Appendix 12). 
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2.16.2. Measurement of the corrected calcium concentration 
Corrected calcium concentration was calculated after analysis of the calcium 
and albumin blood tests using a chemical analyser by Konelab 20. It was a 
fully open system which allows for a fully flexible solution to meet any 
colorimetric or enzymatic requirements (see insert sheets in Appendix 13 and 
14). The calibration was by an automated series dilution from a stock 
calibrator.  
Corrected calcium was calculated using the formula of Jain et al. (2008): 
𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑	𝑡𝑜𝑡𝑎𝑙	𝑐𝑎𝑙𝑐𝑖𝑢𝑚	(𝑚𝑚𝑜𝑙/𝐿)= 	𝑡𝑜𝑡𝑎𝑙	𝑐𝑎𝑙𝑐𝑖𝑢𝑚	(𝑚𝑚𝑜𝑙/𝐿) + 	0.01	[30	(𝑔/𝐿) − 	𝑎𝑙𝑏𝑢𝑚𝑖𝑛	(𝑔/𝐿)] 
2.16.3. Measurement of fasting blood glucose concentration 
Fasting blood glucose was measured using a chemical analyser (Konelab) 
(see insert sheet in Appendix 15). Calibration was by an automated series 
dilution from a stock calibrator. Previous studies used the same technique (Al-
Daghri et al. 2012; Al-Othman et al. 2012). Cut-off points for fasting blood 
glucose are listed in section 1.2.2., Table 1.2. (see insert sheet in Appendix 
15) 
2.16.4. Measurement of glycated haemoglobin (HbA1c) 
This study measured HbA1c using a Siemens DCA Vantage immunoassay 
analyser. HbA1c sample volume required was 1µL whole blood.  Preparation 
of the sample required no pipetting or pretreatment. Automatic calibration was 
with every cartridge traceable to International Federation of Clinical Chemistry 
reference materials and test methods for measurement of HbA1c, and results 
came within 6 minutes (see insert sheet in Appendix 16). Cut-off points for 
HbA1c are in section 1.1.2., Table 1.2.  
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2.16.5. Measurement of fasting insulin  
Fasting insulin in similar studies has been determined using a number of 
different techniques, most notably radioimmunoassay (Raghuramulu et al., 
1992; Pittas et al., 2007; Mitri et al., 2011) and enzymatic methods (von Hurst 
et al., 2010; Al-Daghri et al., 2012a). Insulin levels were measured using the 
electrochemiluminescent immunoassay, as used by Nagpal et al., (2009); 
Tarcin et al., (2009); Shab-Bidar et al., (2011). The Roche electro-
chemiluminescent immunoassay was used and analysed using a Cobas E401 
analysis system (see insert sheet in Appendix 17). Controls for the various 
concentration ranges were run individually at least once every 24 hours when 
the test was use, once per reagent kit, and following each calibration and 
stored at 2‑8 °C.  
Table 2.2. Cut-off points of fasting insulin 
Classification Cut-off References 
Optimal level 5 to 11 μU/mL Lee et al., 2006  
Standard level <12 μU/mL 
Insulin resistance levels 12.94 to 17 μU/mL 
2.16.6. Calculating the homeostasis model assessment 
Insulin resistance and β-cell dysfunction have been shown to be vital in the 
pathogenesis of T2DM (Lee et al., 2016). Insulin resistance has been 
assessed by the homeostasis model (HOMA-IR) (Niemczyk et al., 2013). 
HOMA-IR is a frequently used marker in clinical research studies (Katsuki et 
al., 2001; Wallace et al., 2004). β-cell function and insulin resistance can be 
estimated by the homeostasis model assessment (HOMA), derived from 
calculating the balance between hepatic glucose secretion and insulin 
secretion from fasting levels of glucose (in mmol/L) and insulin using the 
following formulas (Matthews et al., 1985; Wallace et al., 2004): 
𝐻𝑂𝑀𝐴 − 𝛽 = 	20 ∗ [𝐼𝑛𝑠𝑢𝑙𝑖𝑛]/	([𝐺𝑙𝑢𝑐𝑜𝑠𝑒	𝑚𝑚𝑜𝑙/𝐿] − 	3.5)  
𝐻𝑂𝑀𝐴 − 𝐼𝑅 =	 [𝐺𝑙𝑢𝑐𝑜𝑠𝑒	𝑚𝑚𝑜𝑙/𝑙] ∗ [𝐼𝑛𝑠𝑢𝑙𝑖𝑛]/	22.5	  
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2.16.7. Measurement of lipid concentrations 
Lipid profiles were measured using a chemical analyser (Konelab, Espoo, 
Finland) for total cholesterol, triglycerides, and high-density lipoprotein 
cholesterol (HDL), (see insert sheet in Appendices 18, 19 and 20).   Calibration 
was by an automated series dilution from a stock calibrator.  Previous studies 
have used the same analysis (Al-Daghri et al., 2012a; Al-Othman et al., 2012).  
Low-density lipoprotein cholesterol (LDL) levels were calculated using the 
Friedewald Formula as follows, (all measurements were in mmol/L). It was 
estimated to be most accurate for triglyceride concentrations below 4.5 mmol/L 
(de Cordova and de Cordova, 2013). It was calculated as: 
𝐿𝐷𝐿	 = 	𝑇𝑜𝑡𝑎𝑙	𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙	– 	𝐻𝐷𝐿	–	(𝑇𝑜𝑡𝑎𝑙	𝑡𝑟𝑖𝑔𝑙𝑦𝑐𝑒𝑟𝑖𝑑𝑒	 ÷ 	2.19) 
Table 2.3. The American Heart Association reference range of lipid profiles and 
classifications 
Lipid profile Cut-off  Classification Reference  
Total 
cholesterol 
Below 5.2 mmol/L Desirable (The American 
Heart 
Association, 
2013) 
5.2-6.2 mmol/L Borderline high 
Above 6.2 mmol/L High 
Triglycerides Below 1.7 mmol/ Desirable 
1.7-2.2 mmol/L  Borderline high 
2.3-5.6 mmol/L  High 
Above 5.6 mmol/L Very high  
HDL 
cholesterol 
Below 1 mmol/L  Poor 
1-1.5 mmol/L  Better 
Above 1.5 mmol/L Best 
LDL 
cholesterol 
Below 1.8 mmol/L Best for people who have heart disease 
or diabetes 
Below 2.6 mmol/L Optimal for people at risk of heart 
disease 
2.6-3.3 mmol/L Near optimal if there is no heart disease. 
High if there is heart disease 
3.4-4.1 mmol/L  Borderline high if there is no heart 
disease. High if there is heart disease. 
4.1-4.9 mmol/L High if there is no heart disease. 
Very high if there is heart disease 
Above 4.9 mmol/ Very high 
2.16.8. Measurement of total antioxidant capacity 
Total antioxidants were measured using a colorimetric method with the 
commercially available OxiSelect (TAC) assay kit (Antibodies-online, 2013). 
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The principal of this kit was to compare the samples with a known 
concentration of uric acid standard within a 96-well microtitre plate. Samples 
and standards were diluted with a reaction reagent and, upon the addition of 
copper, the reaction proceeded for a few minutes. The reaction was stopped 
and the samples read with a standard spectrophotometric microplate reader 
at 490 nm. Antioxidant capacity was determined by comparison with the uric 
acid standards. TAC has been demonstrated to be a reliable method for 
measuring oxidative stress, with a lower TAC value representing higher levels 
of oxidative stress (Ceriello et al., 1997), (see insert sheet in Appendix 21). 
2.17. Data protection  
A MRC data protection certificate had been obtained prior to start of the trial 
from the researcher. All baseline and follow-up data were protected by a 
special coded and encrypted file with a password. All subjects’ names and 
medical patient numbers were with a third party. 
2.18. Data handling and cleaning  
The data cleaning process demanded careful consideration, as it could 
significantly affect the final statistical results. The entire process was guided 
by the preliminary plan of data analysis, which was formulated in the research 
design phase. Cleaning the data required consistency checks and treatment 
of missing responses, generally done through SPSS. Missing responses pose 
problems if their proportion to the total is significant (more than 10 percent) 
(Wilson et al., 2013). The following practices were implemented: 
• Use of study codes on data documents (questionnaire, results, etc) instead 
of recording identifying information and keeping a separate document that 
linked the study code to subjects’ identifying information locked in a 
separate location with restricted access to this document (sole primary 
investigator access); 
• Encryption of identifiable data; 
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• Removal of face sheets containing identifiers (names and addresses) from 
survey instruments containing data after receipt from study participants; 
• Proper disposal, destruction, or deletion of study data/documents; 
• Limited access to identifiable information; 
• Secure storage of data documentation within locked locations; 
• Security codes assigned to computerised records. 
2.19. Statistical analysis  
In this study, we were interested in examining the effects of vitamin D on a 
number of parameters; we did not give vitamin D in the pre-test to the group 
of men who were randomly assigned to three independent groups.  Two levels 
of vitamin D were given for the period of 16 weeks to only two groups, then a 
measure of parameters was obtained again post-test. This design consisted 
of one subject variable (test), with two times (pre and post), and one between 
subjects variable (therapy), with three groups (control, 100μg and 50μg vitamin 
D). 
Mixed ANOVA was also applied to examine if there was an interaction 
between these two factors (time and groups) on the dependent variable 
(parameter). For example, the researcher used a mixed ANOVA to determine 
whether any change in calcium (i.e., the dependent variable) was the result of 
the interaction between the type of treatment (i.e., the 100 or 50μg level of 
vitamin D; that is, the "conditions", which was the "between-subjects" factor) 
and "time" (i.e., the within-subjects factor, consisting of two time points). If 
there was no interaction, follow-up tests could still be performed to determine 
whether any change in calcium was simply due to one of the factors (i.e., 
groups or time). Mixed ANOVA was additionally applied to test if there was 
cooperation between these two components (time and groups) on the reliant 
variable (parameter). For instance, the specialist utilised a Mixed ANOVA to 
decide if any adjustment in calcium (i.e., the dependent variable) was the 
consequence of the correlation between the kind of treatment (i.e., the 100 or 
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50μg of vitamin D; that is, the "conditions", which is the "between-subjects" 
factor) and "time" (i.e., the inside subjects factor, comprising of two time 
points). In the event that there was no correlation, follow-up tests could in any 
case be performed to decide if any adjustment in calcium was just because of 
one of the variables (i.e., groups or time). 
The F-test was used by ANOVA to examine significant difference, namely if 
the p-value of the test was less than 0.05, the difference was statistically 
significant. 
2.20. Normality 
The normality assumption was checked, and all the measurements were 
approximately normally distributed. The values for asymmetry and kurtosis 
between -2 and +2 are considered standard in order to prove normal univariate 
distribution (George & Mallery, 2010). 
Table 2.4. The normality of data 
Group Skewness Kurtosis 
 Std. Error  Std. Error 
A BMI pre 0.972 0.361 0.282 0.709 
BMI _post 1.316 0.361 0.749 0.709 
Vit D (nmol/l)_pre 0.065 0.361 -0.954 0.709 
Vit D (nmol/l)_post 0.774 0.361 0.467 0.709 
Ca 
(mmol/l)_pre 
-0.105 0.361 -0.672 0.709 
Ca 
(mmol/l)_post 
0.502 0.361 1.289 0.709 
ALB IT 
(g/L)_ pre 
1.175 0.361 0.460 0.709 
ALB IT 
(g/L)_ post 
1.203 0.361 0.791 0.709 
Corrected Ca 
 (mmol/L)_ pre 
0.461 0.361 0.788 0.709 
Corrected Ca 
 (mmol/L)_ post 
0.551 0.361 1.140 0.709 
glucose (mmol/l)_ 
pre 
0.774 0.361 -0.512 0.709 
glucose (mmol/l)_ 
post 
0.901 0.361 0.706 0.709 
HbA1c (%)_pre 1.562 0.361 2.082 0.709 
HbA1c (%)_post -0.316 0.361 0.010 0.709 
B BMI pre 2.244 0.365 2.680 0.717 
BMI _ post 2.065 0.365 2.000 0.717 
Vit D (nmol/l)_ pre 0.421 0.365 -0.475 0.717 
Vit D (nmol/l)_ post 0.394 0.365 -0.545 0.717 
47 
Ca 
(mmol/l)_ pre 
-0.317 0.365 -0.651 0.717 
Ca 
(mmol/l)_ post 
0.915 0.365 1.415 0.717 
ALB IT 
(g/L)_ pre 
0.518 0.365 -0.755 0.717 
ALB IT 
(g/L)_ post 
0.823 0.365 -0.043 0.717 
Corrected Ca 
 (mmol/L)_ pre 
-0.099 0.365 -0.864 0.717 
Corrected Ca 
 (mmol/L)_ post 
0.873 0.365 1.021 0.717 
glucose (mmol/l)_ 
pre 
0.856 0.365 0.138 0.717 
glucose (mmol/l)_ 
post 
1.099 0.365 2.060 0.717 
HbA1c (%)_pre 1.532 0.365 1.745 0.717 
HbA1c (%)_post 1.193 0.365 1.982 0.717 
C BMI pre 0.672 0.361 -0.789 0.709 
BMI _ post 0.611 0.361 -0.988 0.709 
Vit D (nmol/l)_ pre -0.043 0.361 -0.746 0.709 
Vit D (nmol/l)_ post -0.039 0.361 -0.463 0.709 
Ca 
(mmol/l)_ pre 
0.321 0.361 0.519 0.709 
Ca 
(mmol/l)_ post 
1.566 0.361 1.006 0.709 
ALB IT 
(g/L)_ pre 
0.285 0.361 -0.906 0.709 
ALB IT 
(g/L)_ post 
0.469 0.361 -0.893 0.709 
Corrected Ca 
 (mmol/L)_ pre 
0.831 0.361 0.209 0.709 
Corrected Ca 
 (mmol/L)_ post 
1.825 0.361 1.542 0.709 
glucose (mmol/l)_ 
pre 
0.546 0.361 -0.601 0.709 
glucose (mmol/l)_ 
post 
0.893 0.361 0.180 0.709 
HbA1c (%)_pre 2.050 0.361 2.031 0.709 
HbA1c (%)_post 0.342 0.361 -0.209 0.709 
Valid N (listwise)     
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3.1. Introduction  
More than 422 Million people who suffer from diabetes mellitus around the 
world, and about 90% of these suffer with T2DM (Roglic & World Health 
Organization, 2016). During the last two decades, the prevalence of T2DM has 
spread globally (WHO, 2011). The Middle East and North Africa has the 
second highest of increase in the prevalence of T2DM. It has been predicted 
that people who have diabetes will increase by 96.2% in 2035 (Guariguata et 
al., 2014). Based on the International Diabetes Federation estimates, the 
prevalence of T2DM in Saudi Arabia is in the top ten countries worldwide 
(Khan & Hamdy, 2017). In the 1980’s, studies in Saudi Arabia determined the 
prevalence of T2DM as being between 2.4% to 4.3% (Abuyassin & Laher, 
2016), while its prevalence dramatically increased estimated to 25.4% in a 
recent study (Al-Rubeaan et al., 2015).  
The prevalence of T2DM has been documented with increasing age (Thibault 
et al., 2016). Ageing is the gradual deterioration of bodily functions over the 
lifetime of the individual, which occurs at different rates among individual 
organs and tissues in the body. Advancing age is linked to changes in glucose 
intolerance functions (Kalyani & Egan, 2013); thus, facilities for diabetic 
screening of older adults in hospitals is necessary (Al Saif & Alsenany, 2015). 
In this study, the age range was 18-60 years to enable comparison with the 
studies of Mitri et al. (2011) and Al-Daghri, et al., 2012b). 
Family history and increasing the risk of diabetes in the population have been 
shown to have a positive association (Hariri et al., 2006; Zhang et al., 2015). 
Genetic factors play an important role in increasing the risk of having diabetes. 
Also, lifestyle factors such as smoking, diet and lack of physical activity have 
been linked to a higher risk of having diabetes (Jankowich et al., 2011). Lack 
of physical activity will increase the chance of obesity. Obesity carries a 
significant risk of impaired glucose tolerance and a higher prevalence of 
obesity with 80% to 90% of people diagnosed with T2DM (Daousi et al., 2006). 
Thus, increased educational level will help to expand the perceptions in health 
and diabetic education. It assists in reducing risk factors for diabetes and 
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achieves the self-care, healthy diet and doing physical activity to control the 
possibility of diabetes (Shrivastava et al., 2013; Agrawal, 2016).  
The aim of this chapter was to identify the relevant adjustable and non-
adjustable risk factors and to control for their effects. The following parameters 
were measured: age; duration of T2DM; family history; educational level; 
smoking status across the two intervention groups A (100 µg vitamin D3) and 
B (50 µg vitamin D3), and compared against the control group. 
3.2. Methods 
This was a parallel, double-blind, randomised control trial of 156 men with 
poorly controlled T2DM with HbA1c levels greater than 8.0%. Ethical approval 
was granted by the Manchester Metropolitan University Ethics Committee as 
stated in section 2.2. All participants were recruited from King Fahad Medical 
City hospital in Saudi Arabia, and informed consent was obtained as detailed 
in sections 2.7. There were 128 subjects who met the inclusion criteria who 
were randomly allocated to one of the three test groups. These were as 
follows: 50µg vitamin D per day, 100µg vitamin D per day, or a placebo, as 
described in section 2.5. Participants were also asked to attend a meeting and 
complete a pre-study screening questionnaire at baseline and a debriefing 
questionnaire at 16 weeks as per sections 2.10 and 2.15.   
3.3. Results 
A total of 128 male patients with T2DM were included in this study, after 
recruitment of 156 participants at baseline. 28 T2DM male patients were not 
included in the study. The reasons for this attrition between the pre-test 
(baseline measurements) and post-test (16 weeks after the baseline) sample 
are listed in Table 3.1. Non-compliance in taking the vitamin D supplements 
was seen in about quarter of each group (13.2%-17.6%). Supplement non-
compliance was classed as those who had taken less than 80% of the tablets 
and these subjects were excluded from the study. Compliance was 
encouraged in the present study by reducing the number of capsules 
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(Maningat et al., 2013). This method of compliance calculation has been used 
to determine the acceptable level of supplements for compliance (Osterberg 
&  Blaschke, 2005;  Mitri et al., 2011). 
Participants excluded from the intervention study in group A were 9 subjects; 
one subject had their diabetic medication changed during the intervention, 
Non-compliance with taking vitamin D supplements and took additional vitamin 
D during the study . Three subjects had their diabetic medication changed. 
One subject had a medical condition; and one subject had a medical condition 
and took additional vitamin D during the study. Three subjects were non-
compliant about taking vitamin D supplements and one of them took additional 
vitamin D during the study. In group B, 9 participants were excluded. Five 
subjects were non-compliant about  taking vitamin D supplements and took 
additional vitamin D during the study. Two subjects  changed diabetic 
medication during the intervention and were non-compliant about taking 
vitamin D supplements. One subject’s diabetic medication was changed 
during the intervention as well as having a medical condition and being non-
compliant about taking vitamin D supplements. One subject had a medical 
condition and was non-compliant about  taking vitamin D supplements. In 
group C, 10 subjects were excluded from the study. One subject was non-
compliant about taking vitamin D supplements. Four subjects were non-
compliant about taking vitamin D supplements and took additional vitamin D 
during the study. Two subjects had diabetic medication changed during the 
intervention and were non-compliant about  taking vitamin D supplements. 
Two subjects had a medical condition, changed diabetic medication during the 
intervention and were non-compliant about  taking vitamin D supplements and 
one of them took additional vitamin D during the study. In the end, there were 
43 participants in group A, 42 participants in group B and 43 participants in 
group C, as shown in Table 3.1. 
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Table 3.1. The reasons for excluding subjects between the pre-test measurements 
and post-test (after 16 weeks) 
Reason Group A 
(100 µg) 
Group B 
(50 µg) 
Group C 
(placebo) 
n % n % n % 
Non-compliance with taking vitamin D 
supplements 
9 17.3 9 17.6 7 13.2 
Contracted gastrointestinal 
malabsorption during the intervention 
2 3.8 2  3.9 2  3.8 
Changed diabetic medication during the 
intervention 
4 7.7 3  5.9 4  7.5 
Took additional vitamin D during the 
study 
3 5.8 5 9.8 5  9.4 
Table 3.2. Distribution of sample number of the three groups 
Group Number of 
participants 
Percentage  
A  
(100 µg vitamin 
D3) 
Included 43 82.7% 
Excluded 9 17.3% 
Total 52 100.0% 
B  
(50 µg vitamin 
D3) 
Included 42 82.4% 
Excluded 9 17.6% 
Total 51 100.0% 
C  
(placebo) 
Included 43 81.1% 
Excluded 10 18.9% 
Total 53 100.0% 
3.3.1. Demographics   
The demographic characteristics of the 128 participants groups A, B, and C, 
as reported in the pre-test questionnaire are shown in Table 3.3. It was seen 
that all selected patients were Saudi men. The majority of participants were 
married, which are represented as 97.7% in group A, 90.5% in group B and 
95.3% in group C.  The average age range for the participants was more than 
45 years. The highest percentage of a similar age group was about 86.1% of 
45 to 60 years in group A. Then, the age group of 45 to 55 was more than half 
(59.5%) of group B and the age group of 55-60 years was also more than half 
(58.1%) of group C. The average ages were very similar between the three 
groups. It was 51.67+/-7.48 years for group A, was 52.29+/-7.127 years for 
group B and was 50.33+/-9.54 years for group C. Statistically, there was no 
significant difference in age between the three groups (F=0.649, p-
value=0.524). 
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The educational level between the three groups covered high school, diploma 
and bachelor’s degree. Specifically, these levels were represented by more 
than half (58.2%) of group A, the majority (81%) of group B, and more than 
half (60.5%) of group C. Regarding the occupation, the participants were 
observed to be employed (60.5% in group A, 59.5% in group B and 44.2% in 
group C). This was followed by the retired (32.6%, 35.7% and 46.5% for A, B 
and C, respectively), who were fewer in number than the employed 
participants.   
Table 3.3. Distribution of demographic characteristics of participants of the three 
groups (n = 128) 
Characteristic Category Group 
A (100 µg) B (50 µg) C (placebo) 
n % n % n % 
Nationality Saudi 43 100 41 97.6 43 100 
Age 18-24 years 1 2.3 2 4.8 1 2.3 
25-34 years 1 2.3 2 4.8 2 4.7 
35-44 years 4 9.3 12 28.6 9 20.9 
45-55 18 41.9 25 59.5 6 13.9 
55-60 years 19 44.2 1 2.4 25 58.1 
Mean+/-SD 51.67+/-
7.48 
52.29+/-
7.127 
50.33+/-9.54 
Marital Status Single 1 2.3 3 7.1 2 4.7 
Married 42 97.7 38 90.5 41 95.3 
Education No schooling 5 11.6 1 2.4 5 11.6 
Primary school 4 9.3 2 4.8 3 7 
Secondary school 4 9.3 4 9.5 6 14 
High school 10 23.3 16 38.1 8 18.6 
Diploma 3 7 6 14.3 7 16.3 
Bachelor’s degree 12 27.9 12 28.6 11 25.6 
Postgraduate degree 5 11.6 1 2.4 3 7 
Employment Student 1 2.3 1 2.4 2 4.7 
Employed 26 60.5 25 59.5 19 44.2 
Unemployed 2 4.7 1 2.4 2 4.7 
Retired 14 32.6 15 35.7 20 46.5 
3.3.2. Health information  
The health characteristics of the 128 participants, classified A, B, and C, as 
reported in the pre-test questionnaire, are summarised in Table 3.4. Most the 
participants were found to be non-smokers, and they did not follow any 
particular diet. About two-third of the participants in each group (65.1% in A, 
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71.4% in B and 69.8% in C) took multi-vitamin supplements (not containing 
vitamin D but containing calcium or iron) before or during the study.  
The family history of diabetes ranged from 81% to 86% within the three groups. 
Duration of T2DM was seen to be more than eight years for more than half of 
participants (62.8% in group A, 71.4% in group B and 79.1% in control group). 
For health complications, nephropathy was 2.3% for group A, while it was not 
seen for the other groups. Also, neuropathy (30%-58%), diabetic cataract 
(26.2%-32.6%), cardiovascular disease (39.5%-45.2%), dyslipidaemia 
(60.5%-67.4%) and retinopathy (14%-18.6%) was observed in the sample.  
Table 3.4. Health characteristics of participants at baseline 
Characteristic Category Groups 
A  
(100µg) 
B  
(50µg) 
C  
(placebo) 
n % n % n % 
Smoking No 5 11.6 3 7.14 2 4.65 
Diet No special diet 43 100 42 100 43 100 
Duration of T2DM 1-2 years 3 7.0 1 2.4 2 4.7 
3-5 years 7 16.3 9 21.4 3 7.0 
6-8 years 6 14.0 2 4.8 3 7.0 
> 8 years 27 62.8 30 71.4 34 79.1 
Family history of diabetes Yes 36 83.7 34 81.0 37 86.0 
Health Complications Yes 43 100 42 100 43 100 
Nephropathy 1 2.3 0 0 0 0 
Neuropathy 13 30 16 38.1 25 58.1 
Diabetic 
Cataract 
14 32.6 11 26.2 13 32.2 
Cardiovascular 
disease 
17 39.5 19 45.2 18 41.9 
Dyslipidaemia 26 60.5 26 61.9 29 67.4 
Retinopathy 6 14 6 14.3 18 18.6 
Medical condition Thyroid and 
parathyroid 
disease 
4 9.3 6 14.3 5 11.6 
Multi-vitamin supplement 
doesn’t contain vitamin D 
Yes 28 65.1 30 71.4 30 69.8 
Taking vitamin D 
supplements three 
months before study date 
No 43 100 42 100 43 100 
3.4. Discussion  
As T2DM has the highest incidence rate, several biological and lifestyle factors 
are believed to increase the possibility of developing T2DM even earlier in life 
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as these factors may influence the genetic causes of T2DM. These factors 
include age, duration of diabetes, family history, educational level, and 
smoking were discussed. 
3.4.1 Age  
Epidemiological studies have shown that the risk of developing diabetes 
mellitus increases with age (Maruthur, 2013). The average age in this study 
was similar between the three groups. The mean ± SD was 51.67±7.48 years 
in group A and about 86.1% were in the age group 45 - 60 years. The mean 
±SD was 52.29±7.127 years for group B, of which more than half (59.5%) were 
around 45 - 55 years in age. The mean ± SD was 50.33±9.54 years for group 
C of which 58.1% were in the age group 55 - 60 years. Statistically, there was 
no significant difference in age between the three groups (F=0.649, p-
value=0.524) 
The risk of developing T2DM is reported to be increased by 40% by the age 
of 40-49 years (Thibault et al., 2016). The Decode study group found that the 
risk of developing T2DM was higher in men aged between 40 and 59 years 
old (Tuomilehto et al., 2003). The prevalence of diabetes mellitus was higher 
in men over 50 years in age when compared with women of a similar age 
range in a Saudi community (Alqurashi et al., 2011). Another study found an 
increased in the prevalence of diabetes in people aged 58.5 years or older (Al 
Saif & Alsenany, 2015)  
The incidence of T2DM is predicted to increase by 44.1% in 2022 among 
Saudi young adults age >25 years (Al-Quwaidhi et al., 2014). An 
epidemiological study of diabetes stated that the incidence of diabetes would 
significantly increase by 4.4% in 2030 (Wild et al., 2004). This change in the 
incidence rate of T2DM could be due to hormonal changes caused by age, 
obesity and the modernisation of lifestyles (Alqurashi et al., 2011). 
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3.4.2. Duration of diabetes 
Poorly controlled of diabetes is linked to the long duration of diabetes. The 
long-term of diabetes increases the glycated haemoglobin (HbA1c) or insulin 
levels (Verma et al., 2006; Sherwani et al., 2016). Long-term duration diabetes 
increases the insulin levels with insulin sensitivity linked negatively with fasting 
insulin and insulin levels.  
In our study, male patients with poorly controlled T2DM had long-term duration 
of diabetes (eight years or more). They were more than half (62.8% in group 
A, 71.4% in group B and 79.1% in group C) of the study population. Another 
study found that 178 Libyan men who were suffering from poorly-controlled 
diabetes showed a significant association between the long term of duration 
diabetes and HbA1c (Bastos et al., 2016). In a further study, there was a 
significant relationship between the duration of diabetes and 500 patients who 
had HbA1c over 8% (Shera et al., 2004). 
3.4.3. Family history  
The link between the risk of diabetes and family medical history has been 
demonstrated in the literature (Akhuemonkhan & Lazo, 2017). Family medical 
history is essential to clear a basic approach of health prospective (Tarini & 
McInerney, 2013). Family history is useful to assess for diabetes risk and other 
medical conditions (Hariri et al., 2006). 
In this study, the family history of diabetes was high and similar between the 
interventions groups and control group (83.7% group A, 81% group B and 86% 
control group). Regular physical activity for those with a diabetic family history 
might reduce the development of hyperglycaemia and T2DM (Valdez et al., 
2007). Knowing the family history with regard to diabetes not only highlights 
genetic or environmental factors but it also helps to build health strategies to 
prevent diabetes (Das et al., 2012). 
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3.4.3. Educational level  
Educational level is essential to controlling the risk of developing diabetes 
(Yoon et al., 2013). Educational level also helps individuals to understand the 
health information that affects health and reduces the diabetes epidemic 
(Powers et al., 2017). In this study, the educational level was between high 
school, diploma and bachelor’s degree. Specifically, these educational levels 
were represented by more than half (58.2%) of group A, the majority (81%) of 
group B, and more than half (60.5%) of group C. Specifically, Bachelor’s 
degrees (n = 12 about 27.9%) in group A, in group B were n=12 (about 28.6%), 
and n = 11 (about 25.6%) in group C. Postgraduate degrees were n= 5 (about 
11.6%) in group A, n= 1 (about 2.4%) in group B and n= 3 (about 7.0%) in 
group C. 
3.4.4. Smoking levels 
Smoking has a critical effect on increasing the development of diabetes 
(Chang et al., 2012). Smokers are associated with insulin resistance, 
inflammation and dyslipidaemia (Chang et al., 2012). Smoking affects the 
stimulation of insulin, thereby effecting glucose transport into the cell by 10% 
to 40% in men who smoked compared with men who were non-smokers. 
(Chang et al., 2012; Sharip et al., 2017). One hour after smoking, insulin 
resistance was significantly increased (Wang et al., 2015). Diabetics who 
smoked had a high level of triglycerides as well a low level of HDL (Freeman 
et al., 1993; Tirosh et al., 2008). Lastly, smoking increases inflammation and 
oxidative stress (Lee et al., 2012) directly damages β-cell function 
(Woynillowicz et al., 2012) and impairs endothelial function (Ozaki et al., 
2010). 
However, in this study, the participants were found to be almost all non-
smokers. The low prevalence of male smokers in this study may be explained 
by cultural factors (Abdalla et al., 2007; Mohammadnezhad et al., 2015). Most 
of the patients answered that they did not smoke because it would affect their 
social prospects in Saudi Arabia (Abdelwahab et al., 2013). 
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3.5. Conclusion  
This chapter examined the demographic characteristics of patients with poorly 
controlled diabetes. The significant findings to emerge from this study are that 
the incidence of poorly controlled diabetes in middle-aged, educated, working 
patients was linked to family medical history. The most important limitation lies 
in the fact that their non-smoking status is due to Saudi cultural factors. 
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Chapter 4 The effect of vitamin D3 supplementation on vitamin D 
concentration and BMI in men with poorly- controlled type-2 diabetes 
after 16 weeks 
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4.1. Introduction  
Vitamin D is essential to prevent cardiovascular disease and cancer (Martin & 
Campbell, 2011), and it helps the body to absorb and use calcium by helping 
with its storage and making use of calcium in bones (Ahmadieh & Arabi, 2011). 
The ideal serum vitamin D concentration is 50 nmol/L or above (Holick et al., 
2011). Vitamin D deficiency is defined as ≤ 50 nmol/L, and insufficiency is 
defined as a serum level between 50 nmol/L and 80 nmol/L (Sadat-Ali et al., 
2009; Wakayo et al., 2016). Vitamin D deficiency is prevalent among Saudi 
Arabian men, with a rate of 72.4% (Alsuwadia et al., 2013; Alfawaz et al., 
2014). This could be related to melanin, which causes darker skin to respond 
less to sun exposure, affecting the skin’s ability to make vitamin D (Nair & 
Maseeh, 2012). 
Current dietary reference intake recommendations state that adults should 
take 20 µg of vitamin D per day (Institute of Medicine, 2011). Vitamin D3 
supplementation should be prescribed in subjects who need to achieve the 
serum of vitamin D level to 100 nmol/L or 150 nmol/L (Martin & Campbell, 
2011). High supplement doses of vitamin D3 are more potent than vitamin D2 
(Binkley et al., 2007). A daily 50 µg of vitamin D3 is recommended for Arab 
patients with T2DM, a protective effect for cardiologic health indices having 
been found at this vitamin D intake (Al-Daghri, et al., 2012a). The tolerable 
upper limit for vitamin D has been raised to 250 µg/day (Hathcock et al., 2007). 
High doses of vitamin D supplementation above 250 µg lead to toxic 
hypercalcaemia (Alshahrani & Aljohani, 2013; Vogiatzi et al., 2014). 
Hypercalcaemia is responsible for vitamin D toxicity. The early symptoms of 
vitamin D toxicity are anorexia, diarrhoea, constipation, nausea, and vomiting. 
Then, other symptoms can appear within a few days or weeks such as 
frequent urination, extreme thirst, nervousness and kidney stones (Alshahrani 
& Aljohani, 2013). The vitamin D metabolism can be excreted through the bile 
into the faeces, and very few are eliminated through the urine, due to renal 
reuptake of vitamin D metabolites bound to DBP, as mediated by the 
cubilinmegalin receptor system (Nykjaer et al., 2005). For this reason, this 
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study measured calcium and serum vitamin D concentrations before and after 
supplementation to ensure subject safety throughout the study. 
Vitamin D deficiency is linked with obesity and it is the main risk factor in the 
development of T2DM (Wakayo et al., 2016). Saudi Arabia has the world’s 5th 
highest rate of diabetes, with 20% of the population being affected and 26% 
of males having obese weight (Abuyassin & Laher, 2015). Obesity and being 
overweight have a number of contributing factors that up lead to them, which 
include metabolic, genetic, environmental, and behavioural influences 
(Alqarni, 2016). The rapid increases in obesity rates are directly contributed by 
environmental and behavioural factors, rather than the biological factors 
(Alqarni, 2016). People in urban areas have higher obesity rates as compared 
people in rural areas, possibly due to the intake of high-fat diets and more 
sedentary lifestyles (Alqarni, 2016). Saudi Arabia has of the highest obesity 
and overweight prevalence rates (De Nicola et al., 2015), where 7 out of 10 
people experience the problem (Memish, 2013). There is a lack of literature 
on average body mass index (BMI) in Saudi Arabia. However, in Palestinian 
and Lebanese people the average BMI in diabetics was 33.7 kg/m2 and 30.8 
kg/m2, respectively (Abuyassin & Laher, 2016).   
In the published literature, low concentrations of vitamin D have been found in 
obese patients, and obese patients need a higher intake of vitamin D than 
those of normal weight (Ekwaru et al., 2014). Vitamin D deficiency increases 
parathyroid hormone concentrations (Sadat-Ali et al., 2015), which increase 
cytosolic calcium level (Christakos et al., 2011). The optimal concentration of 
vitamin D might enhance the mobilisation of fat, increasing lipolysis and thus 
decreasing intracellular fat accumulation (Chang & Kim, 2016). 
The aim of this study was to examine the effect of vitamin D3 supplementation 
on serum vitamin D concentration and BMI in men with poorly controlled T2DM 
after 16 weeks. 
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4.2. Methods 
This was a parallel, double-blind, randomised control trial of 128 participants. 
Blood samples were collected from all participants at baseline and at 16 weeks 
using the aseptic technique described in section 2.11. Vitamin D status was 
measured using the Roche electrochemiluminescent protein-binding assay 
COBAS E411, as per section 2.16.1. Anthropometric measurements were 
taken at baseline and 16 weeks and calculated using the BMI formula, as 
described in section 2.11. 
4.3. Results 
4.3.1. Vitamin D Status  
A total of 128 male patients with T2DM took part in the study. There were 43 
participants in group A (supplementation with 100 µg vitamin D3), 42 
participants in group B (supplementation with 50 µg vitamin D3), and 43 
participants in group C (control, placebo group). The mean concentrations of 
vitamin D were analysed among the three studied groups: group A, group B, 
and C, and differences between the pre-test and post-test mean vitamin D 
concentrations among the groups were analysed. A two-way mixed ANOVA 
statistical test was used to compare the groups. The results (Table 4.1) 
showed that there was a statistically significant difference in the mean vitamin 
D concentrations measured at baseline and at the end of the 16-week-long 
intervention (F=93.53, p <0.001). Furthermore, there was a significant 
difference in mean vitamin D concentrations between the intervention and 
control groups when measured post-test (F=14. 02, p <0.001, Table 4.1). 
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Table 4.1. Two-way mixed ANOVA comparing the mean differences of serum levels 
of Vitamin D upon vitamin D supplementation 
Source of difference F-test P-value 
Between times (pre- and post-test) 93.53** <0.001 
Interaction between different doses, 
intervention period and groups 
71.59** <0.001 
Between groups in per-test 0.810 0.447 
Between groups in post-test 14.02** <0.001 
The comparisons included: the difference in mean Vitamin D concentration in vitamin D 
supplementation groups (group A - 100 µg and group B - 50µg) and a control group (placebo) 
between baseline and after intervention, between different doses and intervention period, 
between the groups in pre-test measurement, and between groups in post-test, **indicates a 
significant difference at p < 0.01  
Table 4.2. Post-hoc comparisons of the mean vitamin D serum concentration (nmol/L) 
between intervention groups and a control group at baseline and after the intervention 
period (16 weeks) 
Group Baseline After 16 weeks  Mean difference p-valueb 
A 77.85±5.27 115.14±5.082 37.28** <0.0001 
B 85.04±5.26 94.58±4.66 9.53** <0.001 
C 86.03±5.83 81.50±5.70 -4.51 0.074 
Intervention groups: A - 100µg vitamin D, and B - 50µg vitamin D; control group (C) - placebo. 
**indicates a significant difference at p < 0.001; b indicates adjustment for multiple 
comparisons; mean ± standard deviation 
Comparison of the pre- and post-test results for each group showed that in 
group A the vitamin D increased significantly after 16 weeks (mean 
difference=37.28, p <0.001, see Table 4.2). For group B, the vitamin D also 
increased significantly after 16 weeks (mean difference=9.53, p <0.001). The 
results of measurements of the vitamin D concentration among intervention 
groups A and B and a control group C, at baseline and after the intervention 
period are also presented in Figure 4.1. 
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Table 4.3. Post-hoc comparisons of the mean vitamin D concentrations among the 
intervention and the control groups after 16 weeks 
Time Group Group Mean difference p-valueb 
16 weeks 
A B 20.56** 0.002 
A C 33.56** <0.001 
B C 13.08* 0.044 
Intervention groups A, 100µg vitamin D supplementation and group B, 50µg vitamin D are 
compared with control (placebo) group C after 16 weeks of intervention. **indicates a 
significant difference at p < 0.001; *indicates a significant difference of p < 0.05; b indicates 
adjustment for multiple comparisons. 
After 16 weeks, the results (as analysed by two-way mixed ANOVA, Table 
4.1), showed that there was a significant difference in vitamin D between the 
three groups (F=14.02, p <0.001). As the one-way ANOVA statistical analysis 
of the results of a post-hoc testing showed, the mean vitamin D concentration 
in group A was significantly higher than in group B (mean difference=20.56, p 
<0.002, (see Table 4.3). Furthermore, the mean post-intervention 
concentration of vitamin D in group A was significantly increased than in group 
C (mean difference=33.56, p <0.001) and the post-intervention mean vitamin 
D concentration in group B was significantly increased than in group C (mean 
difference=13.08, p <0.044). 
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Figure 4.1. Changes in the mean vitamin D status concentrations (nmol/L) in 
intervention and control groups between the pre-test and post-test measurements 
The bar chart shows intervention groups (group A - 100µg vitamin D3 (n=43) and group B, 
50µg vitamin D3 (n=42) compared with the placebo group (C) as control (n=43) between pre-
test and post-test measurements. Results are presented as mean ± SD (n=128). Statistically 
significant differences are marked with ** of p < 0.001) and with * of p < 0.005. 
4.3.2 Corrected calcium  
A total of 128 male patients with T2DM took part in the study. There were 43 
participants in group A (supplementation with 100 µg vitamin D3), 42 
participants in group B (supplementation with 50 µg vitamin D3) and 43 
participants in group C (control, placebo group). The changes in the mean 
corrected calcium values were analysed among groups A, B and C placebo 
pre- and post-test, as well as in relation to the duration of treatment, by two-
way mixed ANOVA. The results of the two-way mixed ANOVA test (Table 4.4) 
showed that there was no significant difference in mean corrected calcium 
between the pre- and post-tests (F=0.052, p-value=0.82), nor between the 
groups post-test (F=1.48, p-value=0.23). In addition, the interaction between 
treatment duration and the effect was not significant (F=0.4, p-value=0.669).  
66 
Table 4.4. Two-way mixed ANOVA analysis of differences in the mean corrected 
calcium upon vitamin D supplementation 
Source of difference F-test P-value 
Between times (pre- and post-test) 0.052 0.821 
Interaction between different doses, 
intervention period and groups 
0.403 0.669 
Between groups in per-test 1.123 0.329 
Between groups in post-test 1.482 0.231 
The comparisons included: the difference in mean corrected calcium concentration in vitamin 
D supplementation groups (group A - 100 µg and group B - 50µg) and a control group 
(placebo) between baseline and after intervention, between different doses and intervention 
period, between the groups in pre-test measurement, and between groups in post-test.  
Table 4.5. Post-hoc comparisons of the differences between the mean corrected 
calcium (mmol/L) among groups (intervention and control) at baseline and after the 
intervention study 
Group Baseline After 16 weeks Mean difference p-valueb 
A 2.24±.17 2.24±.15 0.01 0.820 
B 2.24±.14 2.31±.26 0.03 0.481 
C 2.25±.15 2.26±.24 -0.02 0.584 
Intervention groups A, 100µg vitamin D3 supplementation and B, 50µg vitamin D3 and control 
(C), placebo group. b indicates adjustment for multiple comparisons; mean ± SD. 
The mean corrected calcium concentrations among the intervention groups 
and control group from the baseline to after the intervention period were 
calculated (as summarised in Table 4.5). There was no significant difference 
in the mean corrected calcium values in groups A, B and C, between baseline 
and after 16 weeks of treatment (see Table 4.5 and Figure 4.2). 
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Figure 4.2. Corrected calcium (mmol/L) before and after vitamin D3 supplementation 
The bar chart shows intervention groups A, 100µg vitamin D3, (n=43) and B, 50µg vitamin D3, 
(n=42) compared with the placebo group (C) as control (n=43), between pre-test and post-test 
measurements. Corrected calcium remained unchanged after vitamin D3 supplementation. 
Results are presented as mean ± SD (n=128). 
4.3.3 Body mass index (BMI) 
A total of 128 male patients with T2DM took part in the study. There were 43 
participants in group A (supplementation with 100 µg vitamin D3), 42 
participants in group B (supplementation with 50 µg vitamin D3), and 43 
participants in group C (control, placebo group). The changes in the mean 
percentage of BMI were analysed among groups A, B and C, pre- and post-
test, by two-way mixed ANOVA. The results of the mixed ANOVA test (Table 
4.6) showed that there was a significant decrease in the mean percentage of 
BMI between the pre- and post-tests (F=30.34, p-value=0.001, see Table 4.6). 
In addition, the interaction between treatment duration and treatment effect 
was statistically significant (F=6.19, p-value=0.001). 
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Table 4.6. Two-way mixed ANOVA test comparing the mean differences of BMI upon 
vitamin D supplementation 
Source of difference F-test P-value 
Between times (pre- and post-test) 30.34** <0.001 
Interaction between different doses, 
intervention period and groups 
6.19** <0.001 
Between groups in per-test 0.021 0.979 
Between groups in post-test 0.76 0.467 
**indicates a significant difference at p < 0.001 
The comparisons included: the difference in mean BMI in vitamin D 
supplementation groups (group A - 100 µg and group B - 50µg) and a control 
group (placebo) between baseline and after intervention, between different 
doses and intervention period, between the groups in pre-test measurement, 
and between groups in post-test.  
Table 4.7. Post-hoc comparisons of the differences between the mean BMI (kg/m2) 
among groups (intervention and control) at baseline and after the intervention study 
Group Baseline After 16 weeks  Mean difference p-valueb 
A 30.42±5.27 29.63±5.08 -0.794** 0.001 
B 30.28±5.26 29.00±4.66 -1.27** <0.001 
C 30.53±6.53 29.69±6.28 0.22 0.690 
Intervention groups: group A, 100µg vitamin D3 supplementation, and group B, 50µg vitamin 
D3 and control (C) placebo group. **indicates a significant difference between the groups at 
p < 0.001; b indicates adjustment for multiple comparisons; mean ± SD. 
The mean levels of BMI % among the intervention groups and control group 
at the baseline and after the intervention period were calculated (see Table 
4.7). Comparison of the pre- and post-test results for each group revealed that 
in group A BMI decreased significantly after 16 weeks (mean difference = -
0.794, p-value<0.001). For group B, the BMI decreased significantly (mean 
difference= -1.27, p-value<0.001). The differences in mean BMI % in the 
groups from baseline to 16 weeks post-treatment are also presented in Figure 
4.3. However, there were no statistically significant difference compared with 
control groups in both intervention treatment groups (see Table 4. 8).  
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Table 4.8. Post-hoc comparisons of BMI (kg/m2) between the intervention groups and 
control after 16 weeks 
Time Group Group Mean difference p-valueb 
16 weeks 
A B 0.62 0.594 
A C -0.816 0.484 
B C -1.44 0.220 
Intervention groups A.100µg vitamin D3 supplementation, and B, 50µg vitamin 
D3 compared with control (placebo) group C after 16 weeks of intervention. b 
indicates adjustment for multiple comparisons. 
 
Figure 4.3. The comparisons of mean BMI (kg/m2) after vitamin D3 treatment 
The bar chart shows intervention groups A, 100µg vitamin D3 (n=43), and B, 50µg vitamin D3 
(n=42) compared with the placebo group (C) as control (n=43), between pre-test and post-test 
measurements. Results are presented as mean ± SD (n=128). 
4.4. Discussion  
This study found a significant improvement in vitamin D  status at both vitamin 
D doses (100 µg and 50 µg vitamin D3), from 77.85 ± 5.27 to 115.14 ± 5.082, 
and from 85.04 ± 5.26 to 94.58 ± 4.66 nmol/L, respectively. Previous studies 
that have noted that the concentrations of serum vitamin D or, as it is defined 
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25(OH)D, increase by approximately 0.7 to 1.0 nmol/L for every 1 µg/day of 
vitamin D3 supplementation (Dawson-Hughes et al., 2010). A daily dose of 25 
µg of vitamin D3 over 11 weeks increased the 25(OH)D concentration from 49 
to 72 nmol/L, and the vitamin D levels plateaued in participants on that regimen 
for 6 weeks (Holick, 2008).  A weekly dose of 1,250 µg of vitamin D3, led to a 
high serum levels of 25(OH)D remaining steady for 2 weeks then dropping 
gradually (Armas et al., 2004; Alshahrani &  Aljohani, 2013). Vitamin D2 is 
absorbed as vitamin D3, however, the vitamin D2 concentration dropped after 
3 days (Alshahrani & Aljohani, 2013). 
A study of hip-fracture patients with vitamin D insufficiency who were given 
25µg of vitamin D3, showed that after 3 months, the level of 25(OH)D had 
increased by 31%–52% (Glendenning et al., 2009). A dose 100 µg/day of 
vitamin D3 was observed to effect a 1.7-fold rise in vitamin D level for 2 weeks 
(Trang et al., 1998; Mastaglia et al., 2006; Alshahrani & Aljohani, 2013). In our 
study, the mean increase in serum 25(OH)D concentration after vitamin D3 
supplementation increased by 37.28 nmol/L (p <0 .001) for 100 µg/day vitamin 
D3 supplementation, and by 9.53 nmol/L (p <0.001) after 50 µg/day vitamin D3 
for 16 weeks. Our study showed significant improvement in serum vitamin D 
in both intervention groups, with the majority of participants in group A 
reaching optimal concentrations of vitamin D after 16 weeks. The current study 
used safe doses of 100 µg/day and 50 µg/day of vitamin D3, with no adverse 
effect on the serum concentration of corrected calcium. 
Vitamin D deficiency (< 50 nmol/L) is commonly seen clinically in patients with 
T2DM (Sugden et al., 2008). Supplementation to achieve higher levels of 
vitamin D remains a promising adjuvant therapy for T2DM patients (Al-Daghri, 
et al., 2012a). Nutritional recommendations for correcting deficient vitamin D 
levels involve treatment doses of 1,250 µg/week of vitamin D3 for 6–8 weeks, 
thereafter 20-25 µg/per day of vitamin D3 (Dawson-Hughes et al., 2010). 
Secondly, patients with insufficient vitamin D levels (50–75 nmol/L) need a 
treatment dose with 20-25µg/day of vitamin D3. This will increase the vitamin 
D level to 7 nmol/L over 3 months (Ross et al., 2011; Aljohani, 2016). The final 
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optional recommendation is a dose of 7,500 µg one or two times per year for 
increasing serum vitamin D level (de Torrente de la Jara et al., 2006). 
The absorption of calcium in the small intestine can be adversely affected by 
low vitamin D levels (about 10%–15% absorption), but calcium absorption 
rises to about 30%–40% when the optimal vitamin D level is attained (Holick, 
2004). In this study, no significant increase was observed in mean corrected 
calcium concentration in intervention group A (100 µg vitamin D3) or B (50 µg 
vitamin D3). Neither of the intervention groups exceeded the normal range (< 
2.5 nmol/L), supporting the safe dose of vitamin D used to avoid 
hypercalcemia (Sugden et al., 2008). Hypercalcaemia results when the 
calcium concentration exceeds 3.5 nmol/L (Mirrakhimov, 2015), and serum 
vitamin D levels above 325 nmol/L are considered as vitamin D toxicity (Ozkan 
et al., 2012). Hypercalcemia affects cardiac, nervous system, renal, and 
gastrointestinal functions (Ozkan et al., 2012). 
There is an association between vitamin D and adipose tissue (Piccolo et al., 
2013). Each 2-unit increase of BMI (kg/m2) is associated with 1.15% decrease 
in the concentration of vitamin D (Vimaleswaran et al., 2013). In this study, 
there appeared a link between vitamin D levels and BMI in T2DM patients. It 
found an improvement in lowering the mean BMI in both groups A (100 µg 
vitamin D3) and B (50 µg vitamin D3) from 30.42 ± 5.27 kg/m2 to 29.63 ± 5.08 
kg/m2 and from 30.28 ± 5.26 kg/m2 to 29 ± 4.66 kg/m2, respectively. However, 
no significant difference was observed when comparing the intervention 
groups with the control after 16 weeks. Supporting this finding there was no 
significant association with changes in adipose tissue or circulating vitamin D3 
levels and reduced weight (Sebekova et al., 2015). 
One of the issues that emerges from these findings is that most of the T2DM 
patients in King Fahad Medical City were treated by high doses of vitamin D 
(50 µg/week vitamin D3). Amongst our exclusion criteria was if to any patients 
had taken vitamin D 3 months prior the study so as to avoid any confounding 
results as vitamin D has a circulating half-life of 15 days and a turnover in the 
body of two months (Aljohani, 2016). Patients were requested to return the 
vitamin D bottle to the clinical pharmacy to avoid non-compliance. However, 
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some of those retuned the vitamin D calendar sheet. Future trials should set 
up a reminder for patients to take the capsule to minimise non-compliance. It 
also recommends increasing the dose of vitamin D so it would be taken once 
a week, also to reduce non-compliance. 
4.5. Conclusion  
This study investigated vitamin D and BMI in men with poorly controlled T2DM. 
The results of this investigation show that intake of vitamin D3 was associated 
with a significant increase in the serum concentration of vitamin D (p < 0.001) 
and a reduction in BMI, and also that the supplementation had no adverse link 
to the corrected calcium levels.  
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Chapter 5 Effect of vitamin D3 supplementation on glycaemia in poorly-
controlled type-2 diabetes after 16 weeks 
  
74 
5.1. Introduction 
T2DM is a chronic metabolic disorder and has a major effect on increasing 
morbidity and mortality, (Altinok et al., 2016). Controlling blood glucose levels 
helps to reduce the development of microvascular and macrovascular 
complications (Chawla et al., 2016). Glycaemic control is indicated by HbA1c, 
which is the most important laboratory parameter (Kohnert et al., 2015). The 
general target of HbA1c is ≤7% for glycaemic control, with values over 7% 
showing poor glycaemic control (Phillips & Leow, 2014). Poor glycaemic 
control has been related to vitamin D deficiency (Kant et al., 2010; Unadike, 
2010).  
Vitamin D plays a vital role in dysfunctions of glucose and insulin metabolism, 
and therefore is conceivably linked with the development of T2DM (Jamka et 
al., 2015). A systematic review indicates that the risk of diabetes can 
potentially be modified by vitamin D (Danescu et al., 2009). There is now 
convincing evidence of the role of vitamin D in insulin secretion from the 
pancreas and in insulin sensitivity, and therefore the effect it has on the 
pathogenesis of diabetes (Borissova et al., 2003; Chiu et al., 2004). Vitamin D 
deficiency may affect glycaemia by impairing insulin secretion and insulin 
resistance in T2DM (Talaei et al., 2013). Vitamin D receptors are found on 
pancreatic β-cells, and vitamin D is essential for normal insulin secretion 
(Johnson et al., 1994; Mitri & Pittas, 2014). Subsequently, vitamin D is a 
regulator of insulin secretion from pancreatic β-cells (Zeitz et al., 2003). Also, 
vitamin D stimulates the expression of the insulin receptor (Maestro et al., 
2000).  
The aims of this study are to determine the effect of vitamin D3 
supplementation on controlling glycated haemoglobin, reducing glucose 
levels, and improving insulin resistance and β-cell function in poorly-controlled 
type-2 diabetic Saudi men. 
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5.2. Methods 
Blood samples were taken from all 128 participants at baseline and 16 weeks 
using the aseptic technique described in section 2.13. Fasting insulin was 
measured using the Roche electrochemiluminescent immunoassay COBAS 
E411 as described in section 2.16.5. Fasting glucose levels were determined 
using the Konelab, reference method described in section 2.16.3. β-cell 
function and insulin resistance were calculated according to the homeostasis 
assessment model as described in section 2.16.6. Glycated haemoglobin 
levels were determined using the Siemens DCA Vantage Analyser as per 
section 2.16.4.  
5.3. Result  
5.3.1. Analysis of the serum levels of glycated haemoglobin (HbA1c) in 
the intervention and control groups 
A total of 128 male patients with T2DM took part in the study. There were 43 
participants in group A (supplementation with 100 µg vitamin D3), 42 
participants in group B (supplementation with 50 µg vitamin D3) and 43 
participants in group C (control, placebo group). The mean concentrations of 
HbA1c were analysed for the three study groups, and differences between the 
pre-test and post-test mean HbA1c concentrations between the groups were 
analysed. A Two-way mixed ANOVA statistical test was used to compare the 
groups, and the summary of the results are presented in Table 5.1. The results 
show that there was statistically significant difference in the mean HbA1c 
concentrations between the measurement at baseline and at the end of the 
16-week-long intervention (F=131.51, p-value<0.001, Table 5.1.). 
Furthermore, there was a significant correlation between the duration of the 
intervention (“time”) and treatment effect, indicating that the effect of 
intervention, in at least one group, depended on the time of treatment 
(F=34.45, p <0.001). A significant difference in the mean HbA1c concentrations 
was found between the intervention and control groups when measured post-
test (F=14.47, p-value<0.001). 
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Table 5.1. Two-way mixed ANOVA comparing the mean differences of serum levels 
of HbA1c upon vitamin D supplementation 
Source of difference F-test P-value 
Between baseline and 16-wk intervention 131.51** <0.001 
Interaction time and groups 34.45** <0.001 
Between groups in pre-test 2.25 0.110 
Between groups in post-test 14.47** <0.001 
The comparisons included: the difference in mean HbA1c concentration in vitamin D 
supplementation groups (group A - 100 µg and group B - 50µg) and a control group (placebo) 
between baseline and after intervention, between the groups in pre-test measurement, and 
between groups in post-test. **indicates a significant difference at p < 0.001. 
Table 5.2. Post-hoc comparisons of the mean HbA1c serum concentration (%) among 
intervention groups and a control group at baseline and after the intervention period 
Group Baseline After 16 weeks Mean 
difference 
p-valueb 
A 9.77±.1.67 7.67±0.98 -2.10** <0.001 
B 9.20±1.10 8.24±1.02 -0.95** <0.001 
C 9.21±1.44 9.01±1.42 -0.20 0.222 
Intervention groups A, 100µg vitamin D, and B, 50µg vitamin D and control group (C), placebo. 
**indicates a significant difference between pre-test and post-test at p < 0.001; b indicates 
adjustment for multiple comparisons; mean ± SD. 
Comparison of the pre- and post-test results for each group showed that in 
group A the HbA1c decreased significantly after 16 weeks (mean difference     
=-2.10, p-value<0.001, see Table 5.2). For group B, the HbA1c also decreased 
significantly after 16 weeks (mean difference=-0.95, p-value=<0.001). The 
results of measurements of the HbA1c levels among intervention groups A and 
B and a control group C, at baseline and after the intervention period are also 
presented in Figure 5.1. 
After 16 weeks, the results (as analysed by two-way mixed ANOVA, Table 
5.1), showed that there was a significant difference in HbA1c between the three 
groups (F=14.47, p <0.00, Table 5.1). As the one-way ANOVA statistical 
analysis of the results of a post-hoc test showed, the mean HbA1c 
concentration in group A was significantly lower than in group B (mean 
difference=-0.57, p-value=.023, (see Table 5.3). Furthermore, the mean post-
intervention concentration of HbA1c in group A was significantly lower than in 
group C (mean difference=-1.34, p <0.001) and the post-intervention mean 
HbA1c concentration in group B was significantly lower than in group C (mean 
difference=-0.75, p <0.003). 
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Table 5.3. Post-hoc comparisons of the mean HbA1c concentrations among the 
intervention and the control groups after 16 weeks 
Time Group Group Mean difference p-valueb 
After 16 weeks 
A B -0.57 0.023 
A C -1.34** 0.001 
B C -0.75* 0.003 
Intervention groups A, 100µg vitamin D supplementation and B, 50µg vitamin D; are compared 
with control (placebo) group C after 16 weeks of intervention. **indicates a significant 
difference of p < 0.001; *indicates a significant difference of p < 0.05.  
 
Figure 5.1. Mean changes of HbA1c concentration with vitamin D treatment 
The bar chart shows intervention groups A, 100µg vitamin D3 (n=43) and B, 50µg vitamin D3 
(n=42) compared with the placebo group (C) as control (n=43), between pre-test and post-test 
measurements. Results are presented as mean ± SD (n=128). Statistically significant 
differences of p < 0.001 are marked with (**) and of p < 0.05) are marked with (*). 
5.3.2. Comparison of fasting blood glucose levels between the 
intervention and control groups  
A total of 128 male patients with T2DM took part in the study. There were 43 
participants in group A (supplementation with 100 µg vitamin D3), 42 
participants in group B (supplementation with 50 µg vitamin D3) and 43 
participants in group C (control, placebo group). Analysis of the changes in 
concentrations of blood glucose between the intervention groups A, B and the 
control (C) group), pre- and post-intervention, was performed using a two-way 
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mixed ANOVA test. The results of the analysis are shown in Table 5.4. As the 
results of the mixed ANOVA showed, there was a highly significant difference 
in mean glucose concentration between the baseline and the 16-week point 
(F=67.46, p <0.001, Table 5.4). The interaction between time and treatment 
was also statistically significant (F=28.07, p <0.001), indicating that the 
treatment effect in at least one group depended on the duration of the 
treatment. 
Table 5.4. Two-way mixed ANOVA analysis of differences in the mean fasting blood 
glucose concentrations upon vitamin D supplementation 
Source of difference F-test P-value 
Between times (pre- and post-test) 67.46** <0.001 
Interaction time and groups 28.07** <0.001 
Between groups in pre-test 1.47 0.232 
Between groups in post-test 10.95** <0.001 
The comparisons included: the difference in mean fasting blood glucose concentrations in 
vitamin D supplementation groups (group A - 100 µg and group B - 50µg) and a control group 
(placebo) between baseline and after intervention, between different doses and intervention 
period, between the groups in pre-test measurement, and between groups in post-test. 
Table 5.5. Post-hoc comparisons of the differences between the mean fasting blood 
glucose concentrations (mmol/L) among the intervention and control groups at 
baseline and after the intervention study 
Group Baseline After 16 weeks Mean difference p-valueb 
A 11.80±.4.31 8.22±2.24 -3.58** <0.001 
B 10.46±.3.30 9.78±2.77 -0.67* 0.044 
C 11.51±3.64 11.07±3.64 -0.44 0.179 
Intervention groups A, 100µg vitamin D supplementation and B, 50µg vitamin D and control 
(C), placebo group. **indicates a significant difference between pre-test and post-test of p < 
0.001; *indicates a significant difference between pre-test and post-test of p < 0.05; b indicates 
adjustment for multiple comparisons; mean ± SD. 
The results one-way ANOVA analysis of differences in the mean blood glucose 
concentrations (mmol/L) in the intervention groups and a control group, 
between the baseline and the measurements after the intervention period are 
summarised in Table 5.5, showed that in group A the blood glucose 
concentration decreased significantly after 16 weeks (mean difference=-3.58, 
p <0.001). The mean blood glucose concentration in group B also decreased 
significantly after 16 weeks (mean difference=-0.67, p <0.044). The 
differences in mean blood glucose concentrations (mmol/L) in the groups 
between baseline and after 16 weeks of treatment are also shown in Figure 
5.2. 
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A two-way mixed ANOVA analysis (results given in Table 5.4) showed that 
after 16 weeks there were significant differences in the mean blood glucose 
concentration between the three groups (F=10.95, p <0.001, Table 5.4). Using 
one-way ANOVA analysis of the results of the post-hoc testing (see Table 5.6 
and Figure 5.2), it was established that the mean blood glucose concentration 
in group A was significantly lower than in group B (mean difference=-1.56, p 
=0.012). In addition, the mean blood glucose concentration in group A was 
significantly lower than in group C (mean difference=-2.85, p <0.001). The 
mean blood glucose concentration in group B was also significantly lower than 
in group C (mean difference=-1.28, p =0.038).  
Table 5.6. Post-hoc comparisons of fasting blood glucose levels (mmol/L) among 
intervention groups and control after 16 weeks 
Time Group Group Mean difference p-valueb 
After 16 weeks 
A B -1.56* 0.012 
A C -2.85** <0.001 
B C -1.28* 0.038 
Intervention groups A, 100µg vitamin D supplementation and B, 50µg vitamin D 
supplementation are compared with control (placebo) group C after 16 weeks of intervention. 
**indicates a significant difference between the groups of p<0.001; *indicates a significant 
difference between the groups of p<0.05; b indicates adjustment for multiple comparisons. 
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Figure 5.2. Changes in the mean fasting blood glucose concentrations (mmol/L) in 
intervention and control groups between pre-test and post-test measurements 
The bar chart shows intervention groups A, 100µg vitamin D3 (n=43) and B, 50µg vitamin D3 
(n=42) compared with the placebo group (C) as control (n=43), between pre-test and post-test 
measurements. Results are presented as mean ± SD (n=128). Statistically significant 
differences of p < 0.001 are marked with (**) and of p < 0.005) are marked with (*). 
5.3.3. Analysis of differences in the insulin levels between the 
intervention and control groups 
A total of 128 male patients with T2DM took part in the study. There were 43 
participants in group A (supplementation with 100 µg vitamin D3), 42 
participants in group B (supplementation with 50 µg vitamin D3) and 43 
participants in group C (control, placebo group). The changes in insulin levels 
(µU/mL) were analysed among groups A, B and C pre-test as well as post-
test, by two-way mixed ANOVA statistical analysis. The results (summarised 
in Table 5.7) show that no statistically significant difference (of p<0.05) was 
observed between the pre- and post-hoc insulin levels, nor between the 
groups either pre- or post-test. Furthermore, no significant correlation between 
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the duration of the intervention and the effect on insulin levels was observed 
in the studied groups. 
Table 5.7. Two-way mixed ANOVA test comparing the mean differences of insulin 
levels upon vitamin D supplementation 
Source of difference F-test P-value 
Between times 0.26 0.610 
Interaction time and groups 0.06 0.941 
Between groups in pre-test 0.01 0.985 
Between groups in post-test 0.04 0.961 
The comparisons included: the difference in mean insulin levels in vitamin D supplementation 
groups (group A - 100 µg and group B - 50µg) and a control group (placebo) between baseline 
and after intervention, between different doses and intervention period, between the groups 
in pre-test measurement, and between groups in post-test. 
Table 5.8. Post-hoc comparisons of insulin (µU/mL) levels among the intervention 
and control groups, at baseline and after the intervention 
Group Baseline After 16 weeks Mean difference p-valueb 
A 16.23±2.81 17.79±2.64 1.57 0.581 
B 16.73±2.85 16.88±2.67 0.15 0.956 
C 16.06±2.71 16.86±2.6 0.79 0.779 
Intervention groups A, 100µg vitamin D supplementation and B, 50µg vitamin D and control 
(C) - placebo group. b indicates adjustment for multiple comparisons; mean ±SD. 
Furthermore, the post-hoc comparison between the mean insulin levels 
(µU/mL) in the intervention groups and control, and between the baseline and 
after the intervention period, using the mixed ANOVA test are shown in Table 
5.8, and Figure 5.3), did not reveal any statistically significant changes (of 
p<0.05) in insulin levels between the pre- and post-test (F=0.26, p-
value=0.610, Table 5.7). Similarly, the interaction between duration of the 
treatment and effect on the group was not significant (F=0.06, p-value=0.941), 
nor were there differences between the groups pre- and post-test. 
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Figure 5.3. Mean changes in insulin level (µU/mL) in the intervention groups A and B, 
and the control group C (placebo) 
The bar chart shows intervention groups A, 100µg vitamin D3 (n=43) and B, 50µg vitamin D3 
(n=42) compared with the placebo group (C) as control (n=43), between pre-test and post-
test measurements were not statistically significant. Results are presented as mean ± SD 
(n=128).  
5.3.4. Insulin resistance (HOMA-IR) analysis before and after the 
intervention 
A total of 128 male patients with T2DM took part in the study. There were 43 
participants in group A (supplementation with 100 µg vitamin D3), 42 
participants in group B (supplementation with 50 µg vitamin D3) and 43 
participants in group C (control, placebo group). The homeostatic model 
assessment (HOMA) was used to quantify insulin resistance (IR) in the studied 
patient groups. The changes in the mean calculated HOMA-IR values were 
analysed among groups A, B and C pre- and post-test, as well as in relation 
to the duration of treatment, by two-way mixed ANOVA as summarised in 
Table 5.9). The results of the two-way mixed ANOVA test showed that there 
was no significant difference in mean HOMA-IR between the pre- and post-
tests (F=0.590, p-value=0.444, Table 5.9), nor between the groups in pre- or 
post-test (F=0.105, p-value=0.9, and F=0.349, p-value=0.706, respectively). 
In addition, the interaction between treatment duration and the effect was not 
significant (F=0.199, p-value=0.900).  
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Table 5.9. Two-way mixed ANOVA comparing the mean differences of HOMA-IR 
upon vitamin D supplementation 
Source of difference F-test P-value 
Between times 0.590 0.444 
Interaction time and the three groups 0.199 0.820 
Between the three groups in pre-test 0.105 0.900 
Between the three groups in post-test 0.349 0.706 
The comparisons included: the difference in mean HOMA-IR in vitamin D supplementation 
groups (group A - 100 µg and group B - 50µg) and a control group (placebo) between baseline 
and after intervention, between different doses and intervention period, between the groups 
in pre-test measurement, and between groups in post-test. 
Table 5.10. Post-hoc comparisons of HOMA-IR between groups (intervention and 
control) at baseline and after the intervention study 
Group Baseline After 16 weeks Mean difference p-valueb 
A 8.18±1.48 6.62±1.35 -1.56 0.339 
B 7.50±1.50 16.88±1.37 -0.35 0.828 
C 8.44±1.49 16.86±1.35 0.25 0.876 
Intervention groups A, 100µg vitamin D supplementation and B, 50µg vitamin D; control group 
(C) placebo. b indicates adjustment for multiple comparisons; mean ±SD. 
The mean HOMA-IR concentrations among the intervention groups and 
control group from the baseline to after the intervention period were calculated 
(as summarised in Table 5.10). The small decreases in mean HOMA-IR values 
in groups A, B and C, between baseline and after 16 weeks of treatment, were 
not statistically significant (see Table 5.10 and Figure 5.4). 
 
Figure 5.4. Mean changes in insulin resistance (HOMA-IR) in the intervention groups 
A and B, and the control group C (placebo) 
The bar chart shows intervention groups A, 100µg vitamin D3 (n=43), and B, 50µg vitamin D3 
(n=42) compared with the placebo group (C) as control (n=43), between pre-test and post-
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test measurements were not statistically significant. Results are presented as mean ± SD 
(n=128).  
5.3.5. β-cell function (HOMA-β) analysis pre- and post-intervention 
A total of 128 male patients with T2DM took part in the study. There were 43 
participants in group A (supplementation with 100 µg vitamin D3), 42 
participants in group B (supplementation with 50 µg vitamin D3) and 43 
participants in group C (control, placebo group). The homeostatic model 
assessment (HOMA) was used to quantify β-cell function in the patient groups 
studied. The changes in the mean percentage of β-cell function (HOMA-β) 
were analysed among groups A, B and C pre- and post-test, by two-way mixed 
ANOVA, as summarised in Table 5.11.  The results of the mixed ANOVA test 
showed that there was a significant increase in mean percentage of β-cell 
function between the pre- and post-tests (F=8.03, p-value=0.005, Table 5.11). 
In addition, the interaction between treatment duration and treatment effect 
was statistically significant (F=3.85, p-value=0.024). 
Table 5.11. Two-way mixed ANOVA comparing the mean differences in HOMA-β 
upon vitamin D supplementation 
Source of difference F-test P-value 
Between times 8.03** 0.005 
Interaction time and the three groups 3.85* 0.024 
Between the three groups in per-test 0.533 0.588 
Between the three groups in post-test 2.66 0.073 
The comparisons included: the difference in mean HOMA-β in vitamin D supplementation 
groups (group A - 100 µg and group B - 50µg) and a control group (placebo) between baseline 
and after intervention, between different doses and intervention period, between the groups 
in pre-test measurement, and between groups in post-test.**indicates a significant difference 
at p < 0.01 with * of p < 0.005. 
Table 5.12. Post-hoc comparisons of HOMA-β (%) between the groups (intervention 
and control) at baseline and after the intervention study 
Group Baseline After 16 weeks Mean difference p-valueb 
A 50±9.89 96.96±13.72 46.45** <0.001 
B 60.50±9.99 65.54±13.92 5.04 0.675 
C 46.38±9.87 53.37±13.76 6.99 0.557 
Intervention groups A, 100µg vitamin D supplementation and B, 50µg vitamin D; control group 
(C) – placebo. **indicates a significant difference p < 0.001 b indicates adjustment for multiple 
comparisons; mean ±SD.  
The mean levels of HOMA-β % among the intervention groups and control 
group at the baseline and after the intervention period were calculated (see 
Table 5.12). Comparison of the pre- and post-test results for each group 
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revealed, that in group A β-cell activity increased significantly after 16 weeks 
(mean difference = 46.45, p-value<0.001). For group B, the HOMA-β 
increased slightly, but the result was not statistically significant (mean 
difference=5.04, p-value=0.675). The differences in mean HOMA-β % in the 
groups from baseline to 16 weeks post-treatment are also presented in Figure 
5.5. 
 
Figure 5.5. Mean changes in β-cell function (HOMA-β) in the intervention groups A 
and B, and the control group C (placebo) 
The bar chart shows intervention groups A, 100µg vitamin D3 (n=43) and B, 50µg vitamin D3 
(n=42) compared with the placebo group (C) as control (n=43), between pre-test and post-
test measurements. Results are presented as mean ± SD (n=128). Statistically significant 
differences of p < 0.001 are marked with **  
5.4. Discussion  
The relationship between vitamin D deficiency, glucose metabolism and 
insulin resistance is inconsistent with the literature. This study has found that 
vitamin D supplementation with either 100µg or 50µg per day significantly 
improves the HbA1c and reduces glucose levels as compared to the placebo 
group. In contrast, there were no significant changes in insulin resistance. In 
addition, there was a slight, but not significant, increase in insulin and HOMA-
β at both doses of vitamin D, with 100µg/day producing a larger increase than 
50µg/day compared to the placebo group. These findings support previous 
studies (Yiu et al., 2013; Ryu et al., 2014).  
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This study found a significant improvement in HbA1c in those supplemented 
with vitamin D. After 16 weeks of vitamin D supplementation for group A, the 
HbA1c decreased significantly (mean difference= -2.10, p-value<0.001). For 
group B, the HbA1c also decreased significantly after 16 weeks (mean 
difference=-0.95, p-value=<0.001). Previous studies have found a significant 
association between Hba1c and serum vitamin D levels in diabetic subjects     
(Kositsawat et al., 2010;Tahrani et al., 2010; Mohamad et al., 2016). Tromso 
(2011) also found a significant association between serum vitamin D levels 
and HbA1c (p <0.001) after adjusting for gender, age, BMI, physical activity, 
serum triglycerides, serum calcium, and haemoglobin (Hutchinson et al., 
2011). This association seems to be most obvious in the elderly, obese, and 
in those with the highest triglyceride levels and impaired glucose tolerance risk 
factors for T2DM. A cross-sectional study of 715 T2DM patients found a 
significant association between HbA1c and serum vitamin D (p=0.003) (Zoppini 
et al., 2013). Another a cross-sectional study of 233 T2DM patients, who 
ranged in age from 16 to 96 years and who took vitamin D supplements for a 
six-month period, found an association between vitamin D and the HbA1c 
concentrations (p=0.039) (Sebekova et al., 2015). However, other authors 
have failed to find a significant effect on Hba1c level in subjects with low 
concentrations of serum vitamin D levels (less than 50 nmol/L) (Luo et al., 
2009). Even with glycaemic control, vitamin D supplementation was not found 
to have any affect (Jorde & Figenschau, 2009; Patel et al., 2010). A 
randomised double-blind control trial found no change in HbA1c levels with a 
single intramuscular injection of 7500 µg of vitamin D supplemented after three 
months, in 42 Iranian T2DM patients (Heshmat et al., 2012). That could be 
due to poor glycaemic control, in which vitamin D ineffective due to the low 
activity of 25-hydroxylase in the liver (Zoppini et al., 2013). 
There is an association between vitamin D supplementation and improved 
fasting blood glucose levels (Kayaniyil et al., 2010). In our study, there was a 
significant difference in fasting glucose (p=0.001) among the intervention 
groups (50µg and 100µg vitamin D3) compared to the control group. Fasting 
plasma glucose has also been shown to differ significantly after an intake of 
1250µg vitamin D once a week for eight weeks in 100 Iranian T2DM patients 
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(p=0.05) (Talaei et al., 2013). However, a cross-sectional study of 715 
ambulatory T2DM patients found no significant association with fasting plasma 
glucose (p=0.122) (Zoppini et al., 2013). A meta-analysis of several studies of 
vitamin D supplementation showed no effect on the glucose homeostasis 
(Seida et al., 2014). A randomised control trial did not find a significant 
difference between subjects administered with vitamin D and the placebo 
group on the fasting blood glucose levels after six months’ intake of 1000µg of 
vitamin D per week in 36 subjects with T2DM (Jorde &  Figenschau, 2009). 
Our finding varies from a larger randomised study with 100 T2DM patients with 
an intake of 125µg per day of vitamin D or a placebo for 12 weeks (Yiu et al., 
2013). This could result from the concentration of vitamin D, which was around 
77 nmol/L and above in our study (see Table 4.2). An improvement of 
glycaemic levels has been shown where the vitamin D concentration is above 
80 nmol/L (von Hurst et al., 2010). 
In our study, there was no significant difference in fasting insulin levels, 
HOMA-IR and HOMA-β between the intervention groups (50µg and 100µg 
vitamin D3) compared to the control group. Measure insulin level is the best 
way to calculate insulin resistance (HOMA-IR) and insulin secretion (HOMA-
β) (Laakso, 1993). Previous studies had similar results (Bjordal et al., 2000; 
Jorde & Figenschau, 2009; De Boer, 2008; Heshmat et al., 2012). A 
randomised study of 61 subjects in two intervention groups and a placebo 
group, and intakes of 2500µg or 5000µg vitamin D3 for 16 weeks, did not find 
an improvement in HOMA-IR and HbA1c (Witham et al., 2010). These findings 
have been supported with smaller studies using different supplement dosages 
and durations, which also demonstrated vitamin D to have an effect on insulin, 
HOMA-IR and HOMA-β (Heshmat et al., 2012; Breslavsky, et al., 2013; Ryu 
et al., 2014; Kampmann et al., 2014; Al-Shahwan et al., 2015). Nevertheless, 
an improvement in glucose control found after vitamin D supplementation in 
T2DMmellitus (Borissova et al., 2003; Al-Daghri, et al., 2012a; Mohamad et 
al., 2016). An intervention study in 92 Saudi diabetic patients found a 
significant difference in insulin levels (p<0.001), and an improvement in 
HOMA-IR (p<0.001) and HOMA-β (p< 0.002) in 120 diabetes patients taking 
50µg/day of vitamin D3 for 18 months. It showed that this improvement was 
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more marked in women than in men (Al-Daghri, et al., 2012a). In a randomised 
controlled trial, an intake of 50µg vitamin D3 daily for 16 weeks was found to 
improve β-cell function in those at high risk of diabetes (Mitri et al., 2011). 
Another interventional study with similar doses of vitamin D (50µg/day) found 
a significant difference in HOMA-IR (p=0.052) and insulin (p=0.044) in 45 
Saudi T2DM patients after 12 months’ intervention (Al-Shahwan et al., 2015). 
A daily dose of 100µg for six months improved the HOMA-IR when the vitamin 
D concentration was above 80 nmol/L (von Hurst et al., 2010). Another 
intervention study also found an improvement in HOMA-IR when the vitamin 
D concentration was between 100 and 150 nmol/L, but no improvement when 
the vitamin D concentration was below 100nmol/L (Talaei et al., 2013). Talaei 
(2013) found a significant effect on insulin and HOMA-IR in 100 Iranian T2DM 
patients after an intake of 1250 µg/week for eight weeks.  
On the other hand, insulin resistance and fasting blood glucose levels were 
unchanged after three years of vitamin D supplementation at 17.5 µg per day, 
and both markers had significantly increased in the placebo group (Pittas et 
al., 2007). This suggests that vitamin D may not improve insulin resistance 
and fasting blood glucose levels. The difference in outcomes may be related 
to the different doses used, the low vitamin D concentration, ethnic 
background, and the sample size. Improvements were seen when vitamin D 
doses were 50 µg or higher, the vitamin D concertation was above 80 nmol/L, 
and the sample size was larger. Future studies are essential to understand the 
relationship between glycaemic control and vitamin D in T2DM. Also, there 
needs to be clarification on, for instance, the type of anti-diabetic medication 
taken, as this can lead to confusion.  
5.5. Conclusion 
This study examined the effects of vitamin D on glycaemia and found it 
significantly lowered glycated haemoglobin (p <0.001) and fasting glucose 
levels (p <0.001), in both intervention groups compared with the placebo 
group. There was no significant effect on insulin levels or homeostasis 
assessment models in poorly controlled T2DM. This suggests that vitamin D 
may not be essential to improving the homeostasis assessment model marker, 
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however, vitamin D could have a role in control the development of diabetic 
complications.  
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Chapter 6 Effect of vitamin D3 supplementation on lipidaemia in poorly-
controlled type-2 diabetes after 16 weeks 
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6.1. Introduction  
Vitamin D deficiency is related with atherosclerosis (De Boer et al., 2008), 
obesity (Wortsman et al., 2000), and diabetes (Scragg, 2008). Dyslipidaemia 
is a major risk factor in developing cardiovascular disease (Paciaroni et al., 
2007). Vitamin D deficiency has been related with an increase in total 
cholesterol and increase in triglycerides (Martins et al., 2007; Karhapaa et al., 
2010; Chaudhuri et al., 2013). Also, lower HDL levels have been linked with 
vitamin D deficiency (Wang et al., 2008; Choi et al., 2011). However, the 
relationship between vitamin D and dyslipidaemia is contentious (Filippatos et 
al., 2017).  
Vitamin D deficiency may reduce circulating triglycerides via suppression of 
hepatic triglyceride formation and increased the hepatic calcium intake 
(Wimalawansa, 2016). Another mechanism by which vitamin D might increase 
calcium absorption, reducing fatty acids in the gut, increasing fat absorption 
and lowering triglyceride levels (Zittermann, 2006; Christensen et al., 2009). 
The aim of this study was to investigate the effect of vitamin D on improving 
dyslipidaemia by increasing high-density lipoprotein, and by lowering the 
serum levels of total cholesterol, triglycerides and low-density lipoprotein in 
poorly controlled type-2 diabetic Saudi men. 
6.2. Methods 
Blood samples were taken from all 128 participants at baseline and 16 weeks 
using the aseptic technique described in section 2.13. High-density lipoprotein 
(HDL), low-density lipoprotein (LDL), triglycerides and total cholesterol were 
determined using the Siemens DCA Vantage Analyzer as per section 2.16.7.  
6.3. Results  
6.3.1. Analysis of the serum levels of total cholesterol in the intervention 
and control groups 
A total of 128 male patients with T2DM took part in the study. There were 43 
participants in group A (supplementation with 100 µg vitamin D3), 42 
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participants in group B (supplementation with 50 µg vitamin D3) and 43 
participants in group C (control, placebo group). The mean concentrations of 
total cholesterol were analysed among the three groups A, B and C, and 
differences between the pre-test and post-test mean total cholesterol 
concentrations among the groups were analysed. A two-way mixed ANOVA 
statistical test was used to compare the groups, and the summary of the 
results is presented in Table 6.1. The results have shown that there was a 
statistically significant difference in the mean total cholesterol concentrations 
between the measurement at baseline and at the end of the 16-week long 
intervention (F=19.038, p-value<0.001, Table 6.1). Furthermore, there was a 
significant difference in mean total cholesterol concentrations was found 
between the intervention and control groups when measured post-test 
(F=5.55, p-value<0.005). 
Table 6.1. Two-way mixed ANOVA comparing the mean differences of serum levels 
of total cholesterol upon vitamin D supplementation 
Source of difference F-test P-value 
Between baseline and 16-wk intervention 19.038** <0.001 
Interaction time and the three groups 7.45** 0.001 
Between the three groups per-test 0.951 0.389 
Between the three groups post-test 5.555* 0.005 
The comparisons included: the difference in mean total cholesterol concentration in vitamin D 
supplementation groups (group A - 100 µg and group B - 50µg) and a control group (placebo) 
between baseline and after intervention, between different doses and intervention period, 
between the groups in pre-test measurement, and between groups in post-test.**indicates a 
significant difference at p < 0.01 with * of p < 0.005. 
Table 6.2. Post-hoc comparisons of the mean total cholesterol serum concentration 
(in mmol/L) among intervention groups and a control group at baseline and after the 
intervention period 
Group Baseline After 16 weeks Mean difference p-valueb 
A 4.74±1.38 3.77±0.96 -0.965** <0.001 
B 4.40±1.22 3.89±1.00 -0.513** 0.008 
C 4.42±1.17 4.48±1.17 0.056 0.765 
Intervention groups A, 100µg vitamin D and B, 50µg vitamin D and control group C, placebo. 
**indicates a significant difference between pre-test and post-test of p < 0.001; b indicates 
adjustment for multiple comparisons; mean ±SD. 
Comparison of the pre- and post-test results for each group showed that in 
group A the total cholesterol decreased significantly after 16 weeks (mean 
difference=-0.965, p-value<0.001, see Table 6.2). For group B, the total 
cholesterol also decreased significantly after 16 weeks (mean difference= 
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0.513, p-value=<0.008, Table 6.1). The results of measurements of the total 
cholesterol levels among groups A and B and C, at baseline and after the 
intervention period are also presented in Figure 6.1. 
After 16 weeks, the results (as analysed by two-way mixed ANOVA, presented 
in Table 6.2), showed that there was a significant difference in total cholesterol 
between the three groups (F=5.55, p <0.005, Table 6.1). As the one-way 
ANOVA statistical analysis of the results of a post-hoc testing showed, the 
mean total cholesterol concentration in group A was lower than in group B 
(mean difference=-0.12, (see Table 6.2). Furthermore, the mean post-
intervention concentration of total cholesterol in group A was significantly lower 
than in group C (mean difference=-0.71, p <0.002) and the post-intervention 
mean total cholesterol concentration in group B was significantly lower than in 
group C (mean difference=-0.59, p <0.01). 
Table 6.3. Post-hoc comparisons of the mean total cholesterol concentrations among 
the intervention and the control groups after 16 weeks 
Time Group Group Mean difference  p-valueb 
After 16 weeks 
A B -0.12 0.612 
A C -0.71** 0.002 
B C -0.59** 0.01 
Intervention groups A, 100µg vitamin D supplementation and B, 50µg vitamin D are compared 
with control (placebo) group C after 16 weeks of intervention. **indicates a significant 
difference of p < 0.001. 
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Figure 6.1. Mean changes of total cholesterol concentration in vitamin D treatment 
The bar chart shows intervention groups A, 100µg vitamin D3 (n=43) and group B, 50µg 
vitamin D3 (n=42) compared with the placebo group (C) as control (n=43), between pre-test 
and post-test measurements. Results are presented as mean ± SD (n=128). Statistically 
significant differences of p < 0.001 are marked with (**).  
6.3.2. Triglycerides 
A total of 128 male patients with T2DM took part in the study. There were 43 
participants in group A (supplementation with 100 µg vitamin D3), 42 
participants in group B (supplementation with 50 µg vitamin D3) and 43 
participants in group C (control, placebo group). Analysis of the changes in 
concentrations of triglycerides between the intervention groups A, B and C, 
pre- and post-intervention, was performed using a two-way mixed ANOVA 
test. The results of the analysis are shown in Table 6.4. As the results of the 
mixed ANOVA showed, there was a highly significant difference in mean 
triglyceride concentrations between the baseline and a sixteen-week point 
(F=28.19, p-value<0.001, Table 6.4). The interaction between time and 
treatment was also statistically significant (F=20.02, p-value<0.001), indicating 
that the treatment effect in at least one group depended on the duration of the 
treatment. 
95 
Table 6.4. Two-way mixed ANOVA analysis of differences in the mean triglycerides 
concentrations (mmol/L) upon vitamin D supplementation 
Source of difference F-test P-value 
Between times (pre- and post-test) 28.19** <0.001 
Interaction time and the three groups 20.02** <0.001 
Between the three groups in per-test 0.100 0.91 
Between the three groups in post-test 8.86** <0.001 
The comparisons included: the difference in mean triglycerides concentrations in vitamin D 
supplementation groups (group A - 100 µg and group B - 50µg) and a control group (placebo) 
between baseline and after intervention, between different doses and intervention period, 
between the groups in pre-test measurement, and between groups in post-test.**indicates a 
significant difference at p < 0.01. 
 
Table 6.5. Post-hoc comparisons of the differences between the mean triglyceride 
concentrations (mmol/L) among groups (intervention and control) at baseline and 
after the intervention study 
Group Baseline After 16 weeks Mean difference p-valueb 
A 2.14±0.85 1.3±0.43 -0.833** <0.001 
B 2.07±.1.16 1.97±.1.07 -0.09 0.337 
C 2.16±1.01 2.16±1.24 -0.004 0.972 
Intervention groups A, 100µg vitamin D supplementation and B, 50µg vitamin D and control 
(C) - placebo group. **indicates a significant difference between pre-test and post-test of p < 
0.001; b indicates adjustment for multiple comparisons; mean ± SD.  
The results one-way ANOVA of differences in the mean triglyceride 
concentrations (mmol/L) between the intervention and control groups, 
between baseline and post- intervention period measurements are 
summarised in Table 6.5). These show that in group A the triglyceride 
concentration decreased significantly after 16 weeks (mean difference=-
0.833, p-value<0.001). The mean triglyceride concentration in group B also 
decreased, but not significantly, after 16 weeks (mean difference=-0.09, p 
<0.337). The differences in mean triglyceride concentrations (mmol/L) in the 
groups between baseline and after 16 weeks of treatment are also shown in 
Figure 6.2. 
A two-way mixed ANOVA analysis (Table 6.4) showed that after 16 weeks 
there were significant differences in the mean triglycerides concentration 
between the three groups (F=8.86, p <0.001). Using one-way ANOVA analysis 
of the results of the post-hoc testing (see Table 6.6 and Figure 6.2), it was 
established that the mean triglycerides concentration in group A was 
significantly lower than in group B (mean difference=-0.66, p <0.002). In 
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addition, the mean triglyceride concentration in group A was significantly lower 
than in group C (mean difference= -0.85, p <0.001). The mean triglyceride 
concentration in group B was also lower but not significantly different from 
group C (mean difference= -0.19).  
Table 6.6. Post-hoc comparisons of triglyceride levels (mmol/L) between intervention 
groups and control after 16 weeks 
Time Group Group Mean difference  p-valueb 
After 16 week 
A B -0.66** 0.002 
A C -0.85** <0.001 
B C -0.19 0.377 
Intervention groups A, 100µg vitamin D supplementation B, 50µg vitamin D compared with 
control (placebo) group C after 16 weeks of intervention. **indicates a significant difference 
between the groups of p<0.001; b indicates adjustment for multiple comparisons. 
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Figure 6.2. Changes in the mean triglyceride concentrations (mmol/L) in the 
intervention and control groups pre-test and post-test 
The bar chart shows intervention groups A, 100µg vitamin D3 (n=43) and B, 50µg vitamin D3 
(n=42) compared with the placebo group (C) as control (n=43) between pre-test and post-
test measurements. Results are presented as mean ± SD (n=128). Statistically significant 
differences of p < 0.001 are marked with **.  
6.3.3. High-density lipoprotein (HDL) 
A total of 128 male patients with T2DM took part in the study. There were 43 
participants in group A (supplementation with 100 µg vitamin D3), 42 
participants in group B (supplementation with 50 µg vitamin D3) and 43 
participants in group C (control, placebo group). The mean concentrations of 
HDL were analysed among group A, B and C, and differences between the 
pre-test and post-test mean HDL concentrations among the groups were 
analysed. A two-way mixed ANOVA statistical test was used to compare the 
groups, and the summary of the results is presented in Table 6.7. The results 
show that there was statistically significant difference in the mean HDL 
concentrations between the measurement at baseline and at the end of the 
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16-week long intervention (F=79.52, p-value<0.001, Table 6.7). Furthermore, 
there was a significant difference in mean HDL concentrations between the 
intervention and control groups when measured post-test (F=43.61, p-
value<0.001). 
Table 6.7. Two-way mixed ANOVA comparing the mean differences of serum levels 
of HDL upon vitamin D supplementation 
Source of difference F-test P-value 
Between baseline and 16-wk intervention 79.52** <0.001 
Interaction time and the three groups 39.61** <0.001 
Between the three groups in per-test 0.008 0.992 
Between the three groups in post-test 43.61** <0.001 
The comparisons included: the difference in mean HDL concentrations in vitamin D 
supplementation groups (group A - 100 µg and group B - 50µg) and a control group (placebo) 
between baseline and after intervention, between different doses and intervention period, 
between the groups in pre-test measurement, and between groups in post-test.**indicates a 
significant difference at p < 0.01. 
Table 6.8. Post-hoc comparisons of the mean HDL serum concentration (mmol/L) 
between the intervention groups and control group at baseline and after the 
intervention period 
Group Baseline After 16 weeks Mean difference p-valueb 
A 0.90±.338 1.60±.461 0.70** <0.001 
B 0.89±.311 1.08±.347 0.19** 0.002 
C 0.90±.335 0.90±.247 0.004 0.951 
Intervention groups A, 100µg vitamin D and B, 50µg vitamin D and control group (C), 
placebo.**indicates a significant difference between pre-test and post-test of p< 0.001. b 
indicates adjustment for multiple comparisons; ± mean SD. 
Comparison of the pre- and post-test results for each group showed that in 
group A the HDL increased significantly after 16 weeks (mean 
difference=0.70, p-value<0.001, see Table 6.8). For group B, the HDL also 
increased significantly after 16 weeks (mean difference=0.19, p-value<0.002). 
The results of measurements of the HDL levels among intervention groups A 
and B and a control group C, at baseline and after the intervention period are 
also presented in Figure 6.3. 
After 16 weeks, the results (as analysed by two-way mixed ANOVA, Table 
6.9), showed that there was a significant difference in HDL between the three 
groups (F=79.52, p-value <0.001). As the one-way ANOVA statistical analysis 
of the results of a post-hoc testing showed, the mean HDL concentration in 
group A was significantly increased than in group B (mean difference=0.53, p-
value<0.001, (see Table 6.9). Furthermore, the mean post-intervention 
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concentration of HDL in group A was significantly greater than in group C 
(mean difference= 0.70, p <0.001) and the post-intervention mean HDL 
concentration in group B was significantly greater than in group C (mean 
difference=0.18, p <0.03). 
Table 6.9. Post-hoc comparisons of the mean HDL concentrations between the 
intervention and control groups after 16 weeks 
Time Group Group Mean difference p-valueb 
After 16 weeks 
A B 0.53** <0.001 
A C 0.70** <0.001 
B C 0.18** 0.03 
Intervention groups A, 100µg vitamin D supplementation and B, 50µg vitamin D are compared 
with control (placebo) group C after 16 weeks of intervention. **indicates a significant 
difference of p < 0.001; b indicates adjustment for multiple comparisons.  
 
Figure 6.3. Mean changes of HDL concentration in vitamin D treatment 
The bar chart shows intervention groups A, 100µg vitamin D3 (n=43)  and B,50µg vitamin D3 
(n=42) compared with the placebo group (C) as control (n=43) between pre-test and post-test 
measurements. Results are presented as mean ± SD (n=128). Statistically significant 
differences of p < 0.001) are marked with **.  
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6.3.4. Low-density lipoprotein (LDL) 
A total of 128 male patients with T2DM took part in the study. There were 43 
participants in group A (supplementation with 100 µg vitamin D3), 42 
participants in group B (supplementation with 50 µg vitamin D3) and 43 
participants in group C (control, placebo group). Analysis of the changes in 
concentrations of LDL between groups A, B and C pre- and post-intervention, 
was performed using a two-way mixed ANOVA test. The results of the analysis 
are shown in Table 6.10. As the results of the mixed ANOVA show there was 
a highly significant difference in mean LDL concentration between the baseline 
and 16-week point (F=103.22, p-value<0.001, Table 6.10). The interaction 
between time and treatment was also statistically significant (F=26.65, p-
value<0.001, Table 6.10), indicating that the treatment effect in at least one 
group depended on the duration of the treatment. 
Table 6.10. Two-way mixed ANOVA analysis of differences in the mean fasting LDL 
concentrations (mmol/L) upon vitamin D supplementation 
Source of difference F-test P-value 
Between times (pre- and post-test) 103.22** <.001 
Interaction between different doses, intervention period and 
groups 
26.65** <.001 
Between the three groups in per-test 1.88 .157 
Between the three groups in post-test 13.97** <.001 
The comparisons included: the difference in mean LDL concentrations in vitamin D 
supplementation groups (group A - 100 µg and group B - 50µg) and a control group (placebo) 
between baseline and after intervention, between different doses and intervention period, 
between the groups in pre-test measurement, and between groups in post-test.**indicates a 
significant difference at p < 0.01  
Table 6.11. Post-hoc comparisons of the differences between the mean LDL 
concentrations (mmol/L) among groups (intervention and control) at baseline and 
after the intervention study 
Group Baseline After 16 weeks Mean difference p-valueb 
A 3.56±1.29 1.88±0.98 -1.68** <0.001 
B 3.16±.1.01 2.49±0.97 -0.68** <0.001 
C 3.29±1.11 2.43±1.03 -0.21 0.149 
Intervention groups A, 100µg vitamin D supplementation and B, 50µg vitamin D, and control 
(C) - placebo group. **indicates a significant difference between pre-test and post-test of p < 
0.001; b indicates adjustment for multiple comparisons; ± mean SD. 
The results one-way ANOVA analysis of differences in the mean LDL 
concentrations (mmol/L) in the intervention groups and a control group, 
between the baseline and the measurements after the intervention period are 
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summarised in Table 6.11). These showed that in group A the LDL 
concentration decreased significantly after 16 weeks (mean difference=-1.68, 
p-value <0.001). The mean LDL concentration in group B also decreased 
significantly after 16 weeks (mean difference=-0.68, p-value <0.001). The 
differences in mean LDL concentrations (mmol/L) in the groups between 
baseline and after 16 weeks of treatment are also shown in Figure 6.4. 
A two-way mixed ANOVA analysis results (see Table 6.10) showed that after 
16 weeks there were significant differences in the mean LDL concentration 
between the three groups (F=13.97, p <0.001). Using one-way ANOVA 
analysis of the results of the post-hoc testing (see Table 6.12 and Figure 6.4), 
it was established that the mean LDL concentration in group A was 
significantly lower than in group B (mean difference=-0.61, p =0.003). In 
addition, the mean LDL concentration in group A was significantly lower than 
in group C (mean difference=-1.06, p <0.001). The mean LDL concentration 
in group B was also significantly lower than in group C (mean difference=-
0.453, p =0.03).  
Table 6.12. Post-hoc comparisons of LDL levels (mmol/L) among interventions 
groups and control after 16 weeks 
Time Group Group Mean difference  p-valueb 
After 16 week 
A B -0.61** 0.003 
A  C -1.06** <0.001 
B C -0.453* 0.03 
Intervention groups A, 100µg vitamin D supplementation and group B, 50µg vitamin D are 
compared with control (placebo) group C after 16 weeks of intervention. **indicates a 
significant difference between pre-test and post-test of p< 0.001; *indicates a significant 
difference between pre-test and post-test of p< 0.05; b indicates adjustment for multiple 
comparisons.  
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Figure 6.4. Changes in the mean fasting LDL concentrations (mmol/L) in the 
intervention and control groups between the pre-test and post-test measurements 
Interventions groups A, 100µg vitamin D3 and group B, 50µg vitamin D3 and group C control 
(placebo). Results are presented as mean ± SD (n=128). Statistically significant differences 
of p < 0.001) are marked with ** and of p < 0.005) are marked with *. 
6.4. Discussion 
This study has found that vitamin D supplementation of either 100µg or 50µg 
per day provides a significant improvement in dyslipidaemia. There were 
reductions in total cholesterol, triglycerides and LDL levels as compared to the 
placebo group, and improvements in HDL compared to the placebo group. 
These findings support previous studies (Alkharfy et al., 2013; Mohamad et 
al., 2016). 
A Middle Eastern intervention study of 92 type 2 diabetic Saudi subjects who 
had an intake of 50µg of vitamin D for 18 months, presented a mean serum 
level of vitamin D of 23.5 nmol/L. There was a significant improvement in 
serum total cholesterol as well as LDL (p < 0.001 and p < 0.004, respectively). 
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However, there was no change in serum triglycerides and HDL with an 
increase of 20 nmol/L in the mean serum level of vitamin D across the 
intervention period (Al-Daghri, et al., 2012a). It has been suggested that an 
improvement in lipidaemia requires a higher concentration of vitamin D than 
70-80 nmol/L (Hossein-nezhad & Holick, 2013). In an intervention study of 499 
Saudi type 2 diabetic patients randomly given 50µg vitamin D daily or receiving 
none as control group (who were advised to increase sun-exposure) for 12 
months, found significant improvements in serum triglycerides and total 
cholesterol, as well as HDL were found in men (Alkharfy et al., 2013). Another 
Middle East intervention study was of 100 T2DM patients who had an intake 
of 112.5µg /day of vitamin D for 8 weeks. It found a significant increase in 
serum HDL and a significant decrease in total cholesterol and LDL levels 
(Mohamad et al., 2016). It indicated that a concentration of serum vitamin D 
greater than 49.92 nmol/L was significantly associated with decreased serum 
LDL cholesterol (Chaudhuri et al., 2013) and it suggested that if the vitamin D 
concentration were greater than 152 nmol/L, it would improve the diabetic lipid 
profiles (Mohamad et al., 2016). The mean vitamin D concentration of our 
study was 77.85 ± 5.27 nmol/L and we had a significant improvement in male 
diabetic subjects that supports the suggestions of Chaudhuri et al., (2013) and 
Mohamad et al., (2016).  
A Middle Eastern cross-sectional study of 108 Iranian T2DM patients who 
were aged between 20 and 80 years, found an association between serum 
vitamin D concentrations and triglycerides (Saedisomeolia, 2014). Another 
Middle Eastern cross-sectional study of 309 Emirati obese and T2DM patients 
found a correlation between serum vitamin D and reduced serum triglycerides, 
LDL (p<0.01) and a relationship between serum vitamin D and serum HDL, 
LDL, total cholesterol and triglycerides which was stronger in men than in 
women (Sadiya et al., 2014). Serum triglyceride reduction could involve 
vitamin D and intestinal calcium absorption increases by vitamin D. Then, this 
calcium might reduce the triglyceride levels via the reduction of hepatic 
triglyceride formation and secretion through a suppressive effect of vitamin D 
on the concentration of parathyroid hormone (Eftekhari et al., 2014). 
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A consecutive study of 28 type 2 diabetic patients who were treated with 400 
µg of vitamin D per week for 2 months found a significant decrease in serum 
total cholesterol (p<0.04), and decreased serum LDL, cholesterol and 
triglyceride levels. However, these findings were not statistically significant. 
There was no change in serum HDL cholesterol levels (Ramiro-Lozano & 
Calvo-Romero, 2015). The meta-analysis of Wang et al., (2012) conducted on 
12 intervention studies of 1,346 patients, found a pooled effect on serum LDL 
whereas there were no statistically significant effects on serum total 
cholesterol, HDL and triglyceride levels after an intake of vitamin D (Wang et 
al., 2012). It was stated that the significant result on serum LDL levels of 
vitamin D supplementation was seen in obese subjects and in short study 
interventions, whereas in long trials, a significant effect on serum HDL level 
was observed (Wang et al., 2012).  
Some interventions failed to find significant results in improving lipid 
metabolism (Yiu et al., 2013; Ryu et al., 2014). An intervention study of 100 
Iranian type 2 diabetics with an intake of 1250 µg/week of vitamin D for 8 
weeks, indicated that there was no significantly different change in the levels 
of serum total cholesterol, LDL, HDL or triglycerides (Talaei et al., 2013). This 
outcome could be because it was a single-blind study without comparison with 
a placebo. A double-blind randomised clinical trial of 87 Emirati obese type 2 
diabetic subjects with an intake of 150 µg/day of vitamin D for 12 weeks, then 
another 75 µg/day for 12 weeks, showed the mean vitamin D concentration 
was 61.4 ± 18.8 nmol/L and it found no effect on the lipid profile (Sadiya et al., 
2015). This could be because it did not reach sufficiently high vitamin D 
concentrations of >75 nmol/L. Another double-blind, randomised, placebo- 
controlled trial had 70 Iranian type 2 diabetics who were aged 30-75 years and 
given 0.50 µg of vitamin D/day. It was found that there was a significant 
decrease in serum total cholesterol, triglycerides and LDL levels, p< 0.05, in 
both intervention and placebo groups. However, there was no change in serum 
HDL levels in the intervention group, and there were no statistically significant 
changes between all the variables of the groups (Eftekhari et al., 2014). In an 
intervention study of 36 type 2 diabetic patients with normal serum levels of 
vitamin D and an intake of 1000 µg/week of vitamin D for 6 months, and no 
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change in lipid profiles was found (Jorde & Figenschau, 2009). Another study 
was of 151 subjects with a high risk of cardiovascular disease and who had 
vitamin D deficiency.  An intake of 1250 µg/week of vitamin D for 8 weeks was 
found to have no effect on the lipid profile (Ponda et al., 2012). Also, a study 
of 24 T2DM subjects with an intake of 25µg/day of vitamin D for 12 months 
and a mean serum concentration of vitamin D of 29.45 nmol/l, found no 
significant result on serum total cholesterol, LDL, HDL or triglycerides levels. 
Furthermore, the mean serum concentration of vitamin D was only 43.92 
nmol/l after the intervention study (Breslavsky et al., 2013). Vitamin D 
concentration was below the sufficient vitamin D concentration level, which 
confirmed the suggestion that it must be 75 nmol/L to have a good 
improvement in lipid metabolism. 
The effects of vitamin D supplementation studies on improving dyslipidaemia 
are inconsistent (Eftekhari et al., 2014; Mohamad et al., 2016). It is too 
complex to draw a conclusion for a variety of reasons such as the designs of 
the studies, doses, ethnic background, duration of the studies and sample 
sizes. A significant improvement in dyslipidaemia has been found in Middle 
Eastern studies when the vitamin D dose is 50µg/day or high, when 70 
participants or more are included and when the duration of the study is 16 
weeks or greater. Also, if concentrations of serum vitamin D above 152.25 
nmol/L have been achieved, they have shown significant improvement in 
lipidaemia. The limitation of these studies is that they lack comparison of the 
different T2DM therapies and how they affect vitamin D supplementation and 
metabolic changes, not only by gender, but also by the presence of the 
disease itself.   
6.5. Conclusion  
This study investigated the effects of vitamin D on dyslipidaemia and found a 
significant improvement in total cholesterol (p <0.005) and triglycerides, HDL 
and LDL (p <0.001), in both intervention groups compared with the placebo 
group after the intervention. This was in Saudi men with poorly controlled 
T2DM. This suggests that vitamin D may be essential to improve the lipid 
biomarkers’ profile.       
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Chapter 7 Effect of vitamin D3 supplementation on oxidative stress in 
poorly-controlled type-2 diabetes after 16 weeks 
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7.1. Introduction  
Oxidative stress is a major factor facilitating the development and 
pathogenesis of complications in T2DM mellitus (Cavalcante et al., 2015). In 
diabetes, persistent hyperglycaemia distorts the endogenous antioxidant 
defence mechanisms in type-2 diabetic patients (Ceriello, 2000). 
Hyperglycaemia also increases free radicals (Ullah et al., 2016). The 
endogenous antioxidant defence system is composed of the non-enzymatic 
and enzymatic pathways (Sebekova et al., 2015). These pathways play a 
crucial part in counterbalancing toxic reactive oxygen species (ROS) (Picu et 
al., 2017). Regulation of oxidising and reducing states is important for various 
organ functions, and cell proliferation, activation and viability (Shab-Bidar et 
al., 2015). 
Advanced glycation end products, also known as AGEs, are a group of 
compounds involved in the pathophysiology of diabetic complications (Ahmed, 
2005). Vitamin D may minimise various depositions of AGEs in type-2 diabetic 
patients (Sebekova et al., 2015). Vitamin D may influence oxidative stress as 
it reduces the formation of plasma free radicals and increases antioxidant 
defences in diabetic patients (Singh et al., 2002; Saif-Elnasr et al., 2017). The 
relation between vitamin D and AGEs is limited and it has been established 
only in diabetic rats (Salum et al., 2013). 
The aim of this chapter was to investigate the effect of vitamin D3 on oxidative 
stress in improving the antioxidant capacity and reducing the AGEs in poorly-
controlled type 2 diabetic Saudi men. 
7.2. Methods 
Blood samples were taken at baseline and after 16 weeks of vitamin D3 
supplementation (or placebo) from 128 participants using the aseptic 
technique described in section 2.13. Total antioxidant capacity was 
determined using OxiSelect™ Total Antioxidant Capacity (TAC) Assay Kits as 
per section 2.16.8 and AGEs were determined using an AGE skin 
autofluorescence reader as described in section 2.12.  
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7.3. Results  
7.3.1. Total antioxidant capacity (TAC) 
A total of 128 male patients with T2DM took part in the study. There were 43 
participants in group A (supplementation with 100 µg vitamin D3), 42 
participants in group B (supplementation with 50 µg vitamin D3), and 43 
participants in group C (control, placebo group). The changes in total 
antioxidant capacity (in mM) were analysed among groups A, B and C (control 
group) pre-test as well as post-test, by two-way mixed ANOVA statistical 
analysis. The results, summarised in Table 7.1, show that no statistically 
significant difference (of p ≤ 0.05) was observed between the pre- and post-
hoc total antioxidant capacity, nor between the groups either pre- or post-test. 
Furthermore, no significant correlation between the duration of the intervention 
and the effect on insulin levels was observed in the studied groups.  
Table 7.1. Two-way mixed ANOVA test comparing the mean differences of total 
antioxidant capacity upon vitamin D supplementation 
Source of difference F-test p-value 
Between times 3.882 0.051 
Interaction between different doses, intervention period and groups 1.17 0.365 
Between the three groups pre-test 0.637 0.530 
Between the three groups post-test 1.02 0.361 
The comparisons included: the difference in mean TAC in vitamin D supplementation groups 
(group A - 100 µg and group B - 50µg) and a control group (placebo) between baseline and 
after intervention, between different doses and intervention period, between the groups in pre-
test measurement, and between groups in post-test. 
Table 7.2. Post-hoc comparisons of total antioxidant capacity (mM) concentration 
among the intervention and control groups, at baseline and after the intervention 
Group Baseline After 16 weeks Mean difference p-valueb 
A 0.61±0.14 0.66±0.27 0.054 0.077 
B 0.65±0.23 0.71±0.28 0.050 0.103 
C 0.63±0.18 0.63±0.16 -0.001 0.982 
Intervention groups A, 100µg vitamin D supplementation and group B, 50µg vitamin D and 
control (C)-placebo group; b indicates adjustment for multiple comparisons; mean ± SD. 
Furthermore, the post-hoc comparison between the mean total antioxidant 
capacity (mM) in the intervention groups and control, between the baseline 
and after the intervention period, using the mixed ANOVA test (Table 7.2, and 
Figure 7.1), did not reveal any statistically significant (p >0.05) changes in the 
total antioxidant capacity between duration of the treatment and the effect on 
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the group (F=1.17, p-value ≤ 0.36, Table 7.1.), nor were there significant 
differences between the groups pre- and post-test. 
 
 
Figure 7.1. Mean changes in plasma total antioxidant capacity (mM) in the 
intervention groups A and B, and the control group C (placebo) 
Interventions groups A, 100µg vitamin D3 and group B, 50µg vitamin D3, and group C, control 
(placebo). Mean total antioxidant capacity measured pre- and post-test; Results are presented 
as mean ± SD (n=128). The calculated differences in mean total antioxidant capacity between 
pre- and post-test were not statistically significant. 
7.3.2. Advanced glycation end products (AGEs) 
A total of 128 male patients with T2DM took part in the study. There were 43 
participants in group A (supplementation with 100 µg vitamin D3). 42 
participants in group B (supplementation with 50 µg vitamin D3), and 43 
participants in group C (control, placebo group). The changes in the mean 
AGEs values were analysed among groups A, B and C (placebo) pre- and 
post-test, as well as in relation to the duration of treatment, by two-way mixed 
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ANOVA is summarised in Table 7.3. The results of the two-way mixed ANOVA 
test showed that there was no significant difference in mean skin AGEs 
between the groups in pre- or post-test (F=.0.32, p-value > 0.57, and F=0.25, 
p-value > 0.77, respectively, Table 7.3.). In addition, the interaction between 
treatment duration and the effect was not significant (F=0.57, p-value ≤ 0.57). 
Table 7.3. Two-way mixed ANOVA comparing the mean differences of AGEs upon 
vitamin D supplementation 
Source of difference F-test p-value 
Between times 4.24 0.050 
Interaction between different doses, 
intervention period and groups 
0.57 0.571 
Between the three groups in pre-test 0.327 0.722 
Between the three groups in post-test 0.258 0.773 
The comparisons included: the difference in mean AGEs in vitamin D supplementation 
groups (group A - 100 µg and group B - 50µg) and a control group (placebo) between 
baseline and after intervention, between different doses and intervention period, between 
the groups in pre-test measurement, and between groups in post-test. 
Table 7.4. Post-hoc comparisons of AGEs between groups (intervention and control) 
at baseline and after the intervention study 
Group Baseline After 16 weeks Mean difference p-valueb 
A 2.35±0.49 2.34±0.39 -0.001 0.745 
B 2.36±0.55 2..32±0.52 -0.038 0.113 
C 2.43±0.50 2.39±0.50 -0.039 0.104 
Intervention groups A, 100µg vitamin D supplementation, and group B 50µg vitamin D; 
control group (C) – placebo; b indicates adjustment for multiple comparisons; mean +/-SD. 
 
The mean AGEs among the intervention groups and control group from the 
baseline to after the intervention period were calculated (as summarised in 
Table 7.4). The small decreases in mean AGE values in groups A, B and C, 
between baseline and after 16 weeks of treatment, were not statistically 
significant (see Table 7.4 and Figure 7.2). 
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Figure 7.2. Mean changes in AGEs (UV) in the intervention groups A and B, and the 
control group C (placebo) 
Interventions groups A: 100µg vitamin D3 and B: 50µg vitamin D3 and group C: control 
(placebo). Mean AGEs measured pre- and post-test; Results are presented as mean ± SD 
(n=128). The calculated AGEs between pre- and post-test were not statistically significant. 
7.4. Discussion 
In this study, vitamin D supplementation of either 100µg or 50µg per day failed 
to demonstrate any improvement in oxidative stress as compared to the 
placebo group. There was a slight increase in total antioxidant capacity for 
both intervention groups, but it was not statistically significant when compared 
with the control group. Also, mean skin AGEs were not significantly different 
between the vitamin D3 treatment groups and control group.  
Clinical ﬁndings on total antioxidant functions of vitamin D in diabetes are 
limited and the previous evidence (Yiu et al., 2013; Shab-Bidar et al., 2015) 
provided conflicting findings with range of oxidative stress biomarkers having 
been used. A randomised, controlled trial of 100 T2DM given supplements in  
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fortified yogurt that contained 25µg of vitamin D3, showed a significant 
improvement in serum total antioxidant capacity (p≤ 0.03) and 
malondialdehyde (p ≤ 0.002) after 12 weeks (Shab-Bidar et al., 2015). A 
double blind, randomised, placebo-controlled trial conducted with 40 non-
diabetic elderly women receiving 5000µg of vitamin D3 or a placebo for one 
month found a significantly increased total antioxidant capacity (p ≤ 0.03) 
(Cavalcante et al., 2015). In a cross-sectional study conducted in 200 patients 
with T2DM or healthy controls, a significant, positive association was found 
with total antioxidant capacity (p ≤ 0.05) compared to a healthy group 
(Saedisomeolia et al., 2013). However, this finding was contradicted in the 
literature and it was based on limited evidence (Salum et al., 2013).  
Another clinical ﬁnding used different biomarkers for testing antioxidant 
activity. An intervention study of 90 T2DM subjects aged 30-50 years used 
supplements with fortified yogurt that contained 25µg of vitamin D3. After 12 
weeks, significantly increased levels of the antioxidant superoxide dismutase 
(p ≤ 0.025) were found (Nikooyeh et al., 2014). In addition, a Turkish study of 
23 subjects deficient in vitamin D who took 250µg/day of vitamin D3 for 12 
weeks, determined that vitamin D had a significant effect on reducing oxidative 
stress (Tarcin et al., 2009). A study by (Salum et al., 2013) compared diabetic 
rats that received 12.5µg/day of vitamin D3 for 10 weeks with diabetic rats that 
did not receive treatment. The researchers found there was a significant 
improvement in the total antioxidants in diabetic rats with an intake of vitamin 
D3 compared with diabetic rats without treatment (p ≤ 0.001). In contrast, no 
significant change was found in the antioxidant superoxide dismutase in T2DM 
subjects after an intake of 125µg of vitamin D for 12 weeks (Yiu et al., 2013). 
They also showed a reduction of malondialdehyde after 0.25µg of vitamin 
D/day for 12 weeks but this was not statistically significant (Eftekhari et al., 
2014).  
In addition, one of the oxidative stress biomarkers used in this study was skin 
AGEs. Skin autofluorescence has been used as a measure of AGEs’ 
accumulation, and evidence for a relationship between vitamin D3 and AGEs 
accumulation is, so far, is scarce. In this study, there was no significant 
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reduction in skin AGEs and these findings are supported by similar studies 
conducted in 245 patients with T2DM who were randomly assigned to receive 
either vitamin D3 1250µg/month or a placebo for 6 months. There was no effect 
was observed on skin AGEs’ accumulation compared to the placebo (Krul-
Poel et al., 2015a). In a cross-sectional study, in a total of 233 type-2 diabetics, 
no association between vitamin D status and skin AGEs or plasma AGE-
fluorescence was seen (Sebekova et al., 2015). That could have resulted from 
using an AGE reader to measure the AGEs accumulated in the skin and this 
may not to be enough to measure all the AGE types such as circulating AGEs 
and AGEs without fluorescent properties (Krul-Poel, et al., 2015a).  
On the other hand, an intervention study that used an alternative biomarker of 
AGEs in 90 type-2 diabetic subjects aged 30-50 years who took supplements 
with fortified yogurt that contained 25µg of vitamin D3 for 12 weeks. A 
significant decrease in serum AGEs (p ≤ 0.003) was found (Nikooyeh et al., 
2014). The literature review demonstrated that the relation between AGEs and 
vitamin D is limited to having been seen in diabetic rats (Salum et al., 2013; 
Lee et al., 2014). Vitamin D may reduce the accumulation of AGEs, and 
vitamin D supplementation provides an important protection from the oxidative 
damage associated with the development of diabetic vascular complications 
(Salum et al., 2013). It suggests that using a different way of measuring AGEs, 
such as serum of AGEs and receptor AGEs would have provided a different 
result, and that using a variety of biomarkers to measure oxidative stress is 
warranted. A longer duration of the intervention than the present study is also 
needed.  
7.5. Conclusion  
This study investigated the effects of vitamin D on oxidative stress and found 
no significant improvement in the total antioxidant status and reduction of the 
AGEs in either intervention group compared with the placebo group in Saudi 
men with poorly-controlled T2DM. There is a lack of research in the literature 
as well as studies in the field to assess the effect of vitamin D on oxidative 
stress. It would be recommended to study a variety of biomarkers of oxidative 
stress and also to use AGEs in both skin and serum.   
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Chapter 8 General discussion 
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8.1. General Discussion 
Diabetes is a group of metabolic diseases characterised by hyperglycaemia. 
Hyperglycaemia is the result of a disorder in insulin secretion and insulin 
sensitivity and causes disturbances of carbohydrate, fat and protein 
metabolism (Alotaibi et al., 2017). The incidence of T2DM has increased for 
the past two decades and this number is estimated to go beyond 435 million 
worldwide by 2030 (Nguyen et al., 2017). This number is expected to increase 
to 642 million by 2040 (Ogurtsova et al., 2017). The largest numbers of people 
with diabetes are in China, about 109.6 million, and India, about 69.2 million. 
H, however, the highest prevalence rates of diabetes are found in the Pacific 
Islands and the Middle East (Unnikrishnan et al., 2017).  In Saudi Arabia, the 
recent prevalence of T2DM is 32.8%, and therefore will expected to increase 
to 35.37% by 2020 and 45.8% by 2030 (Meo, 2016).  
Hyperglycaemia also increases the production of advanced glycation end 
products (AGEs) (Bos et al., 2011). AGEs and diabetes are associated with 
several complications, including oxidative stress (Chang et al., 2011). 
Diabetes mellitus type 2 in combination with a deficiency of vitamin D levels 
has been associated with increased markers of oxidative stress in literature 
reviews (Codoñer-Franch et al., 2012; Talaei et al., 2013). In Saudi men, the 
prevalence of vitamin D deficiency is between 28% and 37% although Saudi 
is a sunny country (Sadat-Ali et al., 2009). Since dark skin absorbs a reduced 
amount of ultraviolet radiation B (UVB) light, then it is less able to synthesis 
vitamin D (Holick, 2004). The presence of vitamin D receptor gene 
polymorphisms can also impair the production of vitamin D and result in a 
higher risk of T2DM (Yang et al., 2017).  
In the present study, there was no relationship between vitamin D and 
oxidative stress in Saudi male patients with T2DM, whether in improving the 
total antioxidant or reducing the accumulation of AGEs. Our finding is contrast 
with (Cavalcante et al., 2015) who found a significantly increased total 
antioxidant capacity. The previous finding was limited to T2DM subjects and it 
was observed only in diabetic rats (Salum et al., 2013). However, vitamin D 
demonstrates an effect on glycaemic control (Rolim et al., 2016). Prior studies 
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have observed a significant association between HbA1c and serum vitamin D 
levels in diabetic subjects (Kositsawat et al., 2010; Tahrani et al., 2010). Our 
intervention study found a significant reduction in HbA1c in both groups A 
(100µg vitamin D3) and B 50µg (vitamin D3), with a mean difference = -2.10, 
p<0.001 and mean difference= -0.95, p <0.001, respectively. In addition, it 
found a significantly reduced fasting glucose (p <0.001) among the 
intervention groups (50µg and 100µg vitamin D3) compared to the control 
group (placebo). An improvement of glycaemic levels has been shown where 
the vitamin D concentration is above 80 nmol/L and that concentration is in our 
intervention study (von Hurst et al., 2010). 
Vitamin D supplementation plays a role in stimulating insulin release by the 
vitamin D receptor and the active form of vitamin D (1,25(OH)2D) which is 
found in the pancreatic β-cell (Wimalawansa, 2016). Support for the 
hypothesis of an improvement in insulin resistance after vitamin D 
supplementation has been highlighted by Al-Shahwan et al. (2015). However, 
in our intervention study, we did not observe a significant change in insulin 
resistance (HOMA-IR or HOMA-β). Previous studies had similar results for 
HOMA-IR or β-cell function (HOMA-β) (Bjordal et al., 2000; de Boer, 2008; 
Jorde & Figenschau, 2009; Heshmat et al., 2012). A high level of vitamin D 
could be connected with a lower risk of T2DM and a recommendation that 
maintaining optimal vitamin D status may be a strategy to avert the 
development of T2DM (Liu et al., 2010). 
Dyslipidaemia is a common feature, and one of the most important risks, of 
atherosclerosis in diabetes (Mooradian, 2009). It consists of increased 
triglyceride and/or cholesterol levels and decreased HDL cholesterol levels 
(Martinez-St John et al., 2016). The diabetic dyslipidaemia pathophysiology is 
not fully understood, although insulin has an important function in regulating 
the metabolism of lipids (Verges, 2015; Schofield et al., 2016). Vitamin D 
supplementation plays a role in the improvement in lipid levels by the vitamin 
D receptor, which enhances the absorption of fat in the gut (Pilz et al., 2016). 
Vitamin D also reduces the circulating triglycerides via suppression of hepatic 
triglyceride formation and increases in the hepatic calcium intake 
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(Wimalawansa, 2016). In the present intervention study, there were reductions 
in total cholesterol, triglycerides and low-density lipoprotein (LDL) levels, and 
improvements in high-density lipoproteins (HDL) compared to the placebo 
group, supporting the suggestions of (Chaudhuri et al., 2013; Mohamad et al., 
2016). Serum HDL concentrations were increased in both intervention groups 
compared to the placebo group (p<0.001). The serum concentrations of LDL 
were reduced after treatment with vitamin D3 by -1.68 mmol/L in group A 
(100µg vitamin D3) and -0.68 in group B (50µg vitamin D3.). Triglycerides also 
had a significant reduction (p <0.001) but only at the higher dose of vitamin D 
group (100µg vitamin D3) with no significant reduction in group B (50µg vitamin 
D3). Serum concentrations of total cholesterol were significantly reduced after 
the 16 weeks’ treatment with vitamin D; mean difference -0.97 mmol/L in group 
A (100µg vitamin D3) and -0.513 mmol/L in group B (50µg vitamin D3). 
Unfortunately, it is difficult to draw a conclusion from this owing to the 
inconsistent results from previous studies (Kampmann et al., 2014; Mohamad 
et al., 2016). These studies had a variety of designs, doses, subjects’ ethnic 
background, duration of the studies and sample sizes. It is recommended that 
to observe a significant improvement in dyslipidaemia in Middle Eastern 
subjects, the vitamin D dose should be 50µg/day or higher, include 70 
participants or more, that the duration of the study be 16 weeks or longer, and 
that serum vitamin D concentrations be above 152.25 nmol/L (Al-Daghri, et 
al., 2012a; Alkharfy et al., 2013; Mohamad et al., 2016).  
Vitamin D supplementation may also have diverse positive effects, such as 
improvement in muscle performance that could lead to augmented physical 
activity and weight loss and, thus, lessen insulin resistance (Mason et al., 
2016). In the present study, an improvement in lowering the mean BMI was 
found in both groups A (100µg vitamin D3) and B (50µg vitamin D3) from 30.42 
± 5.27 to 29.63 ± 5.08 kg/m2 and from 30.28 ± 5.26 to 29 ± 4.66 kg/m2, 
respectively. However, it was not statistically different when comparing the 
intervention groups with the control after 16 weeks, supporting the finding of a 
double-blind study by (Mason et al., 2014).  
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Figure 8.1: The beneficial changes observed in the biomarkers after vitamin D 
supplementation in this intervention study. Vitamin D supplementation in this 
study improved the biomarkers for glycaemia and lipidaemia in both groups 
compared to control.  
8.2. Limitations of the trial  
It is plausible that a number of limitations could have influenced the results 
obtained. To begin with, the length of the intervention was short, which to have 
an effect on insulin resistance or β-cell function, warrants a longer study 
duration. In addition, Middle Eastern studies require a high dose of the vitamin 
D greater than or equal to 50µg per day. Despite this, the present study was 
unable to investigate a significant relationship of vitamin D and oxidative 
stress. It suggests that measuring different types of AGEs, such as serum of 
AGEs and receptor AGEs, would have provided a different result. Also, using 
a variety of biomarkers to measure oxidative stress is warranted.  
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8.3. Future work   
The findings of this study have a number of important implications for future 
practice. A further study could assess the long-term effects of vitamin D 
supplementation on insulin resistance, β-cell function or oxidative stress, for 
which a longer trial is warranted. Further studies need to be carried out in order 
to validate which marker is most effective in oxidative stress as well as 
measuring different types of AGEs, such as serum of AGEs and receptor 
AGEs. Another possible area of future research would be to investigate how 
different therapies of T2DM affect vitamin D supplementation and metabolic 
changes. Also, it recommends conducting research in increasing of diabetes 
genetically, finding the obesity cut-off points for the risk of diabetes and 
conducting community studies to increase the awareness of the epidemic of 
diabetes. 
8.4. Conclusion  
This study investigated the effects of vitamin D on glycaemia, dyslipidaemia, 
and oxidative stress. Vitamin D3 has been shown to control glycaemia 
significantly and improved lipid metabolism in both intervention groups 
compared with the placebo group in Saudi men with poorly-controlled T2DM. 
However, there was no relationship between vitamin D and oxidative stress or 
insulin sensitivity and secretion. Observational studies mostly showed that 
vitamin D intake and supplements reduce the risks of developing T2DM. The 
intervention trials showed mixed results and were inconclusive on this matter. 
Large doses of vitamin D, nevertheless, have shown some protective factors 
for those at risk in developing T2DM. Even if the exact functions of vitamin D 
in helping to control blood glucose remain inadequately understood, vitamin D 
status seems to have a significant role in controlling the development and 
treatment of diabetes. It is likely that optimised levels of serum vitamin D may 
be dissimilar for people at risk for developing diabetes. Vitamin D doses of 
1,250 µg/week of vitamin D3 for 6–8 weeks, thereafter 20-25 µg/per day of 
vitamin D3 are highly recommended (Dawson-Hughes et al., 2010).    
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Favourable Opinion and you may now commence the project. 
 
MMU requires that you report any Adverse Event during this study immediately to 
the Head of Ethics (Prof Bill Gilmore) and the Administrator (Elanor Henry). Adverse 
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INFORMATION ABOUT THE PROJECT 
Project title: The effect of vitamin D3 on biomarkers of glycaemia and 
oxidative stress in Saudi men with poorly-controlled type 2 Diabetes 
Mellitus  
Appendix 6: MMU informed consent form 
 
 
 
 
Dear Participant, 
This document gives details about and explains a PhD project in Nutrition and Physiology at 
Manchester Metropolitan University (MMU).  
 
The information collected in the study includes: 
• Pre-screening study questionnaire:  
You will be given a questionnaire to finish at your convenience. The questionnaire will take 
between five and ten minutes to complete. 
• Anthropometric Data: 
Your height, weight and waist circumference will need to be measured at the beginning and 
at end of the project. 
• Blood samples: 
A blood sample needs to be taken at the beginning of the project and again 16 weeks later. 
• Intervention: 
Those taking part in the study will need to take a tablet of vitamin D or placebo once a day 
for 16 weeks and to write down each day if the tablet was taken or if it was missed.  
• Debriefing questionnaire 
The debriefing questionnaire will follow the same principles as the medical questionnaire. 
This questionnaire contains questions about the need for assistance and the presence of 
questionnaire items which were confusing, difficult to answer or upsetting. 
 
Confidentiality and data protection 
You can choose whether to answer any or all of the questions you are asked. If at any point 
in the study you would like to end your participation, you are free to do so. All information 
from you will be treated confidentially, but you may be asked if you will allow information to 
be quoted anonymously. You can choose for the information apart from these quotations to 
be included simply as part of the study’s background, together with printed material, Internet 
sources and the information others provide. The Data Protection Act applies to all the 
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Please initial 
Are  
 
information you give. Your information will not be used for any purpose other than this PhD 
research project.  
No information that could be used to identify you, such as your name, will be published in 
the research paper based on this study.  There will also be no information that could lead to 
your address being known. The data provided will only be available to the study group, 
except if the information includes evidence of criminal activities. No possible risks have been 
identified for participants because of their involvement with the study. 
If you would like to know more or have questions about the research project, please write to 
me at the email address below. Your participation in this project is highly appreciated.  
Thank you.  
Hend Faisal H Alharbi 
E-mail  10976029@stu.mmu.ac.uk 
Consent form 
Project title: The effect of vitamin D3 on biomarkers of glycaemia and oxidative 
stress in Saudi men with poorly-controlled type 2 Diabetes Mellitus  
 
 
 
 
Have you read the information sheet?  
  
Do you understand what the project is about? 
 
Are you aware that you will be asked to complete a medical background 
questionnaire? 
 
Are you aware that you will be asked to complete a 24-hour food diary?  
 
Are you aware that two blood samples will be taken? 
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Are you aware that these blood samples will be analysed? 
 
Are you aware that you need to consume a vitamin D tablet or placebo on a daily 
basis? 
 
Are you aware that you can stop participating in the study at any time?  
 
Are you willing for your blood to be used for further analysis? 
Are you willing to take part? If yes, please sign your name below.  
I ................................................................ agree/do not agree to take part in the 
above research study. 
I am aware that all information will be kept confidential in line with the Data Protection 
Act and that I can withdraw at any time. 
Signed...................................................................... 
Date..........................................................................        
Should you have any questions about this research project please contact Hend 
Alharbi on this E-mail 10976029@stu.mmu.ac.uk  
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Appendix 7: King Fahad Medical City informed consent form  
 
King Fahad Medical City 
ﻣدﯾﻧﺔ اﻟﻣﻠك ﻓﮭد اﻟطﺑﯾﺔ  
Riyadh, Kingdom of Saudi Arabia 
اﻟرﯾﺎض- اﻟﻣﻣﻠﻛﺔ اﻟﻌرﺑﯾﺔ اﻟﺳﻌودﯾﺔ  
 
CONSENT BY SUBJECT FOR PARTICIPATION IN RESEARCH 
أﻗرار ﺑﺎﻟﻣواﻓﻘﺔ ﻋﻠﻲ اﻟﻣﺷﺎرﻛﺔ ﻓﻲ دراﺳﺔ ﺑﺣﺛﯾﺔ  
CONSENT BY SUBJECT FOR 
PARTICIPATION IN RESEARCH 
 
ﻣواﻓﻘﺔ ﻟﻠﻣﺷﺎرﻛﺔ ﻓﻲ اﻟﺑﺣث  
 
Protocol Number:       رﻗم اﻟدراﺳﺔ       
Name of Subject: 
      
اﺳم اﻟﻣﺷﺎرك       
Medical Record Number:       
 
رﻗم اﻟﺳﺟل اﻟطﺑﻲ       
Study Title: The effect of vitamin D3 on 
biomarkers of glycaemia and oxidative 
stress in Saudi men with poorly controlled 
Type 2 Diabetes Mellitus (T2DM). 
 
ﻋﻧوان اﻟدراﺳﺔ  " ﺗﺄﺛﯾرﻣﻛﻣﻼت ﻓﯾﺗﺎﻣﯾن دال ﻋﻠﻰ 
اﻟﻣؤﺷرات اﻟﺣﯾوﯾﮫ ﻟﻧﺳﺑﮫ اﻟﺳﻛر ﺑﺎﻟدم و اﻻﺟﮭﺎد 
اﻟﺗﺎﻛﺳدي ﻟدي اﻟرﺟﺎل اﻟﻣﺻﺎﺑون ﺑﺎﻟﺳﻛري اﻟﻧوع 
اﻟﺛﺎﻧﻲ اﻟﻐﯾر ﻣﻧﺗظم"  
Principal Investigator: Dr. Naji Aljohani 
Hend Alharbi 
 
اﻟﺑﺎﺣث اﻟرﺋﯾس د. ﻧﺎﺟﻲ اﻟﺟﮭﻧﻲ  
                  ھﻧد ﻓﯾﺻل اﻟﺣرﺑﻲ  
Address:       
 
اﻟﻌﻧوان       
Telephone:             رﻗم اﻟﮭﺎﺗف  
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A member of the research team will explain 
what is involved in this study and how it will 
affect you.  This consent form describes the 
study procedures, the risks and benefits of 
participation, and how your confidentiality 
will be maintained.  Please take your time 
to ask questions and feel comfortable 
making a decision whether to participate or 
not.  This process is called informed 
consent.  If you decide to participate in this 
study, you will be asked to sign this form 
and will be given a copy for your records. 
Throughout this consent form, “you” will 
refer to you or your child, as appropriate.  
ﺳﯾﺷرح ﻟك ﻋﺿو ﻣن ﻓرﯾق اﻟﺑﺣث ﻣﺣﺗوﯾﺎت ھذه 
اﻟدراﺳﺔ وﺗﺄﺛﯾرھﺎ ﻋﻠﯾك. و ﯾﺻف ھذا اﻹﻗرار 
إﺟراءات اﻟدراﺳﺔ ، واﻟﻣﺧﺎطر واﻟﻔواﺋد ﻣن 
اﻟﻣﺷﺎرﻛﺔ ، وﻛﯾﻔﯾﺔ اﻟﺣﻔﺎظ ﻋﻠﻰ ﺳرﯾﺔ اﻟﻣﻌﻠوﻣﺎت. 
اﻟرﺟﺎء اﺧذ اﻟوﻗت اﻟﻛﺎﻓﻲ ﻓﻲ طرح اﻷﺳﺋﻠﺔ ﻟﻛﻲ 
ﺗﺗﺧذ ﻗرارك ﻣﺎ إذا ﻛﻧت ﺳﺗﺷﺎرك أم ﻻ. وھذه 
اﻟﻣواﻓﻘﺔ ﺗﺳﻣﻰ اﻟﻣواﻓﻘﺔ  اﻟﻣﺳﺗﻧﯾرة. إذا ﻗررت 
اﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ  ، ﺳﯾطﻠب ﻣﻧك اﻟﺗوﻗﯾﻊ 
ﻋﻠﻰ ھذا اﻹﻗرار وﺳﺗﻌطﻲ ﻧﺳﺧﺔ ﻟﺳﺟﻼﺗك. وطوال 
ھذا اﻹﻗرار اﻟﻠﻔظ، "أﻧت" ﺳوف ﯾﺷﯾر إﻟﯾك أو إﻟﻰ  
طﻔﻠك ، ﺣﺳب اﻻﻗﺗﺿﺎء.  
 
 
WHY IS THIS STUDY BEING DONE? 
To determine whether vitamin D3 
supplementation can reduce biomarkers of 
inflammation and oxidative stress in Saudi 
men aged between 18 to 60 years with type 
2 Diabetes Mellitus 
 
ﻟﻣﺎذا ﺗﺟري ھذه اﻟدراﺳﺔ؟ ﺗﺣدﯾد ﻣﺎ اذا ﻓﯾﺗﺎﻣﯾن دال 
ﻣﻣﻛن ان ﯾﻘﻠل ﻣن اﻟﻣوﺷرات اﻟﺣﯾوﯾﮫ ﻟﻼﺟﮭﺎد 
اﻟﺗﺎﻛﺳدي ﻓﻲ اﻟرﺟﺎل اﻟﺳﻌودﯾﯾن اﻟﻣﺻﺎﺑون ﺑﻣرض 
اﻟﺳﻛري اﻟﻧوع اﻟﺛﺎﻧﻲ اﻟﻐﯾر ﻣﻧﺗظم اﻟذﯾن ﺗﺗراوح 
اﻋﻣﺎرھم ﻣن ١٨-اﻟﻲ ٦٠ ﻋﺎﻣﺎ  
 
Cultural Bureau in London (Qassim 
University) 
 
اﻟﻣﻠﺣﻘﯾﮫ اﻟﺛﻘﺎﻓﯾﮫ اﻟﺳﻌودﯾﮫ ﺑﻠﻧدن )ﺟﺎﻣﻌﮫ اﻟﻘﺻﯾم(  
 
HOW MANY PEOPLE WILL TAKE PART 
IN THE STUDY?  
135 patients will be randomly in 3 groups 
(45 in each groups) 
وﻛم ﻋدد اﻟﻣﺷﺎرﻛﯾن ﻓﻲ ھذه اﻟدراﺳﺔ ؟  
135 
 
WHAT WILL HAPPEN IF I TAKE PART IN 
THIS STUDY?  
Your part in the study will confirm if vitamin 
D will reduce the biomarker of oxidative 
stress with T2DM poorly controlled.  
 
 
ﻣﺎذا ﺳﯾﺣدث إذا ﺷﺎرﻛت ﻓﻲ ھذه اﻟدراﺳﺔ ؟  
ﻣﺷﺎرﻛﺗك وﻧﺗﺎﺋﺢ اﻟﺗﺣﺎﻟﯾل ﺳوف ﺗﺛﺑت ﻣﺎ ان ﻓﯾﺗﺎﻣﯾن 
دال ﯾﻘﻠل ﻣن اﻟﻣوﺷرات اﻟﺣﯾوﯾﮫ ﻟﻼﺟﮭﺎد اﻟﺗﺄﻛﺳدي.  
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Study location: 
Riyadh  
. ﻣوﻗﻊ اﻟدراﺳﺔ  
اﻟرﯾﺎض  
WHAT IS EXPECTED OF ME DURING 
THE STUDY? 
You will complete a medical questionnaire 
then you will be given randomly vitamin D 
supplements (2000IU or 4000IU) or 
placebo to take them and you will have a 
blood test at baseline and after 4 months. 
Also, the skin autofluorescence reader will 
measure AGE.  
ﻣﺎ ھو ﻣﺗوﻗﻊ ﻣن ﺧﻼل دراﺳﺔ ﻟﻲ؟  
ﺳوف ﺗﻘوم ﺑﺗﻌﺋﺑﮫ اﻻﺳﺗﺑﯾﺎن اﻟﺧﺎص ﺑﺎﻟدراﺳﮫ اوﻻ 
وﻣن ﺛم ﺳوف ﻧﺧﺗﺎر ﻋﺷواﺋﯾﺎ ﻻﻋطﺎء ﺣﺑوب ﻓﯾﺗﺎﻣﯾن 
دال ﺑﺟرﻋﺗﯾن ﻣﺧﺗﻠﻔﺗﯾن  (2000IU or 
4000IU) اودواء وھﻣﻲ  placebo ، و ﺳوف 
ﻧﻘوم  
ﻋﻣﻠﯾﮫ ﺳﺣب دم ﻻﺟراء اﻟﺗﺣﺎﻟﯾل اﻻزﻣﮫ ﻓﻲ ﺑداﯾﮫ 
اﻟدراﺳﮫ و ﺑﻌد ٤ اﺷﮭر. و ﻗﯾﺎس AGE ﺑﻘﺎرﺋﻲ 
ﺿوﺋﻲ ﻣن ﺳطﺢ اﻟﺟﻠد.  
HOW LONG WILL I BE IN THE STUDY? 
4 Months 
 
ﻣﺎ ھﻲ ﻣدة اﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ؟  
٤ اﺷﮭر  
 
CAN I STOP BEING IN THE STUDY? ھل أﺳﺗطﯾﻊ إﻧﮭﺎء اﻟﻣﺷﺎرﻛﺔ ؟  
Yes.  You can decide to stop at any time.  
Tell the study doctor if you are thinking 
about stopping or you’ve decided to stop.  
He or she will tell you how to stop your 
participation safely.  No one will try to get 
you to change your mind.  
 
ﻧﻌم. ﯾﻣﻛﻧك أن ﺗﻘرر اﻟﺗوﻗف ﻓﻲ أي وﻗت. ﻓﻘط اﺧﺑر  
اﻟطﺑﯾب إذا ﻗررت اﻟﺗوﻗف. ﻟﯾوﺿﺢ ﻟك ﻛﯾﻔﯾﺔ إﻧﮭﺎء 
ﻣﺷﺎرﻛﺗك ﺑﺄﻣﺎن. ﻻ أﺣد ﺳﯾﺣﻣﻠك ﻋﻠﻲ ﺗﻐﯾﯾر رأﯾك.  
 
ARE THERE RISKS IF I STOP BEING IN 
THE STUDY? 
There is not any risk.  
ھل ھﻧﺎك ﻣﺧﺎطر ﻣﺗوﻗﻌﺔ إذا أﻧﮭﯾت اﻟﻣﺷﺎرﻛﺔ ﻓﻲ 
اﻟدراﺳﺔ ؟  
ﻟﯾس ھﻧﺎك اي ﺿرر.  
 
 
WHAT SIDE EFFECTS OR RISKS CAN I 
EXPECT FROM BEING IN THE STUDY? 
There are not any side effects. 
 
ﻣﺎ ھﻲ اﻟﻣﺧﺎطر أو اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ اﻟﺗﻲ ﯾﻣﻛن ﺣدوﺛﮭﺎ 
ﻣن ﺟراء اﻟﻣﺷﺎرﻛﺔ ﻓﻲ اﻟدراﺳﺔ؟  
ﻻ ﯾوﺟد ھﻧﺎك اي ﻣﺧﺎطر ﺟﺎﻧﺑﯾﺔ  
ARE THERE BENEFITS TO TAKING 
PART IN THE STUDY? 
ھل ھﻧﺎك ﻓواﺋد ﻣن اﻟﻣﺷﺎرﻛﺔ ﻓﻲ اﻟدراﺳﺔ ؟  
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Taking part in this study may or may not 
make your health better.  While doctors 
hope the 
procedure/drug/intervention/device will be 
more effective/have fewer side effects than 
the standard (usual) treatment, there is no 
proof of this yet. 
ﻣﺷﺎرﻛﺗك ﻓﻲ ھذه اﻟدراﺳﺔ  ﻗد ﻻ ﺗؤدي إﻟﻲ ﺗﺣﺳن 
ﺣﺎﻟﺗك.وﻟﻛن ﯾﺄﻣل اﻷطﺑﺎء أن ﯾﻛون اﻻﺟراء / اﻟدواء 
/ اﻟﺗدﺧل / اﻟﺟﮭﺎز اﻛﺛر ﻓﻌﺎﻟﯾﺔ / ﻟﮭﺎ اﻗل اﺛﺎر ﺟﺎﻧﺑﯾﺔ 
ﻣن اﻟﻌﻼج اﻟﻘﯾﺎﺳﻲ او اﻟﻣﻌﺗﺎده، وﻻ ﯾوﺟد دﻟﯾل ﻋﻠﻰ 
ذﻟك ﺣﺗﻰ اﻵن.  
 
WHAT OTHER OPTIONS ARE THERE? 
There are no other options  
Instead of being in this study, you have 
these options:       
 
ﻣﺎ ھﻲ اﻟﺧﯾﺎرات اﻷﺧرى ؟ ﻻ ﯾوﺟد ﺧﯾﺎرات اﺧرى  
ﻟدﯾك ﺧﯾﺎرات أﺧري ﺑدﻻ ﻋن اﻟﻣﺷﺎرﻛﺔ ﻓﻲ اﻟدراﺳﺔ:  
      
WHAT HAPPENS IF I AM INJURED 
BECAUSE I TOOK PART IN THIS STUDY? 
ﻣﺎذا ﯾﺣدث ﻟو أﻧﻧﻲ ﺗﻌرﺿت ﻟﻺﺻﺎﺑﺔ ﺑﺳﺑب 
اﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ ؟  
 
It is important that you tell Dr. Naji Aljohani 
and the researcher Hend Alharbi if you feel 
that you have been injured because of 
taking part in this study.  You can tell the 
doctor in person or call him at 0556605558.  
If you are injured as a result of being in this 
study, treatment will be available.  The 
costs of the treatment may be covered by 
KFMC or the study sponsor, depending on 
a number of factors.  KFMC and the study 
sponsor do not normally provide any other 
form of compensation for injury.  For further 
information about this, you may call the 
office of the Institutional Review Board 
(IRB) at     . 
 
ﻣن اﻟﻣﮭم أن ﺗﺑﻠﻎ دﻛﺗور ﻧﺎﺟﻲ اﻟﺟﮭﻧﻲ وﺑﺎﺣﺛﮫ 
اﻟدﻛﺗوراه ھﻧد اﻟﺣرﺑﻲ إذا ﻛﻧت ﺗظن اﻧك ﻗد ﺗﻌرﺿت 
ﻟﻺﺻﺎﺑﺔ ﺑﺳﺑب ﻣﺷﺎرﻛﺗك ﻓﻲ ھذه اﻟدراﺳﺔ. ﯾﻣﻛﻧك 
أن ﺗﺑﻠﻎ اﻟطﺑﯾب ﺷﺧﺻﯾﺎ أو اﻻﺗﺻﺎل ﺑﮫ ﻋﻠﻲ 
0556605558  . ﻓﻲ ﺣﺎل ﺗﻌرﺿك ﻟﻺﺻﺎﺑﺔ 
ﺳﯾﻛون واﻟﻌﻼج ﻣﺗﺎﺣﺎ. ﺳﺗﻘدم ﻟك ﻣدﯾﻧﺔ اﻟﻣﻠك ﻓﮭد 
اﻟطﺑﯾﺔ ﺗﻛﺎﻟﯾف اﻟﻌﻼج، وﯾﺗوﻗف ذﻟك ﻋﻠﻰ ﻋدد ﻣن 
اﻟﻌواﻣل. ﻋﺎدة ﻻ ﺗﻘدم ﻣدﯾﻧﺔ اﻟﻣﻠك ﻓﮭد اﻟطﺑﯾﺔ أو 
ﻣﻣول اﻟدراﺳﺔ أي ﺷﻛل آﺧر ﻣن أﺷﻛﺎل اﻟﺗﻌوﯾض 
ﻋن اﻟﺿرر. وﻟﻠﺣﺻول ﻋﻠﻰ ﻣزﯾد ﻣن اﻟﻣﻌﻠوﻣﺎت 
ﻋن ھذا اﻟﻣوﺿوع، ﯾﻣﻛﻧك اﻻﺗﺻﺎل ﺑﻣﻛﺗب 
اﻟﻣؤﺳﺳﻲ اﺳﺗﻌراض اﻟﻣﺟﻠس ) IRB ( ﻋﻠﻲ اﻟرﻗم 
     .  
 
 
WHAT ARE THE COSTS OF TAKING 
PART IN THE STUDY? 
وﻣﺎ ھﻲ ﺗﻛﺎﻟﯾف اﻟﻣﺷﺎرﻛﺔ ﻓﻲ اﻟدراﺳﺔ ؟  
 
You will not be charged for any study 
activities.  
Funding has been granted through the 
Saudi Arabian Government Scholarship 
scheme by the Saudi Arabian culture 
bureau.  
 
ﻟن ﺗﺗﺣﻣل ﺗﻛﺎﻟﯾف  أي ﻣن أﻧﺷطﺔ  اﻟدراﺳﺔ.  
ھذه اﻟدراﺳﮫ ﻣدﻋوﻣﮫ ﻣن اﻟﺑﻌﺛﺎت اﻟﺣﻛوﻣﯾﮫ ﻣن ﻗﺑل 
اﻟﻣﻠﺣﻘﯾﮫ اﻟﺛﻘﺎﻓﯾﮫ.  
 
WILL I BE PAID FOR MY TAKING PART 
IN THIS STUDY? 
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 ھل ﺳﺄﺗﻘﺎﺿﻰ اﺟر ﻧظﯾر اﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ 
؟ 
You will not be paid for taking part in this 
study. If you are employer, we can give you 
sick leave on a day when you visit. 
 
ﻟن ﯾﻛون ھﻧﺎك اﺟر.  وﻟﻛن اذا ﻛﻧت ﻣوظف ﺳوف 
ﻧوﻓر ﻟك اﺟﺎزه ﻣرﺿﯾﮫ ﻟﻠﯾوم اﻟذي ﺗراﺟﻊ ﺑﮫ 
ﻟﻠﻣﺳﺗﺷﻔﻰ.  
WILL MY MEDICAL INFORMATION BE 
KEPT PRIVATE? 
 
ھل ﺳﯾﺗم اﻟﺣﻔﺎظ ﻋﻠﻲ اﻟﻣﻌﻠوﻣﺎت اﻟطﺑﯾﺔ اﻟﺧﺎﺻﺔ ﺑﻲ 
ﺑﺳرﯾﺔ ؟  
We will do our best to make sure that the 
personal information in your medical record 
is kept private.  However, we cannot 
guarantee total privacy.  Your personal 
information may be given out if required by 
law.  If information from this study is 
published or presented at scientific 
meetings, your name and other personal 
information will not be used. 
ﺳﻧﺑذل ﻗﺻﺎرى ﺟﮭدﻧﺎ ﻟﻠﺗﺄﻛد ﻣن أن اﻟﻣﻌﻠوﻣﺎت 
اﻟﺷﺧﺻﯾﺔ ﻓﻲ ﺳﺟﻠك اﻟطﺑﻲ ﺗﺣظﻰ ﺑﺎﻟﺳرﯾﺔ. وﻣﻊ 
ذﻟك ، ﻻ ﯾﻣﻛﻧﻧﺎ أن ﻧﺿﻣن اﻟﺧﺻوﺻﯾﺔ اﻟﺗﺎﻣﺔ. ﯾﻣﻛن 
أن ﯾﻔﺻﺢ ﻋن ﻣﻌﻠوﻣﺎﺗك اﻟﺷﺧﺻﯾﺔ إذا اﻗﺗﺿﻰ اﻷﻣر 
وذﻟك ﺑﻣوﺟب اﻟﻘﺎﻧون. ﻟن ﯾﺗم اﻹﻓﺻﺎح ﻋن اﺳﻣك أو 
اﻟﻣﻌﻠوﻣﺎت اﻟﺷﺧﺻﯾﺔ إذا ﺗم ﻧﺷر ﻧﺗﺎﺋﺞ  ھذه اﻟدراﺳﺔ  
ﻧﺷرت أو ﻋرﺿت ﻓﻲ اﻻﺟﺗﻣﺎﻋﺎت اﻟﻌﻠﻣﯾﺔ.  
 
WHAT ARE MY RIGHTS IF I TAKE PART 
IN THIS STUDY? 
ﻣﺎ ھﻲ ﺣﻘوﻗﻲ إذا واﻓﻘت ﻋﻠﻰ اﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه 
اﻟدراﺳﺔ ؟  
Taking part in this study is your choice.  
You may choose either to take part or not 
to take part in the study.  If you decide to 
take part in this study, you may leave the 
study at any time.  No matter what decision 
you make, there will be no penalty to you 
and you will not lose any of your regular 
benefits.  Leaving the study will not affect 
your medical care.  You can still get your 
medical care from KFMC.  Dr . Naji Aljohani 
and the researcher Hend Alharbi may use 
information that was collected prior to your 
leaving the study.  
 
ﻗرار اﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ ﻣن اﺧﺗﯾﺎرك. ﻟك 
ﺣرﯾﺔ اﺧﺗﯾﺎر اﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ أو ﻻ .ﻛﻣﺎ 
ﯾﻣﻛﻧك إﻧﮭﺎء اﻟﻣﺷﺎرﻛﺔ ﻓﻲ أي وﻗت. ﻣﮭﻣﺎ ﻛﺎن 
ﻗرارك ، ﻟن ﯾﻛون ھﻧﺎك أي ﻋﻘوﺑﺔ و ﻟن ﺗﻔﻘد أي ﻣن 
اﻟﻔواﺋد اﻟﻌﺎدﯾﺔ اﻟﺧﺎﺻﺔ ﺑك. ﺗرك اﻟدراﺳﺔ  ﻟن ﯾؤﺛر 
ﻋﻠﻲ اﻟرﻋﺎﯾﺔ اﻟطﺑﯾﺔ اﻟﻣﻘدﻣﺔ ﻟك ﻣن ﻣدﯾﻧﺔ اﻟﻣﻠك ﻓﮭد 
اﻟطﺑﯾﺔ. د.  ﻧﺎﺟﻲ اﻟﺟﮭﻧﻲ وﺑﺎﺣﺛﮫ اﻟدﻛﺗوراه ھﻧد 
اﻟﺣرﺑﻲ ﻗد  ﯾﺳﺗﺧدم اﻟﻣﻌﻠوﻣﺎت اﻟﺗﻲ ﺗم ﺟﻣﻌﮭﺎ  ﻗﺑل 
أن ﺗﺗرك ﻟدراﺳﺔ.  
 
 
We will tell you about new information or 
changes in the study that may affect your 
health or your willingness to continue in the 
study. 
 
وﻧﺣن ﺳوف ﻧﺑﻠﻐك ﺑﻛل اﻟﻣﻌﻠوﻣﺎت واﻟﻣﺳﺗﺟدات أو 
اﻟﺗﻐﯾﯾرات ﻓﻲ اﻟدراﺳﺔ  اﻟﺗﻲ ﯾﻣﻛن أن ﺗؤﺛر ﻋﻠﻰ 
ﺻﺣﺗك أو ﻋﻠﻰ اﺳﺗﻌدادك ﻟﻣواﺻﻠﺔ اﻟدراﺳﺔ .  
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In the case of injury resulting from this 
study, you do not lose any of your legal 
rights to seek payment by signing this form. 
 
وﻓﻲ ﺣﺎﻟﺔ اﻹﺻﺎﺑﺔ اﻟﻧﺎﺗﺟﺔ ﻋن ھذه اﻟدراﺳﺔ  ،ﺑﺗوﻗﯾﻊ 
ھذا اﻹﻗرار, ﻟن ﺗﻔﻘد أﯾﺎ ﻣن اﻟﺣﻘوق اﻟﻘﺎﻧوﻧﯾﺔ ﻓﻲ 
طﻠب اﻟﺗﻌوﯾض.  
 
WHO DO I CALL IF I HAVE QUESTIONS 
OR PROBLEMS? 
 
ﺑﻣن ﯾﻣﻛﻧﻧﻲ اﻻﺗﺻﺎل إذا ﻛﺎﻧت ﻟدي أي أﺳﺋﻠﺔ أو 
ﻣﺷﺎﻛل؟  
 
Before you agree to be in this study, you 
will talk to a study team member qualified to 
tell you about this study.  You can ask 
questions about any aspect of the research.  
If you have further questions about the 
study, you may ask them at any time.  You 
may call 0556605558. 
 
ﻗﺑل أن ﺗواﻓق ﻋﻠﻰ اﻟﻣﺷﺎرﻛﺔ ھذه اﻟدراﺳﺔ  
،ﺳﺗﺗﺣدث إﻟﻰ اﺣد أﻋﺿﺎء ﻓرﯾق دراﺳﺔ اﻟﻣؤھﻠﯾن 
ﻟﯾﺧﺑرك ﻋن ھذه اﻟدراﺳﺔ . ﯾﻣﻛﻧك أن ﺗطرح اﻷﺳﺋﻠﺔ 
ﺣول أي ﺟﺎﻧب ﻣن ﺟواﻧب اﻟﺑﺣث. إذا ﻛﺎن ﻟدﯾك 
اﻟﻣزﯾد ﻣن اﻷﺳﺋﻠﺔ ﻋن اﻟدراﺳﺔ  ،ﯾﻣﻛﻧك اﻟﺳؤال ﻓﻲ 
أي وﻗت. ﯾﻣﻛﻧك اﻻﺗﺻﺎل اﻟﺑﺎﺣث اﻟرﺋﯾس ﻋﻠﻲ 
اﻟرﻗم  
0556605558 
 
 
CONSENT إﻗرار ﺑﺎﻟﻣواﻓﻘﺔ  
Subject: 
 
اﻟﻣﺷﺎرك  
The research and procedures have 
been explained to me.  I have been 
allowed to ask any questions I have at 
this time.  I can ask any additional 
questions I may think of later.  I may 
quit being in the study at any time 
without affecting my health care. 
 
ﻟﻘد ﺗم ﺷرح اﻟﺑﺣث واﻹﺟراءات ﻟﻲ. وﺳﻣﺢ ي ﺑﺄن اﺳﺄل 
أي ﺳؤال ﻟدي ﻓﻲ ھذا اﻟوﻗت. وﯾﻣﻛﻧﻧﻲ أن اﺳﺄل أي 
أﺳﺋﻠﺔ إﺿﺎﻓﯾﺔ ﻓﻲ وﻗت ﻻﺣق. وﯾﻣﻛﻧﻧﻲ إﻧﮭﺎء اﻟﻣﺷﺎرﻛﺔ 
ﻓﻲ اﻟدراﺳﺔ  ﻓﻲ أي وﻗت دون ﯾؤﺛر ذﻟك ﻋﻠﻲ اﻟرﻋﺎﯾﺔ 
اﻟﺻﺣﯾﺔ اﻟﻣﻘدﻣﺔ ﻟﻲ.  
 
 
 
I will receive a signed copy of this 
consent form. 
 
ﺳﺄﺣﺻل ﻋﻠﻲ ﻧﺳﺧﺔ ﻣوﻗﻌﺔ ﻣن ھذا اﻹﻗرار ﺑﺎﻟﻣواﻓﻘﺔ.  
 
I agree to participate in this study.  My 
agreement is voluntary.  I do not have to 
sign this form if I do not want to be part 
of this research study. 
 
إﻧﺎ اﻗر ﺑﺎﻟﻣواﻓﻘﺔ ﻋﻠﻰ اﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ. 
ﻣواﻓﻘﺗﻲ طوﻋﯾﺔ, وﻟﺳت ﺑﺣﺎﺟﺔ إﻟﻰ اﻟﺗوﻗﯾﻊ ﻋﻠﻰ ھذا 
اﻹﻗرار إذا ﻛﻧت ﻻ أرﯾد اﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ 
اﻟﺑﺣﺛﯾﺔ.  
 
 
Subject Signature ﺗوﻗﯾﻊ اﻟﻣﺷﺎرك:  
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Date اﻟﺗﺎرﯾﺦ  
Time (AM    PM    ) اﻟوﻗت  ص              م  
Person Obtaining Consent: 
 
اﻟﺷﺧص اﻟﺣﺎﺻل ﻋﻠﻰ اﻟﻣواﻓﻘﺔ:  
 
I have explained the nature and 
purpose of the study and the risks 
involved.  I have answered and will 
answer questions to the best of my 
ability.  I will give a signed copy of the 
consent form to the subject. 
ﻟﻘد ﺷرﺣت طﺑﯾﻌﺔ اﻟدراﺳﺔ  واﻟﻐرض ﻣﻧﮭﺎ وﻣﺎ ﺗﻧطوي 
ﻋﻠﯾﮫ ﻣن ﻣﺧﺎطر. وﻗد أﺟﺑت وﺳﺄﺟﯾب ﻋﻠﻲ  اﻷﺳﺋﻠﺔ ﻋﻠﻰ 
أﻓﺿل ﻗدر ﻣن اﺳﺗطﺎﻋﺗﻲ. ﺳﺄﻋطﻲ ﻧﺳﺧﺔ ﻣوﻗﻌﺔ ﻣن 
اﻹﻗرار ﺑﺎﻟﻣواﻓﻘﺔ إﻟﻲ اﻟﻣﺷﺎرك اﻟﻣذﻛور أﻋﻼه.  
 
 
Signature of Person Obtaining Consent ﺗوﻗﯾﻊ اﻟﺷﺧص اﻟﺣﺎﺻل ﻋﻠﻰ اﻟﻣواﻓﻘﺔ  
Date اﻟﺗﺎرﯾﺦ  
Time (AM    PM    ) اﻟوﻗت  ص              م  
Principal Investigator: اﻟﺑﺎﺣث اﻟرﺋﯾس :  
 
Signature of Principal Investigator ﺗوﻗﯾﻊ اﻟﺑﺎﺣث اﻟرﺋﯾﺳﻲ  
Time (AM    PM    ) اﻟوﻗت  ص              م  
 
 
[STOP! Do not use the following 
signature lines unless third party 
consent is being requested and has 
been.] 
 
]ﻗف! ﻻ ﺗﺳﺗﺧدم ﺧطوط اﻟﺗوﻗﯾﻊ اﻟﺗﺎﻟﯾﺔ إﻻ إذا طﻠﺑت 
ﻣواﻓﻘﺔ طرف ﺛﺎﻟث [  
 
AND/OR: 
 
و / أو :  
 
Legally Authorized Representative اﻟﻣﻣﺛل اﻟﻣﺧول ﻗﺎﻧوﻧﺎ  
Date  اﻟﺗﺎرﯾﺦ  
Person Obtaining Consent اﻟﺷﺧص اﻟﺣﺎﺻل ﻋﻠﻰ اﻟﻣواﻓﻘﺔ  
Date  اﻟﺗﺎرﯾﺦ  
OR أو  
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The person being considered for this 
study is unable to consent for 
himself/herself because he/she is a 
minor.  By signing below, you are giving 
your permission for your child to be 
included in this study. 
 
اﻟﺷﺧص اﻟﻣﻌﻧﻲ ﺑﺎﻟدراﺳﺔ ﻏﯾر ﻗﺎدر ﻋﻠﻰ اﻟﻣواﻓﻘﺔ ﺑﻧﻔﺳﮫ 
ﻷﻧﮫ / إﻧﮭﺎ ﻗﺎﺻر. ﻣن ﺧﻼل اﻟﺗوﻗﯾﻊ أدﻧﺎه، أﻧت ﺗﻌطﻲ 
إذﻧك ﻟطﻔﻠك ﺑﺎن ﯾﺿﻣن ﻓﻲ ھذه اﻟدراﺳﺔ  
 
 
Parent or Legal Guardian--------------------
------------ 
اﻷﺑوﯾن أو اﻟوﺻﻲ ﻗﺎﻧوﻧﺎ ----------------- 
Date:   /    / اﻟﺗﺎرﯾﺦ:         /    / 
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Appendix 8: Pre-study questionnaire 
Pre-study Screening Questionnaire 
A. Participant Section: 
Background  
Name:…………..……………………………………           Today’s date: 
____/_____/_____ 
Address:………………………………............... 
Telephone:………………………… 
• Are you male or female?  
1) Male      2) Female  
 
• How old are you? 
1) Less than 18         2) 18 - 24          3) 25 -34         4) 35 - 44        5) 45 - 54            6) 
5-60    7) 61 and over             
Date of birth: ------/-------/-------- 
 
• Are you currently? 
1) Single     2) married   3) divorced   4) widowed 
 
• How many children do you have? 
1) 1   2) 2    3) 3   4) 4             5) 5  
6) more than 5 
 
• Please circle the highest year of school completed: 
1) Illiteracy  2) Primary              3) Secondary school   4) high 
school          5) diploma            6) university               7) Higher education  
  
• Are you currently? 
1) Student             2) Employed               3) unemployed                         4) 
Retire 
    
• Do you have any health or nutrition related qualifications? 
1) Yes   2) No 
 
• Do you currently smoke cigarettes or any other tobacco products on a daily basis?  
1) Yes   2) No    
if Yes, How often:            1) often            2) average    3) Not often  4) rarely 
 
• Are you on a special diet? 
1) Yes    2) No     If Yes Please specify:. . . . . . .  
 
Medications  
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• When were you first diagnosed with type 2 diabetes? 
1) 1-2 years          2) 3-5 years                  3) 6-8 years          4) over 8 years 
 
• Has either of your parents, or any of your brothers or sisters been diagnosed with 
diabetes? 
1) Yes              2) No 
 
• Do you have any diabetic complications?  
1) Yes        2) No    3) Don’t know 
If yes please choose form following relevant diabetic complications: 
1) hypoglycaemia diabetic ketoacidosis (DKA)            2) retinopathy  
3) Hyperosmolar hyperglycaemic state HHS)                4) cardiovascular disease  
5) Nephropathy nerves and feet (neuropathy) 
 
• Do you have any of the following medical conditions? Circle every relevant 
condition. 
1) Renal failure                    2) Gastrointestinal Malabsorption (e.g. Crohn’s disease, 
Colitis) 
3) Parathyroid disease         4) Hypercalcaemia 
 
• Are you currently taking prescribed medications 
Name of Drug Dose How many times a day? 
e.g. Metformin 1 tablet of 10g 3 times with meals 
 
• Do you take daily vitamin supplements? 
1) Yes                                  2) No  
If yes, please specify type and brand ......................................................... 
 
• Have you taken vitamin supplements 3 months prior to today’s date?  
1) No                          2) Yes 
If yes, please specify type and brand …………………………… 
 
B. Researcher Section - Anthropometric Measurements 
• Participant’s Height?   ________________cm 
• Participant’s Weight? _________________kg 
• Calculated BMI          _________________m2 
• Waist circumference    ________________cm 
• Current HbA1C          _________________%               Date tested 
____/_____/_____ 
Thank you for your time much appreciated  
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Appendix 9: Debriefing questionnaire 
 
 
 
Debriefing Questionnaire 
Participant Section: 
Background  
Name: …………..……………………………………           Today’s date: 
____/_____/_____ 
Address: …………………………………… 
Telephone: ………… 
 
I know it must be difficult to take medications regularly. How often did you miss 
taking the vitamin tablet? 
(1) Once a week         (2) twice a week          (3) three or more times a week         (4) 
never took them       
 
2- How many times did you forget to record your pill-taking on the calendar? 
(1) Once a week         (2) twice a week          (3) three or more times a week         (4) 
never recorded 
 
3- Have you been prescribed any new medications since you started taking the 
vitamin supplements, if so please specify? 
(1) No        (2) Yes 
If yes, please specify  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
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4- Have you stopped taking any prescribed medications since you started taking the 
tablets? 
(1) No        (2) Yes 
If yes, please explain  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
5- Have the doses of your medications changed since you started taking the 
tablets? 
(1) No        (2) Yes 
If yes, please explain  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
6- Have you taken vitamin supplements other than those supplied during the study? 
(1) No        (2) Yes 
If yes, please explain  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
7- Did you suffer from any of the following medical conditions in the last 16 weeks? 
Circle every relevant condition. 
(1) Renal failure       (2) Gastrointestinal Malabsorption (e.g. Crohn’s disease, 
Colitis) (3) Parathyroid disease (4) Hypercalcaemia    (5) other, please specify . . . . . 
.. .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..  
 
9- Did you start any special diets? 
(1) No      (2) Yes              
If yes, please explain  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
..  
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10- Overall, how would you score your diabetes during the last 16 weeks? 
(1) Better than before     (2) Worse than before          (3) No change          
 
11- Have you been diagnosed with any other conditions? 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . .  
 
Researcher Section - Anthropometric Measurements 
Participant’s Height?    ________________cm 
Participant’s Weight?  ________________kg 
Calculated BMI         ________________m2 
Waist circumference    ________________cm 
Current HbA1C           ________________% 
Calcium level  ________________mmol/l          
Date tested                     ____/_____/_____ 
 
Participant number……………………………. 
 
Checklist: 
Questionnaire complete                         
 
Tablets returned 
 
Calendar returned 
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Anthropometric measures  
 
Blood sample taken 
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Appendix 10: Supplement calendar 
                             
                                    
                                   Supplement recoding calendar  
Participant NO:……………                                                             رﻗم  اﻟﻣﺷﺎرك 
................  
Day / 
week Sunday Monday Tuesday Wednesday Thursday Friday Saturday 
1               
2               
3               
4               
5               
6               
7               
8               
9               
10               
11               
12               
13               
14               
15               
16               
 
 
Researcher Hend Alharbi  
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Appendix 11: Block supplement randomisation 
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Appendix 12: Measurement of the concentration of vitamin D kits 
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Appendix 13: Measurement of the concentration of calcium  
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Appendix 14: Measurement of the concentration of albumin   
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Appendix 15: Measurement of the concentration of blood glucose kit 
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Appendix 16: Measurement of the concentration of glycated 
haemoglobin 
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Appendix 17: Measurement of the concentration of fasting insulin 
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Appendix 18: Measurement of the concentration of cholesterol  
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Appendix 19: Measurement of the concentration of HDL  
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Appendix 20: Measurement of the concentration of triglycerides   
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Appendix 21: Measurement of the concentration of total antioxidant 
capacity 
 
 
